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Pleural disease secondary to non-malignant processes is a significant cause of morbidity and 
mortality. There is currently sparse literature detailing the clinical course and progression of this 
patient cohort.  
The two populations of interest are patients with transudative pleural effusions and patients with 
pneumothorax secondary to underlying lung disease (secondary spontaneous pneumothorax).  
This thesis seeks to expand the understanding of the disease course in these patient populations 
and examine whether ambulatory management would improve outcomes. The hypothesis of this 
thesis is ‘ambulatory management of non-malignant pleural disease will lead to improved patient-
related outcomes and shorter length of hospitalisation’. 
Methods 
Part A: Ambulatory management of transudative pleural effusion  
Analysis of 782 patients, including 356 with non-malignant pleural effusions, demonstrated a high 
1-year mortality in patients with transudative effusions. Analysis of 105 patients with cardiogenic 
pleural effusions found a high rate of symptomatic re-accumulation, with nearly a quarter of 
patients requiring further therapeutic pleural procedures. To investigate the optimal method of 
managing symptomatic, refractory transudative pleural effusions, this thesis details the REDUCE 
trial, a randomised controlled trial in this patient cohort, allocating participants to indwelling 
pleural catheters or therapeutic aspiration.  
Part B: Ambulatory management of pneumothorax 
In order to investigate the disease course of pneumothoraces, this thesis conducted a systematic 
review on the rate of recurrence in patients with a primary spontaneous pneumothorax, 
demonstrating a 32% recurrence rate. A further study examined conservative management in 
patients with traumatic pneumothoraces, demonstrating a role for expectant management. The 
final study, the Hi-SPEC trial, is a randomised controlled trial examining the role of ambulatory 
management of secondary spontaneous pneumothorax, allocating participants to ambulatory 
Heimlich valve or standard care. 
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Discussion  
This thesis adds to our understanding of the prognosis and outcomes of patients with transudative 
pleural effusions. The results from the REDUCE trial will inform on the use of ambulatory 
management in this patient cohort.   
This thesis adds to our understanding of the natural history of pneumothoraces. The results from 
the Hi-SPEC trial will inform on the use of ambulatory management in patients with secondary 
spontaneous pneumothorax.    
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CHAPTER 1. INTRODUCTION  
Pleural disease can lead to accumulation of fluid or air into the pleural space. This can be caused 
by either malignant processes, usually due to cancerous micro-metastasis to the pleural 
membrane, or non-malignant processes.  In the last 10 years, the malignant pleural effusion (MPE) 
has been extensively investigated, leading to increased understanding of the pathophysiology, as 
well as its management and prognostication, allowing for a personalised approach to the 
patient(1). This bench to bedside data is not available in non-malignant pleural disease (NMPD), 
with little high-grade evidence on the clinical course in these patients.  
An area of particular research interest in MPE is the outpatient ambulatory pathway, so as to 
avoid lengthy inpatient stays, maximise mobilisation and minimise the complications associated 
with prolonged bedrest(2-5). With trials demonstrating improvements in patient-centred 
outcomes with this pathway, particularly using the indwelling pleural catheter (IPC) for 
ambulatory drainage, pleural medicine has moved away from an inpatient speciality, to one where 
patients can be managed in the community.    
The aim of this PhD is to improve the understanding of the clinical course and progression of non-
malignant pleural disease, specifically looking at two patient populations: the pleural effusion 
secondary to the refractory transudative effusions and in patients with secondary spontaneous 
pneumothoraces.  
 
1.1. The refractory transudative effusion 
“The customary division of transudates from exudates at the specific gravity of 1.016 has been 
found to be true only in certain diseases” Paddock, 1940(6) 
The history of extravascular fluid analysis is one of correctly identifying the exudate, originally to 
diagnose pleural effusions from tuberculous (TB), and more recently, to identify malignant pleural 
effusions.  Since the early 19th century,  extravascular fluids have been classified based on either 
protein content or specific gravity into either a transudate or an exudate(6). Transudates, with 
low protein, were felt to result from increased intravascular fluid pressures or diminished colloid 
oncotic forces, typically as a consequence of cardiac dysfunction. Exudates with higher protein 
levels resulted from vessel alteration during inflammation, usually either due to infection or 
malignancy. The search for a differentiating test between the two states focused on establishing 
cut-off values for the biochemical properties, such as specific gravity, protein or LDH. Paddock, in 
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a paper published in the 1940s determined from an analysis of 1300 fluids, that using specific 
gravity cut-off of 1.016 misclassed 10% of cardiac effusions and tuberculous effusion, and over 
30% of non-tuberculous infected pleural fluids and 40% of malignant fluids(6). Similarly, no 
singular pleural protein content value, either by itself, or compared to serum protein as a ratio, 
could be found to accurately differentiate exudates from transudates (6-8). The measurement of 
a metabolic enzyme, lactate dehydrogenase (LDH) demonstrated a positive correlation with  
exudative effusions, however it again lacked diagnostic accuracy by itself (9, 10).  
Dr Richard Light proposed simultaneous use of both protein and LDH pleural-serum ratio to 
discriminate between pleural transudates and exudates(11). With the three-part Light’s Criteria,  
an effusion is an exudate when any one of the following findings is present: a ratio of pleural fluid 
protein to serum protein higher than 0.5, a ratio of pleural fluid LDH level to serum LDH level 
higher than 0.6, or a pleural fluid LDH level higher than 200 IU per litre (or >67% of the upper limit 
of the normal range for serum LDH level). This criterion has become the standard approach to the 
initial characterisation of the pleural effusion and has demonstrated high sensitivity in diagnosing 
exudates (98%). The combination of multiple tests in an ‘or’ rule, leads to this increased sensitivity, 
but at the expense of an increased likelihood of false-positive findings. This results in an over-
diagnoses of transudates as exudates(12), with approximately 25% of transudates misclassified 
(13). Additionally, from as early as the 1930s it was appreciated, that along with decreasing the 
effusion volume, diuretics altered the pleural biochemistry(14), with more recent studies 
demonstrating   both protein and LDH increase progressively during diuretic therapy(13). This 
alteration of the pleural biochemical components further increases the rate misclassification of 
transudates as an exudate (pseudoexudate). It has been suggested in these patients that 
calculating the gradient between serum and pleural protein or albumin is more accurate in 
differentiating transudates from exudates whilst on diuretics, as the gradient appears to increase 
less than the ratio whilst on diuretics. NT-proBNP, a hormone produced by cardiomyocytes in 
response to parietal stress in heart failure, has been found to be highly sensitive and specific (94%) 
in differentiating cardiac from non-cardiac effusions(15) and can also be helpful in identifying 
pseudoexudates (16) 
This weighting towards sensitivity in identifying exudative processes was not accidental, as it was 
felt that exudates represented the more serious pathologies such as malignancy and infection, as 
opposed to the transudative processes of heart and liver failure(12). This may have contributed 
to the perception that transudates are of less consequence, reinforced by their nomenclature of 
‘benign pleural effusions ‘.  
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The division of pleural effusion into exudates and transudates forms the initial part of the British 
Thoracic Society (BTS) diagnostic algorithm(17). It advises that patients with a transudative 
effusion be managed with medication to optimise existing organ dysfunction, either 
presumptively   when the clinical picture is suggestive of a transudate or if pleural analysis 
confirms this.  
However, it is increasingly recognised that a proportion of transudative effusions do not respond 
to optimisation of their underlying organ dysfunction and these patients may require invasive 
therapeutic interventions. There has been little research of the outcomes of these transudates 
which are refractory to medical management, or how best to manage them. Any management 
approaches are extrapolated from research in malignant pleural effusion (MPE).  One of these 
management approaches is the use of a tunnelled silicone-coated indwelling pleural catheter (IPC) 
to manage pleural effusions as an outpatient. Whilst these are well established in MPE, there has 
been little research in the role of ambulatory care in patients with transudative effusion, with no 
randomised studies on the use of IPCs in transudative pleural effusions. 
1.1.1. Congestive Heart Failure  
Congestive Heart Failure (CHF) has a prevalence of over 5.8 million in the USA, and over 23 million 
worldwide(18). It is the leading cause of pleural effusions, with an estimated annual incidence in 
the US of 500,000(19), with up to 70% of patients with heart failure thought to develop a pleural 
effusion during their disease course and 87% of patients with acute decompensated heart failure 
demonstrating an effusion on CT imaging(20, 21).  
Normal pleural fluid is both produced and absorbed primarily from  the parietal surface and 
typically originates from the systemic capillaries of the pleura (22, 23). However, in patients with 
CHF there’s debate about whether pulmonary or systemic pressure elevation causes pleural 
effusions(23). Elevated systemic pressure could lead to pleural effusion formation by increasing 
filtration across the systemic circulation of the parietal pleura and by decreasing lymphatic flow 
through increases in the downstream venous pressure. Conversely, elevated pulmonary pressure 
elevation could result in pleural effusion formation by increasing filtration across the pulmonary 
circulation of the visceral pleura (23). The resultant increased cardiac pressures are transmitted 
back, leading to increased pulmonary venous hypertension. This increase in pulmonary venous 
pressure that leads to alveolar oedema increases the interstitial pressure in the subpleural 
regions, with the resultant fluid leaking from the visceral pleural surface, increasing the rate of 
fluid accumulation(24). This has been demonstrated in experimental work and clinical studies. 
Studies on anaesthetised sheep found that fluid leaks directly from the oedematous sheep’s lung, 
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via the visceral pleural, into the pleural space (25). A prospective study of 37 patients on a 
Coronary Care Unit (CCU), with CHF supported these findings.  In the 19 (57%) patients with 
pleural effusions, the pulmonary capillary wedge pressure was significantly higher than those 
without effusions (24.1±1.3 vs 17.2±1.5mmHg) (26).  
Elevated systemic venous pressures can result from transmitted left elevated atrial pressures via 
the right heart or from isolated right heart failure.  The increase in systemic venous pressure could 
produce a net increase of pleural fluid by increasing filtration of fluid from the parietal capillaries 
and by decreasing lymphatic drainage by increasing the outflow pressure in the thoracic duct(24). 
Despite this plausible mechanism, it is felt that pleural effusions are unusual in patients with 
isolated right heart failure (RHF). A small study of 18 patients with severe pulmonary hypertension 
(50±5mmHg), with significant raised right atrial pressures (11±2mmHg) and normal mean 
pulmonary capillary wedge pressures, found no evidence of pleural effusion on x-ray or 
ultrasound(27). A more recent study has challenged this, examining 147 patients with isolated 
RHF, 128 of which had patients had IPAH (idiopathic pulmonary arterial hypertension). In this 
study thirty-one of 147 patients (21.1%) had evidence of pleural effusions.  These effusions were 
generally small, with nearly two thirds of the pleural effusions described as trace to small in size. 
Of the 3 patients with massive effusions, two had ascites, suggesting that translocation from 
ascites might be the possible mechanism. The majority of the effusions were unilateral right sided 
effusions (58%), compared to bilateral (26%). This study was limited by its retrospective nature, 
and that most of the effusions were not sampled, with the authors postulating alternate causes 
of the pleural effusions other that RHF in ten patients(28).  
A large retrospective review of 3245 consecutive patients with acute decompensated heart failure 
(ADHF) looked at the factors which predisposed patients to forming pleural effusion. Pleural 
effusions were detected in 1504 (46%) patients, and with male gender, higher systolic pulmonary 
artery pressure (sPAP), hypoabluminaemia and higher NT proBNP independent predictors of 
pleural effusion development(29). 
The first line treatment of pleural effusion secondary to heart failure is optimisation of medical 
therapy with diuretics therapy, low-salt diet and reducing afterload. These measures improve 
pleural effusions in the majority of patients.  One prospective study of 60 consecutive patients 
hospitalised with CHF, 52 (87%) of which had pleural effusions. At a median follow-up of 16.2 ± 
4.5 days (range 10 to 30 days), 41 of 46 patients (89%) with pleural effusion had complete 
resolution of their pleural effusion during the follow-up period. The remaining patients also had 
partial resolution(20).  Sufficient follow-up data were not obtained in 6 patients because they 
deteriorated during the follow-up period. The management regime consisted of treatment with a 
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combination of oxygen, digoxin, nitrates, diuretics, sympathomimetic agents, and synthetic 
human atrial natriuretic peptide(20). Most of these patients were NYHA class IV (40%) with 28% 
and 32% class III and II respectively. This study had several limitations which affects its 
generalisability to all patients with CHF. It is was a small study, at a single centre, with no CCU. 
The commonest cause of CHF in this patient cohort was degenerative valvular heart disease 
(26/60), with ischaemic cardiomyopathy only accounting for 9/60 of the patients. This was felt to 
be due to patients with IHD preferentially referred to other hospital with CCUs. As mentioned, 
follow data was also incomplete.  
There is limited literature on patients with CHF in whom the effusion is unresponsive to medical 
optimisation.  Devices such as cardiac-resynchronization therapy (CRT) can help optimise cardiac 
function with dyssynchronous left ventricular contraction, and has been shown to increase 
functional capacity, improve quality of life and decrease mortality in selected patients (30). There 
is no literature available on the effect of CRT on pleural effusions and pleural effusions are not an 
indication for their use.  
 
1.1.2. Hepatic Failure  
Patients with liver failure can develop a pleural effusion, known as a hepatic hydrothorax. Liver 
cirrhosis is the commonest underlying liver pathology, with between 5-10% of cirrhotic patients 
developing a pleural effusion (31). Hepatic hydrothorax are typically right sided unilateral 
effusions (73%), although they can be left (17%) or bilaterally (10%)(32). They are often large, with 
one series defining 71% of pleural effusions as large(32). Whilst often associated with ascites, up 
to 10% will not have neither clinically nor radiologically detectable ascites(32).  
There are several proposed underlying mechanisms, including azygous vein hypertension from 
collateral anastomoses between portal and azygous systems, hypoalbuminemia from impaired 
hepatic function, passage of ascitic fluid via transdiaphragmatic fenestrations and possibly 
lymphatic leakage from the thoracic duct(33). Among these, the direct passage of ascitic fluid 
through defects within the diaphragm appears the most plausible (33). The defects originate from 
fluid filled pleuroperitoneal blebs as of result of increased intra-abdominal pressure. This 
increased pressure from ascites then causes the blebs to rupture, resulting in diaphragmatic 
fenestrations. These diaphragmatic defects have been demonstrated both microscopically at 
post-mortem(31) and macroscopically at thoracoscopy(34). Radiological studies have also 
demonstrated transfer of CO2 and radioisotopes from the peritoneal to the pleural cavity(35).  
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The other postulated mechanisms are less convincing in isolation. There appears to be no 
association between low serum albumin and hepatic hydrothorax, and is unlikely to be a cause in 
isolation (36). In a study of 200 cirrhotic patients with ascites, mean albumin levels were nearly 
identical in the group with ascites alone and the group with ascites and HH(37).  Collateral 
anastomoses between the portal and azygos system leads to hypertension in the azygous vein 
system and leakage from this system is a suggested causative mechanism. However, this should 
result in bilateral pleural effusions, which is rare in HH, and so is not generally felt to be a causative 
factor(38, 39). Cirrhosis and ascites causes increased lymph flow in the thoracic duct(40) and it 
has been suggested that resultant lymphatic leakage from the thoracic duct leads to HH 
formation. However, as increased thoracic flow is common in cirrhosis, whilst effusion formation 
rare, it is felt that this is unlikely to have a significant effect in isolation (38). 
The first line management of hepatic hydrothorax is the same for ascites and comprises alcohol 
abstinence, management of underlying liver disease if possible,  restriction of sodium intake to 2 
g/day, avoidance of medications which decrease systemic blood pressure and/or impair renal 
perfusion (ACE-inhibitors, ARBs & NSAIDs), and the use of oral diuretics (spironolactone and 
furosemide in a ratio of 100 : 40mg daily, titrated up as required) (41).  However, approximately  
25% of patients with hepatic hydrothorax have effusions refractory to salt restriction and 
diuretics(41) 
There are a number of invasive interventions for cirrhotic patients which can be used to treat 
hepatic hydrothorax(41). The transjugular intrahepatic portosystemic shunt (TIPS) is an image-
guided procedure which connects the portal vein to the hepatic vein in the liver, creating a porto-
systemic shunt, with the aim of decreasing portal hypertension, and subsequent decrease in 
effusion and ascitic fluid formation. In one series of 24 patients, 58% of patients had complete 
relief of symptoms and did not require further thoracentesis and a further 21% were reported as 
requiring fewer thoracentesis, although there was no comparator arm (42). However, there are 
significant side effects, with 38% developing transient hepatic encephalopathy and a 25% 
mortality rate within 45 days, with one patient dying from procedural complications.  These 
findings are limited by the lack of comparator.   
Liver transplant is the only treatment which confers a survival benefit, improving median survival 
in patients with a hepatic hydrothorax from 1896 days to 321 days(32) However, there are strict 
criteria for transplantation and a significant waiting time for patients which varies by country. In 
the US the median waiting time is 18.5 months(43) and in the UK it is 4.7 months, with 19% dying 
before a transplant organ was available or being removed from the elective list, primarily because 
they became too unwell(44). 
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Human albumin solution (HAS) is a sterile aqueous solution for intravenous use, mainly consisting 
of the albumin component of human plasma. It is used routinely during paracentesis of ascitic 
fluid to prevent paracentesis-induced circulatory dysfunction (PICD). PICD is characterised by 
impairment of circulatory function and occurs in 80% of cases where paracentesis isn’t performed 
with plasma volume expansion(45). The vasoactive and neurohumoral changes in PCID appear to 
have an immediate phase in the first hours, which are predominately beneficially, and later phase, 
which is detrimental and associated with worse outcomes if not corrected. The immediate 
haemodynamic changes are marked decreased in right atrial, pulmonary and mean arterial 
pressure and an increased in cardiac output and systemic vasodilation, with a reduction of plasma 
renin activity (PRA) and aldosterone levels (46). This can occur after removal of a little as 250ml if 
ascitic fluid. These initial changes are predominately beneficial but are typically only transient if 
paracentesis is not followed by plasma expansion.  Otherwise in the following 24 hours, cardiac 
output decreases and PRA and aldosterone  concentrations increase(46, 47). PICD is associated 
with worsening renal function, ascites re-accumulation and poorer prognosis(48).  Intravenous 
HAS administration, at 8g/L of ascites drained, has been shown to be the optimal plasma expander 
in preventing PICD and the administration appears to prevent the resultant hypovolaemic state in 
the majority of patients(49). More recently a half-dose of 4g/L has been shown to be equally 
effective(48). There is little information on the use of HAS in hepatic hydrothorax drainages via 
IPC, and practice is usually guided by local hepatologist.  A retrospective review of patients who 
have undergone IPC placement for hepatic hydrothorax examined the baseline and follow-up 
(mean 29.6 days; range, 1-122 days) albumin levels(50). It found a small downward trend, with a 
decrease of 0.3 g/dL, which is of uncertain clinical significance(50) 
1.1.3. Renal failure  
Pleural effusion secondary to renal impairment is typically an indicator of severe disease and can 
be demonstrated in 20% of patients on haemodialysis(51). There have been several case-series 
examining patients on haemodialysis with pleural effusions(51-53). The studies were 
retrospective and relied mostly on clinical evaluation, with the thoracentesis rate in the two 
earlier studies less than 30%(51, 52). The later study by Rashid-Farokhi et al was the only study to 
use echocardiographic criteria for heart failure, and had a higher thoracentesis rate of 87%(53). 
Cardiovascular disease is common in patients with end-stage renal disease (ESRD)(54) and most 
case-series found that fluid overload, either due to heart failure, or due to another mechanism, 
was the leading cause. Other potential causes of fluid overload in patients with ESRD, aside for 
cardiac dysfunction, are pulmonary over-hydration secondary to water and solute retention; 
hypoproteinemia; high-output arteriovenous fistula or injury of the alveolo-capillary membrane 
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secondary to toxic-lesional factors (55). The study by Jarratt and colleagues found that 46% of 
cases were due to heart failure(52), with the study by Bakirci and colleagues attributed 60% and 
10% to over-hydration and heart failure respectively(51). The study by Rashid-Farokhi and 
colleague found that heart failure was responsible to 20% of cases, with volume overload 6% of 
cases(53). Patients with renal failure are also at increased risk of pneumonia and subsequent 
parapneumonic effusion, due to a depressed humoral and cellular immunity, with parapneumonic 
effusion felt to be responsible for between 10 and 24% of effusions of patients on longer-term 
haemodialysis (51-53). Uraemia can contribute to pleural effusion formation by causing 
necrotizing fibrinous pleural inflammation and resultant typically blood-stained lymphocytic 
exudate formation, although the pathogenesis is poorly understood(56). This uraemic pleuritis is 
attributed to between 4 and 24% of cases in the aforementioned studies (51-53) 
Patients on peritoneal dialysis (PD) can also develop pleural effusion, usually secondary to passage 
of dialysis fluid from the peritoneal cavity(57).  
Effusions secondary to overload can be treated by optimising fluid balance, either with altering 
dialysis regimes or diuretics administering. However, this can be limited by symptomatic 
hypotension and electrolyte disturbances.  Uraemic pleurisy is managed with haemodialysis, 
although it may be refractory to this.   PD related effusions are typically managed with short-term 
switch to haemodialysis.  
1.1.4. Prognosis 
A significant body of literature has been published on the outcomes of refractory malignant 
pleural effusions (MPEs) with several mortality prognosis models available which can be used to 
predict prognosis in the individual patient.  The LENT score is a prospectively validated scoring 
system using patient characteristics, including pleural LDH, ECOG performance status, neutrophil 
to lymphocyte ratio and tumour site, to predict survival (58). More recently, the PROMISE score 
was introduced, an 8 variable prospectively validated model that can accurately predicts 3-month 
mortality in MPEs(59). However, the overall impact of refractory NMPE, as well as long-term 
outcomes are less studied.   
The presence of pleural effusion in patients with heart failure may not, by itself to be a poor 
prognostic marker. A study looked at the effect of small incidental pleural effusion, identified on 
transthoracic echocardiogram (TTE), including 141 patients with heart failure(60), found good 
overall 5-year survival of 70%. However, there was no comparator group of patients without 
pleural effusions and the patients were typically young (mean age 60 years of age) and with 
preserved ejection fractions. A prospective case controlled study of 100 patients with heart 
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failure, 47 with pleural effusion and 53 without, concluded that an accompanying pleural effusion 
did not predict mortality(61). This patient cohort appeared to have well controlled pleural disease, 
with only 3 patients requiring thoracentesis. A recent large retrospective Spanish study of 3245 
consecutive inpatients with a primary diagnosis of acute decompensated heart failure (ADHF) 
appears to support these findings. Whilst pleural effusions were common, present in 46% of these 
patients, it was not independently predictive of 1-year mortality(29). 
 
Refractory transudative effusions, defined in this context as transudative effusions requiring an 
invasive therapeutic pleural procedure, do however, appear to have much poorer outcomes. A 
prospective cohort study examined survival in 308 patients undergoing thoracentesis, 226 of 
which had a non-malignant aetiology(62). It found that found that patients with effusions 
secondary to heart failure had a 1-year survival of 53% compared to 77% in malignant effusion 
(62), and also demonstrated that all patients undergoing thoracentesis for pleural effusion have 
high short- and long-term mortality. 
 
 
1.1.5. Management of the refractory transudative effusion  
As described above, 10% of pleural effusions secondary to CHF and 25% of effusions secondary to 
liver failure are thought to be refractory to medical management. In this PhD we define refractory 
transudative effusions as transudative effusions which require an invasive pleural procedure to 
alleviate symptoms.  
The high diuretic dosage used in the pursuit of reducing the size of pleural effusion and improving 
symptoms can lead to significant side-effects, including acute kidney injury, other electrolytes 
disturbances and postural hypotension. When medical management fails, patients will often 
require a therapeutic aspiration Repeated pleural aspirations, can often only provide transient 
relief and can cause complications such as an associated risk of pain bleeding, infection and other 
complications(63). Thoracentesis is additionally complicated by the fact that many of these 
patients are on a form of oral antiplatelets or anticoagulation, which increases procedural risks. 
The cumulative risk of repeated thoracentesis has been shown to be particularly high in patients 
with hepatic hydrothorax. A comparative case-control study of 82 patients with hepatic 
hydrothoraces demonstrated increased cumulative risk of complications with sequential 
thoracenteses. A complication occurring in the preceding intervention was the strongest predictor 
for subsequent adverse event (OR=17.1, p=0.0013) (64). 
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An alternative strategy is the insertion of a chest drain and instillation of talc pleurodesis. It has 
approximately a  70% success rate in controlling effusions in malignant disease(65), however it 
has not been prospectively studied in patients with non-malignant disease(66-68).  One 
retrospective study of patients with effusions secondary to CHF demonstrated a 75% pleurodesis 
success rate with talc slurry(67). These patients were managed with a combination of large bore 
(n 9) and small bore (n 7) drains. However, it was limited by small sample size of 16, and variable 
follow-up, ranging from 2 months to 3 years. In patient with liver failure, talc pleurodesis is usually 
reserved in patients without ascites and in whom no other options exist(41), as it thought that 
the volume of flow  of ascitic fluid is typically too great to allow time for pleural apposition. The 
combined success rates in case series of patients with hepatic hydrothorax, is approximately 50%, 
which compares unfavourably to the use of talc in MPE(41). 
Indwelling pleural catheters have been shown to be an effective method of controlling pleural 
effusions in malignant disease(2, 69, 70). The evidence base in non-malignant disease is less clear, 
with no randomised studies examining the efficacy of IPCs for these patients. Herlihy et al 
published the first case series on the use of Pleurx® IPC in 5 patients with refractory pleural 
effusion secondary to CHF, demonstrating that the catheter effectively controlled the effusions 
and symptoms(71). However, 2 patients developed pleural infection, one of whom died of 
resultant sepsis. This was a very small case series (n 5) of a very heterogenous group (oldest 
patient was a 92 year old women, youngest a 20 year old man) of highly selected patients and 
limited conclusions can be made from the results.  
Srour et al published a prospective study in patients with cardiogenic pleural effusions, inserting 
43 IPCs in 38 patients (72). This study demonstrated an improvement in breathlessness and a 
proportion of these patients (29%) achieved spontaneous pleurodesis. The study protocol was 
mindful of minimising catheter infections, with drainages performed by trained home-care 
personal with rigorous outpatient monitoring, which may partially explain why there were no 
incidences of empyema. The patients had to see a quaternary centre cardiologist to determine 
failure of maximal medical therapy prior to enrolment.  
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Figure 1. Indwelling pleural catheter with suction bottle attached  
 
Freeman et al preformed a retrospective cohort analysis on 80 patients with recurrent cardiogenic  
effusions, in which 40 patients receiving talc poudrage and 40 patients IPCs (66). They defined 
adequacy of palliation based on reintervention rates, with similarly low reintervention rates in the 
poudrage (5%) and the IPC (2.5%) cohorts. It must be noted that the talc poudrage arm was 
performed under thoracoscopy, with contralateral single lung ventilation under general 
anaesthetic via a single port. This is not a standard method of performing talc instillation, 
particularly with medical patients, and could explain the low rate of reintervention in the talc arm. 
The stated hospital length of stay was significantly shorter and the readmission and complication 
rate lower in the IPC cohort. However, the overall length of follow-up was short in both talc 
poudrage arm (7 ± 3 months) and IPC (6 ± 3 months). This study was also limited by its 
retrospective study design.  
Majid et al examined in a retrospective cohort study 36 patients (43 IPCs placements) with 
cardiogenic effusions. Thirteen patients underwent medical thoracoscopy with talc poudrage, 
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followed by IPC insertion (Group 1). This procedure was performed under ‘moderate sedation’ 
with continuous monitoring by an anaesthetist. The patients had between 4 to 8 g (mean 5g) of 
talc instilled, which is greater than the typical amount used in the UK. At the end of the procedure 
both the IPC and the 24Fr chest tube introduced though the thoracoscopy cannula were left on -
20cm H20 suction until their combined drainage was less than 24 hours. This was not, therefor a 
day-case procedure.   The other 23 patients had standard IPC placement (Group 2)(73). 
Pleurodesis rates were higher in Group 1, with 80% achieving pleurodesis at a median time 11.5 
days, compared to a 25% pleurodesis rate at a median time of 66 day in Group 2. There were 3 
cases (7%) of cellulitis, two in Group 1 and one in Group 2, and 2 cases of pleural infection, both 
in Group 2, which were managed successfully with antibiotics and fluid drainage via catheter. The 
6-month readmission rates were higher in the group 2 (31) than group 1 (15). There was also 
higher number of subsequent therapeutic thoracentesis needed in group 1 (63) than group 2 (33). 
This study was limited by its retrospective and non-randomised study design, with unequal 
number of patients in each cohort (n 13 in group 1 and n 23 in group 2). This invariable lends itself 
to selection biases. Ten patients in group 2 had systolic heart failure compared to 3 in group 2. 
Patients with higher NHYA dyspnoea scores were assigned to the IPC-only group. Additionally, the 
median serum NT-proBNP was markedly different, at 2,780pg/ml in group 1 and 4,764pg/ml in 
group 2. This selection bias makes a true comparison between the two groups difficult. As 
mentioned above, the pleural fluid drainage regime in group 1 was more intensive than is 
generally performed in similar studies. This could all explained the higher pleurodesis rates in 
group 1.  
For hepatic hydrothoraces, there has  been one prospective study(74) and several recent 
retrospective case series(50, 75). A prospective study by Chen et al examined 25 IPC placements 
in 24 patients, and demonstrated a spontaneous pleurodesis rate of 33%, with a mean duration 
of 131.8 days. Pleural infection occurred in 4 in 24 patients, requiring drain removal in 3 patients, 
although there was no associated mortality from sepsis. This was a non-randomised feasibility 
study, and as such is limited by confounders and selection bias. It is unclear how many patients 
were lost to follow-up, although at least one is mentioned in the narrative. No average duration 
of follow-up was provided, and it is unclear how long the subjects were followed up beyond the 
stated clinical follow-up of 2 and 6 weeks.   
Kniese et al conducted a retrospective review of 62 patients with IPCs, with 5 of 62 patients 
achieving pleurodesis at a mean of 118 days. There was a high rate of infection, with 10 of 62 
patients developing empyema, and 3 patients dying from sepsis. There were several 
methodological limitations in the study. There was no standardised drainage regime, reasonably 
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high rates of losses to follow-up (8%) and no documented mean follow-up period. Additionally, 
the only follow-up data was from visits to their own institution and death was recorded as a 
composite end-point of actual date of death or discharge to hospice.  
Shojaee et al conducted a retrospective multicentre study on 79 patients, in which 22 patients 
achieving pleurodesis at a median time of 55 days(75). Again, pleural infection rates were high, 
with 8/79 (8%) of patients developing pleural space infection, 2 of whom died from sepsis.  The 
majority of the IPCs (73%) were inserted with palliative intent, as opposed to a bridge-to-
transplant, and likely represented a very unwell patient cohort. The study was limited by its 
retrospective design and was at high risk of selection bias. All participating institutions were at 
least tertiary care level and may not be generalisable to the overall cohort of patients with HH or 
the level of expertise generally available.  Mean follow-up durations were also not provided.  
As a general point, the reported pleurodesis rates in patients with HH managed with IPCs may be 
overestimated. Most catheters are removed after liver transplant and may be related to 
resolution of portal hypertension, as opposed to pleural space symphysis.  
Indwelling pleural catheters have not been studied extensively in renal failure. One series 
examined the use of IPCs in 8 patients with end-stage renal disease, 7 on whom were on dialysis 
(6 haemodialysis; 1 peritoneal dialysis) (76). The effusions were secondary to a wide range of 
aetiologies (diastolic heart failure/overload, uraemia, peritoneal dialysis and undetermined) 
Breathlessness improved in these patients with a spontaneous pleurodesis rate of 37.5% after a 
median duration of 77 days. This study was limited by its small number of cases, case series design, 
and comprised of a retrospective review of a mostly prospective collected data set.  
A systematic review  identified 13 studies, composed of case series and retrospective reviews, 
concluding that the IPC is effective and a viable option in the management of patients with 
refractory benign pleural effusion(77). Overall, the average rate of spontaneous pleurodesis was 
51.3% (95% CI, 37.1%-65.6%) which is comparable to the pleurodesis rates for IPCs in MPE(78). 
The average rate of all complications was 17.2% (95% CI, 9.8%-24.5%) with empyema developing 
in 2.3% (95% CI, 0.0%-4.7%) of cases. The review concluded that the quality of evidence to support 
the IPC use for BPE was low, and recommended future high-quality RCTs.  The paper was limited 
by several methodological limitations. Its only included papers, for unexplained reasons, from 
January 2011, although there were relevant studies published before this. No date was given 
when the initial literature search was made, and a full search criterion was not detailed.  No details 
were provided if more than one author was included in the screening and selection of papers. The 
study protocol was not published prior to publication on the PROSPERO database, which is 
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desirable in systematic review. The analysis was limited by the inclusion of entirely non-
randomised studies, with significant heterogeneity between studies.   
In summary, with the management of MPE there have been efforts to individualise the patient 
pathway, with options determined by patient choice, disease characteristics including the rate of 
recurrence, presence of trapped lung, and predicted prognosis (79). Presently for NMPE, there is 





1.2. The Pneumothorax 
“I could keep this knight from dying and I feel sure I could save him if I had a reed” Von Eschenbach 
1210 
Pneumothorax, the abnormal collection of air in the pleural space can occur as a result of external 
injury (traumatic) or in its absence (spontaneous). Traumatic pneumothoraces can be sub-
classified as iatrogenic when the trauma is a result of a medical intervention. Spontaneous 
pneumothorax is typically subdivided into patients with no apparent underlying lung disease 
(primary spontaneous) or in the presence of lung disease (secondary spontaneous). 
The pneumothorax has been described since antiquity. A clinical sign of pneumothorax 
‘Hippocratic succussion’ where on shaking a patient a splashing sound was heard, due to a 
hydropneumothorax, was documented as early as the 5th century BC by Greek Physicians. 
Traumatic pneumothoraces account for most of these early descriptions, as a consequence of 
chest wall trauma from violence, and is described from wounds since Graeco-roman antiquity(80). 
Unfortunately, open chest wounds were generally considered at the time to be fatal, and no 
intervention apart from wound packing was typically attempted(81).    There are suggestions in 
historical literature that individual surgeons attempted to aspirate the pneumothorax. A 15th 
century illustrated surgical textbook in the Turkish–Islamic  (Imperial Surgery) appears to 
demonstrate a procedure known as “mihceme” (aspiration by negative pressure), where a  flame 
was placed in a glass to burn the oxygen, creating a vacuum, forming a simple form of 
pneumothorax aspiration(82). A possible description of tube thoracostomy was made by Wolfram 
von Eschenbach’s Parzival, written between 1210 and 1220, where he describes the use of a reed 
inserted into a chest wound inflicted on a wounded knight named Uriens during a joust ‘I could 
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keep this knight from dying and I feel sure I could save him if I had a reed… He grasped a branch 
of the linden tree, slipped the bark off like a tube – he was no fool in the matter of wounds – and 
inserted it into the body through the wound… The hero’s strength revived so that he could speak 
and talk again.”(83)  
Spontaneous pneumothorax (SP) was not identified as a medical complaint until more recently, 
as its presentation was typically less obvious. Jean Marc Gaspard Itard (1774-1838) first used the 
term pneumothorax in his thesis ‘Dissertation sur le pneumo-thorax ou les congestions gaeuses 
qui deforment dans las la poitrine’, published in 1803(84).   At that time, it was almost ubiquitous 
to pulmonary TB, with a report 1880 accounting 78% of 916 patients with SP to tuberculosis. This 
demographic changed with time and in 1932, a Swedish physician described what we would 
typically consider a primary spontaneous pneumothorax (PSP), characterised by  a male 
predominance, association with cigarette smoking, and an asthenic, leptosomic, or ectomorphic 
body habitus, and emphasized the importance  subpleural bleb disease(85).  
During this time, medically induced pneumothoraces became common after a chance observation 
of symptomatic improvement of tuberculous after spontaneous pneumothorax. This led to the 
practice of inducing an artificial pneumothorax by pumping filtered compressed air or nitrogen 
into the pleural space. The perceived benefits were thought to be either due to resting the lung, 
mechanical pressure permitted the drainage and closure of tuberculosis cavities or preventing 
spread of the bacteria to other parts of the lung(86, 87). Carlo Forlanini induced the first artificial 
pneumothorax in 1888, and went on to publish 25 cases(88). This practice continued until the 
1950s, when anti-tuberculous medical treatment became available(88). Inadvertently, this 
procedure demonstrated that patients could comfortably tolerate a unilateral pneumothorax. 
Indeed throughout the early 20th century, the treatment of PSP was predominantly conservative, 
with bed rest for most patients, with invasive treatment reserved for severely symptomatic 
episodes(89). Observational studies on PSP patients demonstrated that the majority of patients 
recovered without the need of invasive intervention (90). Moreover, it was suggested that 
patients managed with a conservative approach had a lower risk of recurrence, due to enhanced 
healing of the pleural defect when the lung was in a collapsed state. However, despite these 
encouraging results with an expectant approach, chest tube drainage become the first-line 
approach, perhaps due to increasing ease of insertion. In the 1980s various authors advocated 
performing needle aspiration, using a using a narrow lumen catheter, to avoid chest tube insertion 
and lengthy hospital stays  (91-94). Comparative studies between chest drainage and needle 
aspiration dominated pneumothorax research during the 1990s and 2000s(95-100). A different 
approach was suggest in the 1960s, with Dr Henry Heimlich describing the attachment of a one-
- 34 - 
 
way flutter valve to the chest drain to facilitate ambulatory management of the 
pneumothorax(101). This appear to be a safe and effective way of managing the pneumothorax, 
however there was little subsequent research to fully support its use. 
This thesis will explore several aspects of the natural history and management of the 
pneumothorax, including the role of conservative management in traumatic pneumothorax, the 
rate of recurrence in PSP, and the role of ambulatory management in secondary spontaneous 
pneumothorax.  
 
1.2.1. Spontaneous pneumothorax  
Pneumothorax is defined as air in the pleural space(102) and is traditionally categorised into 
spontaneous or traumatic. The spontaneous pneumothorax occurs without preceding trauma and 
is further sub-categorised into primary or secondary, depending on the absence or presence of 
underlying lung disease respectively. Traumatic pneumothoraces arise as a result of direct or 
indirect trauma to the chest. When these occur from a medical procedure, the term iatrogenic is 
used.  
Spontaneous Pneumothorax are categorised into primary or secondary, depending on the 
absence or presence of underlying lung disease respectively. Primary Spontaneous Pneumothorax 
(PSP) has an annual incidence of 7.4 per 100,000 population in males and 1.2 per 100,000 in 
females(103). The annual incidence of Secondary Spontaneous Pneumothorax (SSP) is 6.3 per 
100,000 population in males and 2.0 per 100,000 in females(103). There is a bimodal distribution, 
with a peak incidence in young people aged 15-34 and another in those aged over 55(104). These 
peaks are often associated with PSP and SSP respectively. Smoking is the most important risk 
factor in PSP. The relative risk of a first primary spontaneous pneumothorax is increased 22-fold 
in men who smoke compared to non-smokers and nine-fold in women, with a lifetime risk of 
developing pneumothorax of 12% in smoking males compared to 0.1% in non-smoking 
males(105). There is a strong dose-response relationship between the risk of pneumothorax and 
number of cigarettes smoked per day (105).  
Historically, PSP and SSP have been divided into two separate pathophysiology. Secondary 
Spontaneous Pneumothorax, a pneumothorax which occurs in patient with known lung disease, 
occurs in a spectrum of diseases and the pathogenesis is multifactorial. Airways disease (COPD, 
asthma, cystic fibrosis) are the most common underlying disease, though infectious lung disease 
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(Pneumocystis Jiroveci, tuberculosis, necrotising pneumonia), interstitial lung disease, connective 
tissue disease and cancer can be underlying causes (106). 
 
1.2.2. Primary Spontaneous Pneumothorax (PSP) 
Primary Spontaneous Pneumothorax is categorised by the absence of apparent lung disease. It 
has, however, become clearer that the majority of patients with PSP have evidence of lung 
abnormalities, such as emphysema-like changes (ELC), subpleural blebs and bullae.  These ELC 
were identified in a case control series on CT in 81% of non-smokers with PSP, compared with 0% 
in a case control of healthy volunteers(107).  
These lung abnormalities, identified on CT and thoracoscopy, are thought by many to be 
responsible for pneumothorax and are often the target for surgical management. It has been 
hypothesised that there is progression from normal pleural to blebs to the larger bullae which can 
then rupture(108). This view, however, is not universal, with many patients not having detectable 
blebs(109). Furthermore studies comparing appearance of blebs and bullae between first episode 
of PSP with those in recurrent PSP using medical thoracoscopy did not find any significant 
difference in size, number or locations in the blebs and bullae, suggesting they might not be major 
risk factors (110). The concept of pleural porosity is another mechanism which has been proposed 
in the formation of a pneumothorax, in additional to macroscopic changes. This hypothesis was 
investigated by Noppen et al.(111) using Fluorescein during thoracoscopy to visualise 
parenchymal abnormalities of the visceral pleural to determine whether this was localised to 
blebs. Extensive subpleural fluorescein accumulation and fluorescein leakage were exclusively 
present in PSP and were not necessarily associated with blebs or bullae or other abnormalities 
visible with white light inspection. They describe this as pleural porosity, postulating that loss of 
surface mesothelial cells, thinning and rupture of the basement membrane, and/or down-
regulation of junctional proteins may play a role. The concept of diffuse pleural porosity may 
explain the reported significantly higher recurrence rates if pleurodesis of some form is omitted 
during Video-Assisted Thoracoscopic Surgery (VATS)(112).  
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Figure 2. Right sided pneumothorax (lung edge marked with arrows) 
 
Pneumothorax is a heterogeneous condition, influenced by individual modifiable and non-
modifiable risk factors and pathophysiology, and accordingly should be managed in a personalised 
way.   
The immediate management of the spontaneous pneumothorax is determined by several factors. 
If the patient is haemodynamically unstable or has bilateral pneumothoraces, then a chest drain 
should be inserted as first line(113). If tension pneumothorax is suspected this this should be 
managed with needle decompression and chest drain. 
For all other pneumothoraces, the management pathway is outline by the ATS Delphi consensus 
2001 (114) and the BTS guidelines 2010 (113) as determined by: 
a) Whether the pneumothorax is deemed as primary or secondary. 
b) Presence of symptoms 
c) Size of the pneumothorax on chest film 
If a patient has a PSP, is asymptomatic and has a small pneumothorax, then a conservative 
management plan of monitoring is advocated by the BTS(113). The rate of resolution of an 
untreated PSP has been calculated on CT volumetry at 2.2% per day(115).  The use of high flow 
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oxygen in pneumothorax has been showed to speed up the resolution of PSP fourfold when 
patients are admitted for observation(116). 
If the patient is symptomatic, or has a large pneumothorax, an intervention to remove the air 
from the pleural space is advised. The ATS and BTS differ on the definition of a large 
pneumothorax. The ATS suggests >3cm from the apex of the hemidiaphragm to the cupula(114). 
The BTS defines a large pneumothorax as >2cm from lung margin to chest at the level of the 
hilum(113).  
The BTS suggests that if the pneumothorax is large, or the patient symptomatic then simple 
aspiration should be attempted. If this is not successful then the clinician should proceed to chest 
tube insertion, with a recommendation that a small bore (<14 French) Seldinger chest drain 
should be used(113). The ATS advocate proceeding directly to chest tube insertion(114). The 
rationale behind the BTS guidance  are studies(95, 99) and meta-analyses (117-119)that suggest 
that simple aspiration is as successful in treating pneumothorax, and led to fewer bed days.  It is 
recommended that if greater than 2.5L of air is removed via simple aspiration that the physician 
should proceed to chest tube, as it is likely that there is a persistent air-leak (113). 
 
 
1.2.3. Secondary spontaneous pneumothorax (SSP) 
Secondary spontaneous pneumothorax (SSP) refers to a pneumothorax in the presence of known 
underlying lung disease. Many diffuse lung diseases can cause an SSP, with COPD being the 
commonest cause, accounting for around 70% of cases(120). The risk of pneumothorax appears 
to increase with worsening COPD; around 30% of all patients with SSP have an FEV1 below 
1L(121). There also appears to be an association between SSP and increased quantity of CT 
emphysema in patients with COPD(122). The peak incidence of SSP occurs later in life than PSP, 
between 60 and 65, paralleling the peak incidence of chronic lung disease in the general 
population(123).  
Rupture of an emphysematous bullae is the usual cause of SSP, typically at the apex of the 
lung(124). However, unlike PSP, this ruptured bulla can occur anywhere along the lung surface. In 
26% of cases of right sided SSP associated with emphysema, the ruptured bullae responsible for 
pneumothorax is found in the azygoesophageal recess (AER). COPD can cause expansion and 
deformation of the thorax, causing protrusion of the AER into the right thorax, promoting bullae 
- 38 - 
 
formation.  This phenomenon may explain why right sided pneumothoraces are more common in 
patients with SSP (125, 126). 
The requirement for emergency transportation to hospital, hospital length of stay, and in-hospital 
mortality in patients with SSP is greater compared to patients with PSP (125). The mean length of 
stay in a large French epidemiological study for males with SSP was 12.1 days (SD 14.5) compared 
to the PSP length of stay of 5.9 days (SD 6.7)(127). Patients with SSP are more likely to experience 
a recurrent pneumothorax than those with PSP, with a reported rates of 39-47%(121). This is 
presumable as a result of more severe underlying lung pathology and incomplete wound healing.   
The guidance for SSP is similarly based on the size of pneumothorax and symptoms as the 
management of PSP is. Symptomatic patients or those with large pneumothoraces should have 
chest tube inserted. The BTS suggest if a patient is asymptomatic and the pneumothorax is 
between 1-2cm simple aspiration can be attempted. If the pneumothorax is smaller than 1cm 
then admission with observation is recommended. It suggests all patients are admitted to hospital 
(113). 
The frequency of surgical interventions in the SSP patients is generally much lower than patients 
with PSP(125). An annual report of surgery in Japan showed only 2350 patients with 
pneumothorax secondary to COPD had surgery compared to over 11 000 patients with PSP who 
underwent surgical treatment in 2017 (128). This may be due to perceived risk of operating on 
patients with SSP, due to their poorer lung function, older age and comorbidities. Retrospective 
studies have shown morbidity rates ranging 15–27.7% and mortality rates ranging 0–5.5% in 
patients with SSP associated with COPD undergoing surgical therapy(124).  Passlick and colleagues 
described that postoperative complications occurred in 25% of patients with SSP compared with 
only 1.7% of patients with PSP(129). Patients with interstitial lung disease (ILD) appear to be at 
particularly high risk of post-operative complications, with one study demonstrating a significantly 
higher postoperative mortality rate in the ILD group (21.4%) than in the COPD group (1.4%; p = 
0.001)(130). This may be because the lung parenchyma in these patients are fragile and collapse 
easily due to high negative intrathoracic pressure, and the reported increase rates of exacerbation 
of ILD post-operatively.   
1.2.4. Tension pneumothorax  
Tension pneumothorax is an uncommon, life-threatening emergency. It can be defined (131): 
a) Clinically, in terms of haemodynamic compromise improved by decompression,  
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b) In terms of pleural pressures, with ipsilateral pleural pressures exceeding atmospheric 
pressure.  
c) Radiographically, with signs of mediastinal shift (although this can present in non-tension 
pneumothorax).  
 
A tension pneumothorax occurs from a pleural defect forming a one-way valve in the pleural 
membrane, with air entering the pleural cavity on inspiration but unable to exit on expiration.   
A tension pneumothorax can arise in a wide range clinical situation, including ventilated patients, 
trauma, CPR, patients with acute exacerbation of lung disease, blocked chest drains and patients 
receiving non-invasive ventilation. It rarely occurs in primary spontaneous pneumothoraces(113). 
The patient is often very symptomatic, in haemodynamic compromise, with decreased air entry 
the most common sign (50-75%). Trachea deviation always from affected lung, hyper-resonance, 
hypomobility and hyperexpansion occur less frequently(113). It is important to recognise the 
potential differences in the clinical presentation in the ventilated and non-ventilated patients 
(113). Diagnosis of tension pneumothorax in ventilated patients requires a high index of suspicion. 
Its presentation, however, is more consistent than in awake patients,  usually presenting with a 
sudden fall in Sp02 followed by hypotension over a few minutes (131),  with tachycardia, 
decreasing cardiac output, increased inflation pressures and ultimately cardiac arrest(113).  
Awake patients show a greater variability of presentation. They manifest compensatory 
mechanisms and generally have progressive respiratory deterioration with final respiratory arrest. 
The time lag from initial symptoms or thoracic insult to diagnosis ranged from a few minutes to 
over 16 hours(131).  The chest radiograph is not usually useful and can be misleading, with the 
size of pneumothorax and mediastinal displacement not correlating with the degree of 
tension(113).   
The management is high flow oxygen and prompt emergency needle decompression in the Mid-
Clavicular line (MCL), 2nd Intercostal Space (ICS), recommended prior the chest radiograph. A large 
study found the mean chest wall thickness of 2,574 healthy volunteers, as determined by MRI, 
was 5.7 cm on the right and 5.5 cm on the left side in the MCL, 2nd ICS(132), suggesting that a 7cm 
needle may be required(132).   A review article on tension pneumothorax recognised the standard 
14 gauge (4.5 cm) cannula may not be long enough to penetrate parietal pleura in up to one third 
of trauma patients, leading to treatment failure and diagnostic confusion(131). The use of the 
trocar instead (7 cm) may negate this problem and prevent kinking. The BTS recommend that if 
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needle decompression is not possible in the 2nd ICS, then the chest wall may be less deep in the 
fourth and fifth interspace and may be provide an alternative.(113) 
This should be followed-up by a chest tube, with the cannula left in place until bubbling is 
confirmed with an underwater seal system(113). 
 
 Traumatic Pneumothorax  
After rib fractures, traumatic pneumothoraces are the most common chest injuries in patients 
with blunt trauma(133). Approximately one in four blunt traumatic fatalities in North America are 
a direct consequence of chest injuries(134). Blunt trauma to the abdomen may also precipitate a 
traumatic pneumothorax(135). 
 
Traumatic injury to the pleura can lead to air accumulation in the pleural space. Additionally, a 
fifth of traumatic pneumothorax patients have an accompanying haemothorax(136). Whilst an 
uncomplicated traumatic pneumothoraces may be well tolerated, the risk of  tension and 
resultant cardiorespiratory compromise makes identification important, particularly as a simple 
procedure, tube thoracostomy insertion, can potentially avert significant morbidity and 
mortality(134). Because of this, the current guidance by the American College of Surgeons 
Advanced Trauma Life Support (ATLS) advises chest tube placement for any traumatic 
pneumothorax(137). It does state asymptomatic pneumothoraces can be managed with 
observation and aspiration at the treating physician’s discretion and it has been previously 
proposed that small traumatic pneumothoraces can be managed conservatively.  
An early retrospective study of 54 patients demonstrated no clinical deterioration in patients with 
small or moderate sized traumatic pneumothoraces, in the absence of other significant injuries or 
the need for intermittent positive pressure ventilation (IPPV) (138). Another larger study studied 
patients not on IPPV with small unilateral traumatic pneumothorax (<1.5cm on CXR) who were 
managed conservatively. Of the 803 patients, 329 (41%) were treated conservatively and 29 (9%) 
required chest tube placement due to pneumothorax enlargement(139). IPPV, which increases 
gas flow through the pleural defect, is thought to increase the risk of tension pneumothorax (131). 
Because of this, the ATLS recommend that all patients with a traumatic pneumothorax on IPPV 
are treated with chest tube drainage (137)..  
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This concept has been challenged, principally due to the increased use of computerised 
tomography (CT) scans in trauma which identify small, sub-centimetre sized pneumothoraces. 
This has raised the question whether these small ‘occult’ pneumothoraces, which can make up to  
76% of all traumatic pneumothoraces(140), can be left untreated, particularly when invasive 
positive pressure (IPPV) is required.  Despite early studies indicating a high rate of tension in 
conservatively managed patients on IPPV (141), more recent studies (133, 134, 140, 142, 143) 
suggest that occult pneumothoraces can be managed expectantly, including patients undergoing 
IPPV. 
Whether these results can translate to all traumatic pneumothoraces is unclear and needs 
clarification. With increasing availability, the CT is now almost ubiquitous in multiple trauma 
patients, and the distinction between occult and overt pneumothoraces may become antiquated. 
Recent case studies have also suggested it may possible to treat larger pneumothoraces with 
observation (144, 145).  
 
1.2.5. Managing persistent air leak and failure to re-expand   
 Suction 
Routine use of early suction in not recommended by the BTS guidelines (113). A small randomised 
control trial found no significant difference in the rate of lung re-expansion or duration of hospital 
stay with suction compared to no suction(146)  
There may be a role for the use of high volume, low pressure suction in the persistent air-leak 
(arbitrarily defined as continued bubbling greater than 48 hours after chest drain insertion) or 
incomplete re-expansion of the lung, the theory being that the air may be removed from the 
pleural cavity at a greater rate than it enters via the visceral membrane.  The use of suction too 
early can precipitate re-expansion pulmonary oedema, particularly if the pneumothorax has been 
present for more than a few days. High pressure high volume suction may lead to perpetuation 




The BTS recommends that a thoracic surgical opinion should be sought in cases of persistent air 
leak or failure of the lung to re-expand after 3-5 days. 
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The timing of surgical intervention is debated. A study by Chee at al showed that 100% of PSP, 
and 79% with SSP, with persistent air leak of more than 7 days treated with intercostal drain (ICD) 
resolved by day 15 and 14 respectively, with no associated mortality(147). However, surgery 
carries a low morbidity risk, and has good success rates.  
There are two main types of surgery, thoracotomy and VATS, with both performed under general 
anaesthetic (GA). There are several approaches to thoracotomy, either the standard 
posterolateral thoracotomy or methods using smaller incisions, such as axillary thoracotomy, 
anterior thoracotomy or various mini-thoracotomies (106). The procedure consists of excision of 
blebs and bullae, usually via stapling and treatment of smaller bullae with electrocoagulant or 
laser(106). Usually the surgeon will perform a pleurodesis, either by a parietal pleurectomy, or a 
mechanical abrasion of the parietal pleura with gauze. Some surgeons perform a chemical 
pleurodesis. VATS is performed under GA with single lung ventilation. Generally, three ports, a 
thoracoscope and two lung graspers, are inserted, with the patient in the lateral decubitus 
position. The same intrathoracic procedure can be performed by VATs as via open thoracotomy 
(106).  
Analysis of RCTs demonstrated equivalent success rate between VATS and thoracotomy, with 
reduction in analgesia use and shorter hospital stay in the VATS cohort (148). A recent RCT 
comparing mini-thoracotomy with VATS showed equivalent recurrence rates (2.7% and 3%, 
respectively) and postoperative pain, but VATS was associated with higher patient satisfaction. 
(149). A large prospective cohort study of 1415 patients undergoing VATS with talc poudrage 
found a recurrence rate of 1.9% and a complication rate of 2%. Interestingly the recurrence rate 
was much higher in smokers (4.2%) compared to non-smokers (0.2%)(150).  
Accepted indications for surgical advice are shown in Table 1. 
 
Table 1. Indications for surgical opinion in management of pneumothorax (113)  
Second ipsilateral pneumothorax 
First contralateral pneumothorax  
Synchronous bilateral spontaneous pneumothorax 
Persisting air leak (despite 5-7 days of chest tube drainage) or failure of lung-re-expansion  
Spontaneous haemothorax 




Pleurodesis either by chemical irritant, mechanical abrasion, or parietal pleurectomy, aims to 
achieve adherence of the pleural membranes by promoting inflammation. Chemical pleurodesis 
by a sclerosing agent can be delivered by chest tube, medical thoracoscopy, or VATS.  
Chemical pleurodesis with intrapleural administration via a chest tube has been investigated with 
several agents, including antibiotics (minocycline, tetracycline, and doxycycline) and talc 
preparations. It is a suitable option for patients ineligible or unwilling to have surgery, after 
assessment by a respiratory specialist. It has been suggested that chemical pleurodesis is an easy, 
safe, and cost-effective approach for the treatment of spontaneous pneumothorax and could be 
considered as an initial treatment of PSP(151). It has the advantage of being administered by the 
bedside, however potential drawbacks of uneven distribution of talc and the potential for only 
localised symphysis at the site of administration (152).  A randomised trial investigating the use 
of minocycline pleurodesis via chest drain versus chest drain with no pleurodesis in patients with 
PSP showed lower recurrence rates 29.2% vs 49.1% in the minocycline pleurodesis arm(153). It 
has been commented that this trial however had a higher recurrence rate in the control group 
compared to other studies, and compared unfavourably with surgical options(154).  
Talc delivered by medical thoracoscopy under direct vision has good long-term success rates. In a 
randomised control trial in patients with PSP, talc poudrage via medical thoracoscopy had a lower 
recurrence rates when compared to chest tube alone (5% vs 27% respectively) and was more cost-
effective(155).  
 
1.2.7. Prevention of recurrence and risk stratification 
As mentioned in the previous section, surgery and talc poudrage have both been shown to 
dramatically reduce recurrence. The decision to perform a definitive invasive procedure is based 
on the risk of recurrence, and the potential consequences if this occurs. Currently most centres 
wait until the second presentation of PSP before considering definitive management, though it is 
often considered earlier in patients with SSP, due the potentially life-threatening risk of a 
recurrence. However, the decision is made difficult due to a wide range in the quoted recurrence 
Professions at risk (aircraft personal, divers) 
Pregnancy 
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rates, from 13.5–54% (153, 156, 157) and limited data on how individual risk factors affects this. 
The studies examining recurrence have differing methodologies and include epidemiological and 
prospective randomised studies with varied inclusion criteria, timescales and definitions of 
recurrence.   
There are two main sources of determining pneumothorax recurrence.  Clinical studies, either 
randomised or non-randomised, often cite recurrence as a study outcome. Population or 
epidemiological studies obtain from hospital statistics can provide long-term follow up outcome 
data. Both have their prospective advantages and disadvantages. The generalisability of clinical 
studies will be influenced by their inclusion criteria and findings are generally only applicable to 
the populations studied. Their findings will be determined by the study design and their internal 
validity. Specifically, the length of follow-up will have significant influence on the recurrence rate. 
However, clinical studies do have strengths. The follow-up data should be robust, and the 
patient’s characteristics and the interventions received should be clearly recorded. 
Epidemiological studies have the capacity to examine much larger population, and usually for 
longer durations. However, the data is strongly influence by the quality of clinical coding and data 
collection. Clinical coding does not distinguish between PSP and SSP and researchers must rely on 
co-morbidities also being coded. Additionally, these data sources only provide information on 
patients admitted to the hospital, and do not include patients managed in the community.  
In a recent prospective cohort study of 234 consecutive patients with their  first episode of PSP 
admitted and treated conservatively with a chest tube, recurrence was observed in 54% of 
patients, with 30% of these patients experiencing a pneumothorax in the contralateral lung(158). 
Conversely, a recent epidemiological study published by Hallifax et al found a five-year recurrence 
rate of male patients with PSP was 20.6 (20.1-21.1) The study used Hospital In-Patient Enquiry 
(HIPE) 1968-1985) and Hospital Episode Statistics (HES) 1990-2016,  identifying  170 929 hospital 
admissions in England for spontaneous pneumothorax  This risk was higher in the younger cohort 
of patients (15-34 years old of age) that are typically associated with PSP, at 22.0 (21.3-22.6) in 
males and 25.1 (23.8-26.5) in females. Another large epidemiological study by Bobbio et al 
examined 42 595 patients presenting to hospitals in France from 2008 to 2011 with both with PSP 
and SSP. It found that 28% patients had more than one spontaneous pneumothorax-related 
hospital stay over the 4-year period, with majority occurring within 1 year of the first recorded 
episode(127). 
Studies looking at SSP have found that 40-50% of patients will have a second pneumothorax if 
pleurodesis or definitive thoracic surgery is not performed(159). The rate of pneumothorax is also 
thought to increase with every subsequent recurrence. A study from 1963 found that the risk of 
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recurrence after first pneumothorax was 57%, 62% for second and 83% for the third(160). 
However this was only statistically different between the first and third recurrence (161).  
One of the aims in the management of pneumothorax should focus on the identification of 
patients likely to have a recurrence and hence who may benefit from early surgery. Height in men, 
female sex and low bodyweight are associated with increased rate of recurrence(156, 158). 
Smoking is associated with a high risk of recurrence, with smoking cessation after an initial PSP 
associated with a relative risk reduction of over 40% (156).  Since the rupture of blebs or bullae 
are thought to be the main cause of PSP, studies have investigated whether radiology can help in 
predicting the risk of recurrence, providing conflicting answers. A prospective Study by Martínez-
Ramos et al of 55 patients could not demonstrate that the presence, size, or number of bullae on 
CT scans had any influence on recurrence rate(162). A subsequent study using HRCT on 176 
patients with PSP found that the risk of recurrence was significantly related to the presence of 
blebs or bullae or both (163). Another study looked at the role of the Chest X-ray (CXR) in 
determining the risk of recurrence. They looked for radiological abnormalities on CXR including 
pleural thickening; blebs/bullae; pleural irregularities and pleural adhesions. They found that the 
found that the presence of an abnormality (irrespective of the type) increased the likelihood of 
recurrence and the risk of recurrence increased with each additional abnormality. They 
recommended surgical pleurodesis for first episode of PSP when multiple CXR abnormalities are 
identified at the time of diagnosis(164).  It has also been postulated that management of the initial 
PSP influences recurrence. There are advocates for each management pathway. Various authors 
suggest that inserting a chest drain creates pleural inflammation and promote prompt pleural 
apposition, leading to lower rates of recurrence. Conversely, advocates of conservative 
management suggest that allowing the lung to re-inflate gradually promotes greater wound 
healing and subsequent lower risk of recurrence(165). There isn’t enough evidence at the moment 
to determine if management affects recurrence, but the recently conducted Australian study 
comparing patients PSP randomised to either conservative or chest drain might inform on this 
(166). 
 
1.2.8. Evidence on best method of recurrence prevention 
Surgery is the definitive management to reduce recurrence. The two main types of surgical entry 
for pneumothorax management are thoracotomy and VATS to perform blebectomy of visible 
blebs. There is variation of practice on whether pleurodesis, either by pleurectomy or scleroscent, 
is performed.  Analysis of RCTs demonstrated equivalent success rate between VATS and 
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thoracotomy, with a recent RCT comparing mini-thoracotomy with VATS showed equivalent 
recurrence rates (2.7% and 3%, respectively) and postoperative pain(149).  The VATS is becoming 
more popular, due to lower lengths of stay and higher patient satisfaction scores. Patients 
managed with isolated blebectomy appear to have a higher rates of recurrence than blebectomy 
combined with a pleurodesis procedure, with one study of VATS demonstrating that patients 
treated with talc poudrage compared with subtotal pleurectomy alone or alongside ligation or 
stapling of bullae had a recurrence rate of 1.8% compared to 9.2%(167). This supports the concept 
of pleural porosity, proposed by Marc Noppen, who demonstrated with fluorescein imaging, that 
the air-leak in PSP is not isolated the blebs themselves, but via the surrounding inflamed 
pleural(111). 
Currently recurrence prevention surgery is recommended for patients who have had more than 
one recurrence. However, there are advocates for performing surgery as a first-line treatment at 
the patient’s initial pneumothorax. The study by Olesen et al examined performing surgery on 
patients with their first PSP, finding the risk of recurrence was 34% (32/93) in patients managed 
with chest drain compared to 13% (11/88) patients after VATS(168). This represented a number 
need to treat (NNT) of 4.8 patients to have surgery to prevent one recurrence(169). There were 
low reported adverse events with surgery, however they were no reported quality of life data 
included in this paper.  
Other non-operative methods of recurrence prevention include instillation of a pleurodesis agent 
via on the ward. A randomised controlled trial demonstrated that minocycline instillation reduced 
the risk of recurrence from 33.3% in the cohort managed with simple aspiration compared to 
12.9% in patients managed to instillation off 300mg of minocycline via a catheter(170). Talc can 
also be delivered by medical thoracoscopy under direct vision and has demonstrated good long-
term success rates. In a randomised control trial in patients with PSP, talc poudrage via medical 
thoracoscopy had a lower recurrence rates when compared  to chest tube alone (5% vs 27% 
respectively)(155).  
Smoking cessation advice should be given all patients. This decreases the risk of recurrence in 
both the medically, and surgically managed patients(171, 172).   
 
1.2.9. Recurrence prediction  
Presently there is no risk model calculator to determine a personalised recurrence risk for 
patients. There have been a lot of interest in using low-dose CT to determine recurrence risk, with 
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4 studies to date examining whether blebs increase the rate of recurrence in medically managed 
patients. (163, 173-175). These studies have produced conflicting results with two studies finding 
an association between radiographic evidence of blebs and recurrence risk and two studies not. 
A proposed dystrophic severity score (DSS), which assessed both blebs and bullae, appeared to 
be the most useful radiographic scoring system. It demonstrated high negative predictive value 
of >90% but a low positive predictive value of just 68% suggesting a possible value as a rule-out 
test(163). More recently Olesen et al’s study on first-line surgery suggested the benefits of surgery 
were best seen when high-resolution computed tomography demonstrated bullae ≥2cm(168). 
Another possible marker of recurrence is using air-leak data to identify high patients. Digital air-
leak data can provide accurate measurement of air-leak and there is evidence suggesting that a 
high air-leak predicts those patients who will require surgery for persistent air-leak, and there is 
ongoing work on whether this measurement can predict recurrence(176).  
 
1.2.10. Novel management strategies 
 Conservative management 
Conservative management is recommended for patients with a small asymptomatic PSP by the 
BTS (113). The guidelines suggest that selected asymptomatic patient with large PSP may be 
managed by observation alone. It has been hypothesised that the collapsed lung is more likely to 
heal, allowing apposition of the visceral leak sites(90). This is currently under investigation by a 
multicentre trial in Australasia, designed to compare ambulatory conservative management with 
standard management in asymptomatic patients with a large pneumothorax(89). 
Whilst the guidelines advise that the majority of traumatic pneumothoraces need chest tube 
drainage, particularly if IPPV is required, there is a growing literature base that suggests that small 
traumatic pneumothoraces can be managed conservatively including patients receiving IPPV (133, 
134, 140, 142, 143). 
 Use of Heimlich valve and pleural vents 
Approximately 6000 patients are admitted with spontaneous pneumothorax each year in England, 
with person-based admission rate of 11.6 per 100,000 population (95% CI, 11.3-11.9). The 
majority of these admissions are for  patients with chronic lung disease, with 59.4% of  males and 
64.5% of females having secondary spontaneous pneumothorax (177). Patients with SSP typically 
have a longer length of stay than patients with PSP, with one large epidemiological study 
demonstrating a more than double length of hospitalisation than the PSP (14.5 vs 5.9)(127). It is 
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anticipated that shortening the length of stay would reduce healthcare resource cost and increase 
patient mobility. This would be particularly important for patients with SSP, who will be a higher 
risk of complication from prolonged bed-rest.  
The attachment of a one-way flutter (Heimlich) valve to the end of a chest drain, instead of the 
standard underwater seal bottle, has been used since the 1970s(178). Various permutations of 
these devices are available, from the classic Heimlich Valve (HV), to devices which enable 
collection of fluid secretions from the chest drain, such as the Atrium Pneumostat chest drain 
valve.  More recently, self-contained valves, such as Tru-Close Thoracic Vent and Rocket Pleural 
Vent, have become commercially available, which have a catheter attached directly to the valve, 
and therefore do not require prior chest drain insertion. 
Despite being used for over 40 years, there have been limited published randomised controlled 
trials investigating the efficacy of a flutter valve in patients with a pneumothorax and none which 
have looked exclusively at patients with SSP. Two small RCTs have been performed examining the 
use of HVs on patients with pneumothoraces, the first by Roggla et al 1996 which examined 30 
patients with both spontaneous and iatrogenic pneumothoraces. It used a thoracic vent, a 
polyurethane catheter connected to a plastic chamber containing a one-way valve.  It found 
similar rates of lung re-expansion and complications compared to standard chest drain attached 
to an under-water seal attachment, with 70% of patients with thoracic vent successfully managed 
as outpatients(179). Ho and colleagues randomised patients with PSP to needle aspiration (NA) 
or minichest tube (MCT) insertion with Heimlich valve attachment in the Emergency 
Department(97).  The MCT consisted of a 12Fr drain with a Heimlich valve attached to the end. It 
defined two outcomes as its primary outcome, failure rate and admission rate. Failure rate was 
defined as recurrence of pneumothorax; need for a second procedure or need for surgical 
procedure, although they reported these outcomes separately. They estimated they wound need 
100 patients to detect a 25% difference in failure rate. They recruited 48 patients in total and was 
therefore underpowered to detect the differences they sought to find. The groups were not 
similar, with 65% of the NA group having a pneumothorax >5cm from apex, compared to 36% in 
the MCT group.  They found no significant difference in number of patients requiring another 
procedure (35% in NA group, 20% in MCT) and number of admissions from ED (52% in NA group, 
28% in NA). There was a significant difference between patients who had full resolution at their 
first outpatient review (at three days), with 6(24%) of MCT having full re-expansion, compared to 
1(4%) of those who had NA. When admissions from ED and outpatient clinic were combined, both 
groups had high admission rates, at 61% in NA group 44% in MCT group. Overall, the study was 
significantly underpowered to detect the differences they were interested in. There were, 
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additionally, multiple methodological flaws, with poorly defined and reported composite primary 
outcomes.  
A systematic review of ambulatory management in spontaneous pneumothorax examined 18 
studies, comprising of 2 RCTS and 16 non-randomised studies, and included 1235 patients, only 
10% of which were SSP (180). Overall success with a   HV was 86%, success in the outpatient 
setting was 78%. If this figure is replicated in larger studies, the paper suggests the adoption of 
this treatment could save nearly 12 000 bed days per year in England. Additionally, the systematic 
review concluded that complications were rarely reported in the literature.  
There have been no prospective studies which have specifically assessed the effect of HVs in 
patients with SSP. HVs have been shown to reduce levels of pain during activities for patients with 
pneumothorax compared with standard treatment(181) and they may offer significant 
advantages over standard treatment in enabling improved levels of mobility while patients are in 
hospital, with consequent advantages such as the reduction of rates of pneumonia and venous 
thromboembolic disease as well as enabling earlier discharge. Establishing the efficacy of HVs in 
patients with SSP may provide evidence for their use within an outpatient treatment pathway for 
SSP.  
A recent study evaluated the use of HV in patients with iatrogenic pneumothorax post lung 
biopsy(182). In patients with a large/symptomatic pneumothorax at 30 min post biopsy; enlarging 
pneumothorax at 60 min; or persisting or symptomatic pneumothorax, a 8 Fr drain was inserted 
and connected to a Heimlich valve chest drain (HVCD). There were no major complications, and 
the 8 of the 52 patients who HVCD-related pleuritic pain were successfully managed with 10 mL 
of intrapleural 0.5% bupivacaine. All patients had their HVCD removed within 48 hours. These 
results are encouraging, though may not translate to spontaneous pneumothoraces.   
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Figure 3. Flutter valves: a) Heimlich flouter valve b) Atrium Pneumostat c) Rocket Pleural Vent  
 
 
 Endobronchial valves 
Endobronchial valves (EBV), more commonly used as an alternative to lung reduction surgery in 
emphysema, have been used in patients with pneumothorax and a persistent air leak who are 
deemed not fit for surgical management.  These one-way valves inserted via bronchoscopy, aim 
promoting atelectasis of the distal lung, whilst still allowing drainage of secretions. The largest 
study into this was a retrospective, non-randomized study in 40 patient with pneumothoraces 
(iatrogenic, PSP and SSP) and demonstrated that 19 patients (47.5%) had complete resolution of 
acute air leak, 18 patients (45.0%) had reduction, and 2 patients (5.0%) had no change in air leak 
status.(183) This study was limited by with retrospective, nonrandomised design, which included 
a heterogenous population.  
 
 
 Air leak monitoring system 
Digital drainage systems have been used to allow real-time, continuous quantification of air leak.  
These devices have been studied in patients with post lobectomy chest drain, with several studies 
showing a reduction in chest drain duration in patient managed with  digital monitoring of air leak 
compared to a traditional protocol of using visual and subjective assessment of air leak (bubbles) 
(184-186) This was contradicted by a more recent study which showed no change in chest drain 
duration(187).  However, there are no published studies to date looking at the digital assessment 
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of air leak in medical patients with PSP or SSP, and caution most be used in applying post-surgical 
data, in which the outcome was chest drain duration. It is a reasonable suggestion that this is a 
more accurate way of quantifying the air leak than visual inspection of air bubbles in the chest 
drain bottle. It may allow earlier identification of patients whose leak is not settling and would 
benefit from early thoracic surgery. (152) 
 
 
Figure 4. Digital air leak monitoring system (Thopaz Digital Chest Drainage System; Medela Inc. 
Healthcare, McHenry, IL, USA). 
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1.3. Summary 
This thesis will explore the clinical course and progression of non-malignant pleural disease. It will 
focus on the two poorly understood disease processes, the refractory transudative pleural 
effusion and pneumothorax.  
There have been several studies examining the prognostic factors in MPEs, with limited 
comparable datasets on NMPE. The first study outlined in this thesis, survival in refractory 
transudative effusions will provide robust prospectively collected data in patients with pleural 
effusions secondary to organ failures to identify variables which offer prognostic information in 
this patient cohort. This is a first, important step in developing a prognostic model.  
The second study will use a prospectively collected dataset with patients with cardiogenic pleural 
effusions to determine the proportion of patients who required further therapeutic pleural 
procedures. 
The results of these two study, demonstrating poor median survival in patients with refractory 
transudative pleural effusions and high rates of refractory cardiogenic effusions, informed the 
design of the third study outlined in this study, a randomised control trial in this patient cohort, 
allocating participants to indwelling pleural catheters (IPCs) or standard management. The 
primary outcome, breathlessness, was chosen to reflect that symptom control is an important 
outcome in what is for many patients, a palliative condition. A randomised controlled trial design 
was chosen as the optimal way of comparing these two treatment arms.  
As outlined above, there are three main research questions regarding the management of 
pneumothoraces. Firstly, it is unclear what true rate of recurrence in patients who have 
experienced a pneumothorax, and a broad range is cited in the literature.  The fourth part of this 
PhD is a systematic review of papers detailing the incidence of recurrence of PSP, the sub-type of 
pneumothorax with the greatest literature base. The choice was made to examine studies on PSP, 
as opposed to studies with SSP, which is the focus of a later study in this dissertation, as there 
were not sufficient number of studies examining recurrence in SSP to form a valid systematic 
review. Patients with SSP are very unrepresented in clinical studies. 
There is increasing interest in managing pneumothoraces conservatively. To investigate this, the 
fifth study contained in this thesis is an observational study on patients with a traumatic 
pneumothorax (TP) to determine the safety of a conservative approach. This was a prospective 
collected study of patients presenting with TP to major trauma centre, examining clinical 
outcomes in patients managed with an intervention and conservatively. 
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Lastly, whilst a review of the literature suggests that use of an ambulatory devices is safe in the 
management of pneumothorax, there is no randomised data investigating efficacy in patients with 
SSP. The final study in this PhD is an RCT in the use of ambulatory devices in patients with SSP, 
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CHAPTER 2. METHODS  
In this chapter I will outline the study design of 4 non-randomised studies and 2 randomised 
controlled trial undertaken in this thesis. The studies design outlined are: 
• Survival in refractory transudative effusions 
• Natural history of cardiogenic pleural effusions 
• Randomised controlled trial evaluating the efficacy of indwelling pleural catheters in 
persistent non-malignant pleural effusions - the REDUCE trial 
• Results: Recurrence rates in primary spontaneous pneumothorax: a systematic review 
and meta-analysis 
• Conservative Management in Traumatic Pneumothoraces: An Observational Study. 





2.1. Study design: Survival in refractory transudative 
effusions.  
As describe earlier in the thesis, there is a wealth of studies investigating prognosis in exudative 
pleural effusions, with little comparable data in patients with transudative effusions. The use of 
prediction models are intended to help doctors make decisions by providing more objective 
estimates of probability as a supplement to other relevant clinical information (188). To further 
investigate the prognosis of patients with pleural effusions secondary to organ dysfunction, I 
conducted a prospectively observational study on 782 consecutive patients at North Bristol NHS 
Trust. This is the first stage, the development stage, of the consecutive stages to produce a usable 
multivariable prognostic model. It will be conducted to identify important predictors of prognosis 
in this patient cohort.  
I identified 782 consecutive patients in an observational cohort study, presenting with a new 
undiagnosed pleural effusion, to a single UK centre, between 03/2008 and 03/2015. The data was 
collected prospectively and retrospectively analysed. Patients were recruited as both inpatients 
and outpatients.   
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Pleural fluid and serum biochemistry, pleural cytology, thoracic ultrasound (TUS) and a chest 
radiograph were performed on all patients.  Echocardiogram, computerised tomography (CT) 
scans, radiological-guided biopsy and medical thoracoscopy were undertaken as clinically 
indicated. Patients were followed-up for a minimum duration of 12 months or until death, with 
the final diagnosis decided following independent review by two respiratory consultants. Where 
more than one aetiology was felt to be responsible, the principal contributing factor was listed 
first. There was a high level of inter-observer agreement, as calculated by kappa statistics, with a 
κ = 0.942 (95% CI, 0.917 to 0.967). The formula for CI for kappa:  k − 1.96 × SEk to  k + 1.96 × SEk, 
was used. SEk is the standard error of the kappa value and calculated as 0.013.    Patients were 
classified into diagnostic categories for analysis: malignant; CHF; liver failure; renal failure; pleural 
infection (empyema, complicated parapneumonic effusion, simple parapneumonic effusion, TB 
pleuritis); benign asbestos pleural effusion & diffuse pleural thickening (DPT); coronary artery 
bypass graft (CABG), pulmonary embolism, and other (including chylothorax, rheumatic, trauma 
and drug-induced). This was based on the following criteria: 
Malignant pleural effusion 
1. Malignant pleural fluid cytology or biopsy or  
2. Histologically confirmed pleural malignancy or extra-thoracic/pulmonary malignancy 
with radiographic evidence of metastasis to ipsilateral pleura on CT or  
3. Radiological changes meeting Leung’s criteria which have progressed in keeping with 
malignancy on interval CT scan in the correct clinical context or                  
4. Autopsy confirming pleural malignancy   
  
Complicated Parapneumonic Effusion 
Clinical presentation suggestive of sepsis and 
1. Pleural fluid pH ≤7.2 or pleural fluid loculation on ultrasound and follow up for at least 
6months inconsistent with pleural malignancy or 
2. Pleural fluid gram stain or culture positive or 
3. Frank pus or  
4. Pleural infection confirmed by pleural biopsy histology and/or microbiological culture or 
5. CT scan consistent with pleural infection with radiological resolution following 
treatment with antibiotics.  
Simple Parapneumonic effusion 
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Clinical presentation suggestive of sepsis with appropriate chest radiology and pleural fluid 
which is gram stain and culture negative with a pH >7.2 and an absence of loculation on thoracic 
ultrasound and resolution of effusion on CXR after antibiotics  
Connective tissue disease (including RA) 
1. Systemic features or known diagnosis of connective tissue disease and 
2. chest radiology (including CT imaging) showing benign features (e.g. doesn’t meet any of 
Leung’s criteria) with at least 6 months follow-up and /or pleural biopsy negative for 
malignancy.  
Pulmonary embolism  
1. Evidence of PE on CT pulmonary angiogram (CTPA) and 
2. No alternative explanation for pleural effusion on cross sectional imaging or pleural fluid 
analysis. (NB the CT shows no evidence of pleural thickening – which would suggest 
another cause)           
BAPE or diffuse pleural thickening due to asbestos  
History of asbestos exposure or evidence of pleural plaques on CT and  
1. Stable or improving CT appearances with follow-up for at least 12 months (the 
development of enfolded lung is allowed) or 
2. Negative thoracoscopy (benign pleural biopsy). 
Congestive heart failure  
1. History and examination features of CHF or  
2. Evidence of at least moderate LV systolic or diastolic failure or severe valvular disease 
on echo or  
3. Improvement of effusion and symptoms with diuretic therapy. 
CABG 
1. CABG in 3 months prior to development of pleural effusion in the absence of an 
alternative cause  
Hepatic hydrothorax 
1. Known history or clinical presentation consistent with liver disease and   
2. Recurrent transudative pleural effusion and 
3. Negative cytology  
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Renal failure or hypoalbuminaemia 
Biochemical confirmation of renal failure or hypoalbuminaemia in the absence of clinical, 
radiological or pleural fluid analysis suspicious of an alternative cause.  
TB pleuritis 
1. Culture or AAFB positive sputum, pleural fluid or pleural tissue and 
2. Resolution of pleural effusion with anti TB therapy at 6-month follow-up.  
Inflammatory pleuritis (Non-specific pleuritis)  
1. Demonstration of non-specific inflammatory pleuritis on pleural biopsy and 
2. Follow-up for 12 months without progression that would suggest a malignant cause.  
Undiagnosed  
1. Exhaustive investigations including 12 months follow-up with interval CT scans has not 
demonstrated a diagnosis or 
2. Patient unfit for further investigation and follow up or 
3. Patient died without definitive diagnosis and no postmortem examination conducted 
 
Effusions were defined as malignant if either the primary or secondary diagnosis included a 
malignant cause. 
Effusions were classified either as transudative or exudative by Lights criteria(11) and either 
bilateral or unilateral based on PA chest radiograph appearance.  The effusions were categorised 
by cytology as either blood, macrophage, neutrophilic or lymphocytic predominant (>50%), mixed 
if no clear predominance in cytology and eosinophilic if >10% eosinophils. Eastern Cooperative 
Oncology Group Performance score (ECOG-PS)(189) was recorded for 77.6% of patients.  
Survival data was calculated from date of study entry to date of death. Surviving patients were 
censored on 07/2016. 
The study protocol was approved by local ethical approval, South-West Bristol Research Ethics 
Committee (Ref 08/H0102/11), in accordance with the Declaration of Helsinki. Study participants 
gave written informed consent. 
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2.1.1. Statistics Analysis  
Descriptive statistics were used to summarise patient characteristics and clinical data. Means 
(±SD) were calculated for age and percentage values for subgroups. Univariable analysis was used, 
examining the association with each exposure of interest, to provide an initial idea of the variable 
that were strongly associated with survival. Univariables chosen were fluid biochemistry (exudate 
versus transudates), chest radiograph appearance (bilateral versus unilateral) and cell differential 
(blood, macrophage, neutrophilic or lymphocytic predominant, mixed, cytology and eosinophilic. 
These variables were chosen as they are clinically available and objective parameters that have 
been shown to influence prognosis in previous studies(62). Univariables that achieved statistical 
significance (p < 0.05) were selected for multivariate analysis. The analysis was not controlled for 
age or other comorbidities.   
Multivariate proportional hazard ratios were calculated using Cox regression analysis for 6 and 
12-month mortality for presence of bilateral pleural effusion (compared to unilateral), 
transudative effusions (compared to exudative), and the following aetiologies (compared to 
malignant pleural effusion cohort): CHF, liver failure, pleural infection, renal failure, BAPE/DPT, 
CABG, PE, and other. Kaplan-Meier plots for survival probabilities were created for overall 
mortality and stratified for aetiologies, bilateral vs unilateral effusions and transudative for 
exudative effusions. All statistical analyses were performed using IBM SPSS statistics version 23.0 
(SPSS Inc. Chicago, IL) 
 
  
- 59 - 
 
2.2. Natural history of cardiogenic pleural effusions 
The natural history of cardiogenic pleural effusions is unclear. The cited figure of 10% refractory 
to medical management is based on a small study of 60 patients with a short median follow-up of 
16 days(20). In order to get a better idea of the rate of refractory cardiogenic pleural effusions I 
examined patients with cardiogenic pleural effusions in an observational study, documenting the 
rate of pleural re-accumulation in the patient with heart failure.  
The study used the same database are described in the previous study on survival of transudative 
effusions. It was conducted at a later date, including patients from 03/2008 to 03/2017. It was a 
retrospective analysis of consecutive prospectively enrolled patients presenting to the pleural 
service with an undiagnosed pleural effusion were prospectively recruited.  Pleural biochemistry, 
cytology, thoracic USS and chest radiograph were performed at baseline. Patients with unilateral 
and bilateral effusions on CXR were included. Patients without a contemporary echocardiogram 
were excluded.  
As with the previous study, patients were followed-up for a minimum duration of 12 months or 
until death, with the final diagnosis decided following independent review by two respiratory 
consultants. Where more than one aetiology was felt to be responsible, the principal contributing 
factor was listed first. Patients were classified into diagnostic categories for analysis: malignant; 
CHF; liver failure; renal failure; pleural infection (empyema, complicated parapneumonic effusion, 
simple parapneumonic effusion, TB pleuritis); benign asbestos pleural effusion & diffuse pleural 
thickening (DPT); coronary artery bypass graft (CABG), pulmonary embolism, and other (including 
chylothorax, rheumatic, trauma and drug-induced).  
Pleural effusions were considered as secondary to CHF if history and examination features 
indicated CHF or there was evidence of at least moderate LV systolic or diastolic failure or severe 
valvular disease on echo or there was improvement of effusion and symptoms with diuretic 
therapy. Patients were malignancy was a possible secondary contributor to the effusion were 
excluded.  
Effusions were classified either as transudative or exudative by Lights criteria(11) and either 
bilateral or unilateral based on PA chest radiograph appearance.  The transthoracic 
echocardiography (TTE) results were based on reports provided by the sonographer. These 
reports provided variable amounts of descriptive and objective measurements. There was no 
standardised approach.  When ejection fraction was provided, >50% was deemed as persevered 
(normal) systolic function. Descriptive categorisation, provided by the sonographer typically 
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classified the LV function onto normal, mild, moderate or severe. Pulmonary hypertension was 
classified when described as such by sonographer, or a raised pulmonary arterial systolic pressure 
(PASP) >55 mmHg. The presence or absence of atrial fibrillation (AF) was determined by ECG. The 
size of the pleural effusion was graded as per Light’s chest x-ray grading from 0 to 5 (0 for no fluid 
to 5 for complete opacification of hemithorax) for the largest effusion side. NT-proBNP was 
performed as a serum sample. Prior to 2010 a bedside NT-ProBNP assessment was used, which 
had a maximum cut-off value of >3000pg/ml. After this, NT-ProBNP were processed in the 
laboratory, with no upper cut-off.  
The outcome of the study was proportion of refractory cardiogenic effusion. Refractory 
cardiogenic effusion was defined as requiring an additional therapeutic pleural procedure 
(therapeutic aspiration, chest drain drainage or IPC insertion) after initial index aspiration (either 
diagnostic aspiration or therapeutic) in a patient receiving diuretics.    
The study protocol was approved by local ethical approval, South-West Bristol Research Ethics 
Committee (Ref 08/H0102/11), in accordance with the Declaration of Helsinki. Study participants 
gave written informed consent. 
2.2.1. Statistics Analysis  
Descriptive statistics were used to summarise patient characteristics and clinical data. Means 
(±SD) were calculated for age and percentage values for subgroups. Univariable analysis was used, 
examining the association with each exposure of interest, to provide an initial idea of the variable 
that were strongly associated with survival. Univariables chosen were fluid biochemistry (exudate 
versus transudates), chest radiograph appearance (bilateral versus unilateral), Albumin (≥20 
g/liter or < 20 g/liter), gender (male or female), NT-proNBP (>3000pg/l), degree of LV dysfunction 
(severe  vs non-severe), pulmonary hypertension (severe vs non-severe) and presence of cardiac 
rhythm (AF versus sinus rhythm). 
Categorical data was analysed using Chi-squared test. Odd ratios were calculated for the variables. 
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2.3. Study design: A randomised controlled trial evaluating 
the efficacy of indwelling pleural catheters in persistent 
non-malignant symptomatic pleural effusions (REDUCE 
trial) 
As part of this thesis, I conducted a multicentre randomised controlled trial designed to evaluate 
whether the insertion of an IPC is associated with a reduction in breathlessness, as assessed by 
use of a visual analogue scale (VAS) score, compared with repeated thorancentesis in patients 
with a pleural effusion due to heart failure or liver failure.  
The study design was conceived by Prof Maskell and the initial protocol was written by Dr 
Bintcliffe, who conducted the initial site set-ups. I took over trial management after 5 patients had 
been recruited and increased the number of sites from 8 to 14. I completed various minor and 
major amendments. At the time of writing the thesis, 65 patients had been recruited 
An RCT design was decided, as it is considered the gold standard for evaluating efficacy in clinical 
research(190). IPC was chosen as the intervention due to promising retrospective data on 
reducing length of hospital stay and low rate of major complications(77). Studies on IPC in patients 
with MPE have indicated that IPCS are equally as efficacious as talc slurry pleurodesis in controlling 
symptoms of breathlessness and reducing number of pleural procedures needed(191). There is 
no prospective RCT on IPCs in this patient cohort, and limited patient related outcomes data. Talc 
pleurodesis would be an alternate method of managing refractory NMPE. However, the only 
comparative data, in form a propensity-matched cohort study, comparing talc poudrage under 
general anaesthetic and IPC in patients with heart failure demonstrated that IPCs had a 
significantly shorter hospital stay (2±2 days) and a lower rate of operative morbidity and 
readmissions than patients undergoing thoracoscopic pleurodesis. Patients undergoing 
thoracoscopic pleurodesis had 6±4 day hospital length of stay, 23% readmission rate and 5% 
operative mortality. Respiratory insufficiency, pulmonary embolism and atrial fibrillation were 
among the reported complications with overall morbidity of 20% compared to 2.5% morbidity in 
the IPC group(66). In terms in comparator, as-needed thoracentesis as a control group was chosen 
as this represents the most common practice in patient with refractory NMPE.  
 
Patients were identified from respiratory, hepatology and cardiology services and the trial is being 
conducted from centres with established pleural services and experience of pleural trials. Eligible 
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patients had symptomatic non-malignant pleural effusions due to CHF or liver cirrhosis, on 
maximal medical management. Eligible patients had previous sampling of pleural fluid and 
treatment optimised and will have an effusion that persists despite this. Potentially eligible 
patients are screened against the inclusion and exclusion criteria. Suitable patients were given a 
patient information sheet (PIS). A hospital visit is arranged, prior to which the patient will have 
had sufficient time (as defined by the patient) to consider trial participation and read the PIS. 
2.3.1. Inclusion criteria 
1) Clinically confident diagnosis of non-malignant pleural effusion secondary to either 
advanced stage CHF or liver failure requiring, and amenable to, pleural intervention for 
relief of breathlessness  
2) Assessment by a cardiologist or hepatologist determining the presence of established 
heart failure or liver failure and a pleural effusion that persists despite optimised medical 
therapy  
3) At least one previous aspiration of pleural fluid with results consistent with the cause of 
the effusion being due to CHF or liver failure  
Either: 
a) a) A transudate by Light’s criteria in cases of effusions due to liver failure 
OR 
b) b) Either a transudate in effusions due to CHF or an exudate in cases where 
diuretics have been used and CHF can confidently be stated to be the cause 
4) No evidence of malignancy on pleural fluid cytology 
5) Expected survival >12 weeks 
6) Written informed consent to trial participation. 
 
These criteria were chosen as they are the key features for the target population I am seeking the 
examined. The population of interest is patients with CHF and liver failure requiring, and 
amenable to, pleural intervention for relief of breathlessness who have been medical optimised. 
This is consistent with the definition of refractory transudative effusions that has been used 
throughout the thesis, and therefor the results of the previous two studies outlined should be 
applicable to this study. Whilst the second inclusion criteria creates a potential recruitment 
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barrier, by involving additional speciality opinion, is was felt necessary for the trial to be 
translatable to clinical practice.  Allowing both transudates and exudates, secondary to CHF, 
maintained external validity, as this is the case in clinical practice.  
 
2.3.2. Exclusion criteria  
1) Age < 18 years 
2) Known pleural malignancy 
3) Pleural fluid pH < 7.2 
4) Previously sited indwelling pleural catheter on the side requiring intervention or current 
indwelling 
5) Pleural catheter on the contralateral side 
6) Pregnancy, lactation or intention to become pregnant 
7) Inability to give informed consent 
8) Absolute contraindication to IPC insertion or therapeutic aspiration of pleural fluid 
9) Patient has no access to a telephone 
 
The exclusion criteria excluded comorbidities that could bias the results of the study, in this case 
pleural malignancy and pleural infection. Previous exposure to the intervention arm was also felt 
an unnecessary bias, and so these patients were excluded. I also excluded patients with features 
that would increase risk of missed follow-up appointments or pose of safety risk in the 




Patients were randomly assigned to either an IPC (intervention) or a therapeutic aspiration 
(control) for their pleural effusion. Randomisation is minimised with 1:1 allocation. Minimisation 
factors are underlying aetiology of pleural effusion (CHF or liver failure) and the size of the effusion 
as assessed on the pre-randomisation chest radiograph (≥½ hemithorax, <½ hemithorax). 
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2.3.4. Post-randomisation  
The therapeutic aspiration, or IPC insertion were performed according to an established standard 
operating procedure (SOP). Patients in the intervention arm had the catheter placed in a suitable 
procedure room or theatre and are discharged for drainage in the community. Patients in the 
control arm had a pleural therapeutic aspiration of up to 1.5L in a suitable procedure room prior 
to discharged. In both cases, a written SOP for the interventions is provided to all participating 
centres to ensure standardised practice and either procedure should be performed within 24 
hours of randomisation. Patients in the IPC arm were drained at least three times a week for the 
first two weeks, and subsequently at a frequency considered appropriate by clinicians and 
patients. This was undertaken by community district nurses or alternatively by relatives, carers or 
the patient themselves. Records were kept for the dates and volume of drainage. Those in the 
control arm were offered pleural aspirations and further day-case attendances as necessary, 
coordinated through the trial team to control symptoms, reflecting standard practice. The dates 
and volumes of drainage were recorded. 
2.3.5. Follow-up assessments  
All patients were followed up at the recruiting unit as out-patients at four, eight and twelve weeks. 
These assessments included completion of the EQ-5D-5L questionnaire and assessment of the IPC 
site in the intervention arm. A chest radiograph was performed at the discretion of the primary 
physician during the follow-up period and performed at the 12-week assessment in all patients to 
establish if pleurodesis has occurred. 
2.3.6. Human albumin solution   
In the REDUCE trial we recommend that use of HAS infusions is considered in patients with hepatic 
hydrothorax undergoing IPC drainage or repeated therapeutic aspirations. The precise 
administration is not protocolised, and it is advised that clinicians follow local practices and 
policies which may already be in place for this patient group. We advise that HAS is given in 
relation to the volume of fluid drained off. As guidance, a suggested regime of 100ml of 20% HAS 
per 3L of pleural fluid drained may therefore be appropriate.  Albumin levels will be recorded at 
baseline and at the 4, 8 and 12 week clinic appointments. 
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2.3.7. Primary outcome 
The primary outcome is the difference in daily breathless score as assessed by VAS over 12 weeks, 
which has proven to be a robust and clinically important outcome measure in previous studies by 
this collaboration(2). The intention behind pleural aspiration or drainage of cardiac, renal and 
hepatic failure related effusion is relief of disabling breathlessness, and the primary outcome 
measure of this study reflects this outcome which clinically relevant to both patients and 
clinicians. As demonstrated in the subsequent chapters, the median survival of patients with 
refractory transudative effusions is poor, and hence patient centred, symptom-based outcomes 
are important. VAS has been  shown to be useful in demonstrating real-life symptomatic benefit 
in patients post therapeutic  pleural intervention(192). A prospective study demonstrated the 
majority of patients (86%) experienced symptomatic benefit from pleural fluid drainage (mean 
VAS improvement 42.6 mm, SD 24.7, 95% CI 37.9 to 47.3), with a correlation between 
symptomatic benefit and volume of fluid removed (192). Additionally, VAS has been shown to be 
robust in previous randomised studies of IPC in malignant pleural effusion (2). In summary, VAS is 
clinically relevant, sensitive to the effects of the intervention and interpretable. 
Visual analogue scales of breathlessness have been studied in varied aetiologies, with recent RCTS 
in pleural medicine using visual analogue scale for dyspnoea (VASD) to assess mean daily 
breathlessness and determine the efficacy of the study intervention.  The VASD is a patient 
reported outcome, consisting of a 100mm horizontal line, labelled from 0mm with “’Not 
breathless at all’ to 100mm with ‘Worst possible breathlessness’. The score is the measurement 
from 0mm to the mark made by the study participant. Work has been performed to calculate the 
smallest difference in VASD that patients find worthwhile and that would lead to change in 
management(193). This minimal important difference (MID) has been calculated for dyspnoea in 
a range of other  conditions, including asthma and COPD (194, 195). In malignant pleural effusions, 
the population that most closely resembles the population of interest in this study, Mishra et al 
attempted to calculate the  MID (193). This figure was achieved by analysing data collected by the 
authors during their clinical practice, asking 123 patients’ pre-pleural procedure to record their 
baseline VASD and estimated the greatest post-procedural VASD that the patient would consider 
‘worthwhile’. After 24 hours post-procedure the patients completed a post-procedural VAD and 
a 7-point Likert scale. The MID was calculated as 19mm (95% CI 14-24mm), corresponding with ‘a 
small but just worthwhile improvement’ on the Likert scale.  This is a larger MID than 
demonstrated in earlier studies on COPD (MID of 10mm) (196, 197), although similar to the MID 
demonstrated to be meaningful in patients with interstitial lung disease (198). The population in 
the REDUCE study is different from the MPE population, with differing underlying 
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pathophysiology. It is feasible that pleural drainage will have less effect on dyspnoea with 
patients, who with cardiac dysfunction have a pre-existing cause of breathlessness, independent 
of pleural effusion volume. Therefor it is possible these calculated MIDs may not be applicable to 
our patient cohort.  
There are limitations to using a subjective endpoint, such as VAS outcomes as the primary 
outcome. Subjective endpoints are more susceptible to individual interpretations, and this effect 
may be compounded by the unblinded nature of the trial. Efforts have been taken to minimise 
the effect, by having two independent blinded measurements of the VAS score.  
The VAS scores were recorded daily (at the same time each day, ideally in the morning) by 
participants over 12 weeks post-randomisation, with encouragement by the trial team to the 
participants in order to ensure compliance at follow-up visits. VAS score measurements was 
conducted using a standard operating procedure (SOP) with two assessors measuring each VAS 
score independently, with the first person’s measurement taken, where there is a difference of 
≤2mm between the two measurements and in the event of a difference of >2mm a written policy 
will be followed with respect to re-measurement. 
The daily VAS scores will be analysed to provide an average measure of breathlessness for each 
individual. 
 
2.3.8. The secondary outcomes 
• The proportion of patients achieving pleurodesis at 12 weeks. 
• Health related QoL: EQ-5D-5L. 
• Hospital visits and bed days. 
• Number of pleural interventions 
• Volume of fluid drained 
• Cost-effectiveness analysis 
• Albumin levels in patients with liver failure 
• Failure of initially randomised treatment 
• Adverse events attributed to trial intervention. 
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2.3.9. Clarification of secondary endpoints 
  The proportion of patients achieving pleurodesis at 12 weeks. 
The proportion of patients achieving pleurodesis was chosen as a secondary outcome as it has 
important clinical implications for patients. It is recognised that by repeated drainages, and 
apposition of the visceral and parietal pleura, and subsequent adhesion formation, a proportion 
of patients with an IPC will achieve spontaneous pleurodesis. After this pleural symphysis, there 
should be minimal subsequent pleural fluid production, and the IPC can be removed. In patients 
with MPE the average rate of spontaneous pleurodesis was cited at 45%, based on evidence from 
non-randomised controlled trials(78). Subsequent RCTs have provided a more conservative 
estimate of between 17 and 29% (4, 5, 191, 199). In patients with non-malignant pleural effusions, 
an average from non-randomised studies give an average pleurodesis rate of 51.3% (95% CI, 
37.1%-65.6%)(77). In patients with cardiac pleural effusions, with rate was 42.1% (95% CI, 20.1%-
64.1%)(77).  If the experience from MPE studies is repeated, the actual value may be lower.  
The rate of spontaneous pleurodesis, and the subsequent removal of the IPC, is felt to be of 
importance to patients. In this study, we defined pleurodesis as: 
• The most recent CXR showing an effusion less than 1/3 of the total hemithorax on the 
side of the effusion initially randomised. This measure must be agreed by two clinicians, 
at least one of whom must be blind to the treatment allocation. 
AND one of: 
• Less than 50ml aspirated from the IPC on three occasions over no less than 1 week with 
a patent IPC 
• IPC removed and no further pleural intervention required 
• In the control group: no further pleural fluid intervention since the initial aspiration 
• In those who had talc pleurodesis outside study protocol: No pleural fluid intervention 
required since pleurodesis attempt 
 Health related QoL: EQ-5D-5L. 
Although the primary outcome measure in this study is assessment of patient related 
breathlessness (a clinically important and reliable outcome measure), IPCs may have important 
effects on other aspects of health related QoL. The proposed sample size will detect a clinically 
significant difference in health related QoL. 
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 Hospital visits and bed days. 
The number of hospital attendances, excluding trial visits and the number of hospital bed days 
was collected to assess the difference between control and intervention groups. The average 
length of hospital stay for an intervention is felt to be of interest to our patient population.  
 Number of pleural interventions 
The number and type of pleural interventions required during the 12 week trial period was 
collected to include therapeutic aspiration and chest drain insertion during the course of the trial. 
 Volume of fluid drained 
Data regarding the total volume of pleural fluid drained was collected to include the volumes 
removed via therapeutic aspirations, IPC drainage and chest drain insertion. 
 Cost-effectiveness analysis 
Cost per QALY gained was evaluated from utility scores calculated using the UK general population 
tariffs for the EQ-5D-5L.  
 Albumin levels in patients with liver failure 
Albumin levels was recorded at baseline and at the 4, 8 and 12 week clinic appointments. This is 
an important outcome, as the effect of recurrent drainages of hepatic hydrothoraces is unclear.   
 Failure of initially randomised treatment 
Failure of allocated treatment was recorded at the final 12 week appointment. Patients was 
considered to have failed initial treatment if they require a pleural intervention other than that 
which they were randomised to. For example, patients randomised to therapeutic aspirations 
who subsequently undergo talc pleurodesis or have an IPC inserted during the trial period were 
considered to have ‘failed’ standard care. Patients randomised to an IPC were considered to have 
‘failed’ intervention treatment if they require IPC removal for a reason other than pleurodesis and 
go on to require further pleural intervention or if the IPC ceases to function such that other pleural 
interventions are required. 
 Adverse events attributed to trial intervention. 
Any relevant adverse events related to trial interventions (indwelling pleural catheter insertion 
and drainage or therapeutic aspiration) was recorded to evaluate rates of associated 
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complications including pleural infection, chest pain, bleeding or renal impairment attributed to 
pleural fluid drainage. 
2.3.10. Sample Size Calculations 
2.3.11. Pilot Data 
To assess the effect on indwelling pleural catheters on short term breathless control using a daily 
VAS scores we compared breathlessness over 28 days in ten patients with an IPC with ten patients 
receiving standard care (chest drain insertion and talc pleurodesis) in a cohort of patients with 
malignant pleural disease. VAS quantified breathlessness scores were recorded daily and 
corrected for breathlessness not due to pleural effusion. A clinically significant improvement in 
breathlessness was seen in the ambulatory pleural catheter group (ambulatory catheter mean 
daily VAS 14mm (SD +/-11 mm), standard care 21mm (SD +/-10 mm), difference 7mm (95% CI for 
-3 to 17mm). 
2.3.12. Power Calculation 
From this pilot data we can determine this trial will require 78 patients (randomised 1:1) to show 
a benefit with IPCs (alpha 0.05, power 80%). We anticipate a loss to follow-up of 8%. Thus, we 
intend to study 86 patients. 
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2.4. Study design: Recurrence rates in primary spontaneous 
pneumothorax: a systematic review and meta-analysis 
Primary spontaneous pneumothorax (PSP) is a disease of young people, with an annual incidence 
of 7.4 per 100,000 in males and 1.2 per 100,000 in females(103). Current BTS guidelines advise 
that pneumothorax recurrence is an indication for surgery (whether second ipsilateral or first 
contralateral) (113), however the true incidence of recurrence is unknown.  PSP recurrence rates 
are typically cited as between 16 and 52%, which makes counselling about future risk challenging 
and creates uncertainty regarding the optimal management(161).   If recurrence rates are 
genuinely as high as 50%, an argument could be made for definitive surgical repair at an earlier 
stage.  If the true rate is closer to the lower estimate, however, waiting for a recurrent episode 
before considering surgery might be appropriate. The wide range in cited recurrence values is 
likely a result of highly varied study design. The studies providing these estimates are mixture of 
non-randomised and randomised studies. The study population vary from population-based 
studies to studies which examine a small number in a specific populations, such as  women of 
reproductive age(200). They examine a range of interventions, from observational, medical 
pleural drainage and surgery, all of which have the potential to influence recurrence rates.  The 
follow-up periods vary, from 3 months to over a decade.   
There are no factors that precisely predict recurrence and consequently no method for risk-
stratifying patients. Female gender, low body weight, smoking and height in males have all been 
postulated as risk factors for recurrence, however studies have provided conflicting results on 
each of these factors (120, 156, 158, 201). Certain radiographic features have also been suggested 
to confer additional risk, including bullae on CT and pleural thickening on chest radiograph, 
however studies arrive at differing conclusions of the significance of bullae (163, 164, 173).  
Importantly, there is no consensus on which treatment offers the greatest reduction in risk of 
recurrence, with proponents advocating for either conservative and pleural drainage as the 
optimal method of reducing future recurrence (99, 126, 174, 202).  Equally important, there is no 
current method of quantifying how each of these individual factors influence a patient’s risk of 
recurrence and therefor, no way of creating a risk model to calculate an individualised risk score.  
There is little literature detailing the recurrence rates in patients with SSP. The earlier studies did 
not differentiate between PSP and SSP, and even in more recent studies, there often do no 
differentiate to the extent which you can determine a separate recurrence risk. Light et al 
conducted an RCT on tetracycline in patients with spontaneous pneumothorax, 171 of whom had 
SSP. The recurrence rate in the control group with SSP was 43% during the 5-year follow-up 
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period(203). In an observational study conducted between 1975 and 1987, Lippert el al found that 
7 out of their 20 (35%) of patients with SSP had recurrence at 10 years(159). A more recent 
retrospective analysis of 61 patients with SSP at a Japanese hospital found recurrences in 25 
patients (40.9%), over an average observation period was 37.5 ± 30.3 months(204).  Another 
recent Japanese study had recurrence in 39/224 (17.4%) of SSP patients who were managed non-
operatively. Follow up was only described as ‘for a few weeks’, explaining the relative low rates 
(125). The limited number of studies examining recurrence rates in SSP precluded formal meta-
analysis, and a decision was made to focus on patients with PSP in this analysis.  
This thesis undertook a study aimed to systematically review, appraise and synthesise the existing 
literature to determine an accurate estimate of PSP recurrence rates and to describe risk factors 
associated with recurrence.  The primary research question was “what is the rate of recurrence 
of PSP in adults who have undergone medical management and what factors are associated with 
increased risk of recurrence?”. The secondary research question was “what patient factors 
increase recurrence risk?”. 
 
2.4.1. Search Strategy and selection criteria  
A systematic review was conducted to identify English-language studies, including randomised 
trials, non-randomised trials, and observational studies of more than 10 participants.  Review 
articles, editorials, conference abstracts, animal or in vitro studies and studies with no abstract 
available were excluded.  The population of interest was adults (≥18 year of age) with PSP, 
although studies including adolescents of 11 years and older were included if they comprised less 
than 25% of the study population or if recurrence data for adults could be extracted separately.  
Studies that examined patients with first occurrence or subsequent occurrence were included. It 
is recognised that subsequent recurrences increase the risk further recurrence (121). Limiting the 
inclusion to only first recurrence would significantly reduce the number of eligible studies, and 
loss useful information regarding patients who had had previous events.  Secondary spontaneous 
pneumothorax, iatrogenic and traumatic pneumothoraces were excluded and mixed studies 
where PSP recurrence outcomes could not be differentiated from other types of pneumothorax 
(secondary spontaneous, iatrogenic, traumatic) were also excluded. Non-PSPs were excluded due 
to differing underlying pathophysiologies.   Interventions and comparators included in the review 
were conservative management, needle aspiration (NA), intercostal drainage (ICD) and 
ambulatory management. Studies which only examined surgical, thoracoscopic or pleurodesis 
interventions were excluded, as were mixed studies where surgical and pleurodesis outcomes 
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could not differentiated from non-surgical/pleurodesis outcomes. Surgical and pleurodesis 
procedures dramatically decrease the risk of recurrence, typically less than 5%(150). The outcome 
of interest was recurrence (either ipsilateral or contralateral) at any time point. Studies that only 
documented contralateral recurrence rates were not eligible. These studies tended to be surgical 
studies, interested in pneumothorax recurrence post-surgery in the non-operative lung.   
The initial electronic search was performed on 18/1/18 within Medline (Epub Ahead of Print, In-
Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to 
Janaury 2018) and EMBASE (1950 to January 2018). The full search strategy is shown in Appendix 
A and included MeSH headings and keyword searches of “pneumothorax”, “recurrence” and 
“epidemiology”. Two authors (SW and PH) independently screened abstracts for eligibility and 
excluded studies that did not meet the inclusion criteria.  Discrepancies were resolved with 
discussion with third author (NAM).  Eligible studies were obtained in full-text format and 
reviewed independently by two reviewers (SH and PH).  The search was repeated on 22/2/18 to 
capture recently published studies.  
2.4.2. Data-analysis 
Data were extracted independently by two authors (SW and PH), using the data collection sheet 
shown in Appendix A. Name of study, type of study, sex, age, number of PSP cases, interventions, 
whether PSP cases were first or recurrent episode, 1-year; 2-year; and overall recurrence rates, 
and follow-up period were extracted from each study.  
The principal summary measure was overall recurrence rate for all included studies, described 
using basic descriptors (mean, 95% confidence intervals (CI)).  1-year and 2-year recurrence rates 
pooled for all studies that reported these outcomes.  Odd ratios for recurrence were calculated, 
where possible, for different interventions.  Odds ratios were calculated for smokers vs non-
smokers, males vs females, and body mass index (BMI) (greater/less than 20 kg/m2). Hazard ratios 
were extracted for males versus females where available.  In studies with mixed population (e.g. 
PSP and SSP, or adolescents and adults) only data pertaining to adults with PSP were extracted. If 
a study stated in its methodology that data relevant to the PICO criteria was collected but did not 
report it, the authors were contacted and asked to provide raw data.  
Separate meta-analyses were conducted to examine overall recurrence rates, and 1-year and 2-
year recurrence rates. All studies that reported the outcome of interest were included in the 
meta-analyses.  Due to high anticipated heterogeneity between study populations and 
interventions, a random-effects model was used. Heterogeneity in meta-analysis refers to the 
variation in study outcomes between studies.  Heterogeneity was calculated using estimates of I2.  
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The I² statistic describes the percentage of variation across studies that is due to heterogeneity 
rather than chance(205). As I² was anticipated to be high in our study, due to wide variation 
between the trials, a random-effects model was chosen, as it allows the study outcomes to vary 
in a normal distribution between studies. A fixed-effect model would be more appropriate if all of 
the studies examined were considered to have been conducted under similar conditions with 
similar subjects. Pooled recurrence rates were calculated separately for clinical cohorts and 
epidemiological studies reporting data from the general population. Separate meta-analyses were 
performed for studies that reported recurrence stratified by gender, intervention, weight and 
smoking status to provide estimates of recurrence based on patient characteristics.  Random 
effects models were used for all these analyses due to high anticipated heterogeneity. Univariable 
meta-regression was used to assess whether study-level characteristics were associated with 
increased reported recurrence rates. Characteristics examined were type of study (RCT vs non-
RCT), year of publication (before 2000, after 2000), PSP type (first or recurrent), sample size and 
follow-up period (greater or less than two years). All analyses were conducted in Stata MP Version 
13.1 by SW. 
Randomised studies that met the inclusion criteria were assessed using the Cochrane risk of bias 
tool.  Bias was assessed over the following pre-specified domains: random sequence generation, 
concealment of allocation, blinding of participants and personnel, blinding of outcome 
assessment, completeness of outcome data, selective reporting and other potential sources of 
bias. Non-randomised studies that met the inclusion criteria were assessed using the Newcastle-
Ottawa assessment tool over the following pre-specified domains: selection, comparability and 
outcome (15).  Risk of bias was assessed independently by two reviewers (SW and AB). Differences 
of opinion were resolved by discussion or by involvement of a third party (NAM).   
The review was registered prospectively on the PROSPERO database, registration number 
CRD42018089409.  Full methodological details are available at 
http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018089409). 
 
2.5. Study design: Conservative Management in Traumatic 
Pneumothoraces: An Observational Study 
As part of this thesis we were interested in the outcomes of patients with a traumatic 
pneumothorax who were managed without a pleural intervention. I used a large trauma patient 
cohort to create a profile of consecutive patients presenting with traumatic pneumothoraces to 
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examine the outcomes of conservatively managed patients and determine whether there are 
factors that can help predict whether a chest tube is required 
Patients were identified, from April 2012 to November 2016, as part of the Trauma Audit and 
Research Network (TARN) on patients presenting to emergency department at Southmead 
Hospital, a regional UK Adult Major Trauma Centre (MTC). It covers a population of 2.3 million, is 
supported by 6 other trauma unit hospitals and admits over 1000 major trauma patients/year. 
The TARN registry is a prospective, observational registry of hospitalised major trauma patients 
in England and Wales. It holds Health Research Authority CAG section 251 approval for research 
on anonymised data submitted by member hospitals. The TARN database includes all trauma 
patients irrespective of age who have a direct admission or transferred in whose length of stay is 
3 days or more or admitted to a High Dependency Area regardless of length of stay.  It also 
includes deaths of trauma patients occurring in the hospital including the Emergency Department 
and those transferred to other hospital for specialist care or for an ICU/HDU bed. Certain specific 
injuries were excluded), including isolated neck of femur or inter/greater trochanteric fractures 
over 65 years. 
ICD-10 codes included were S270 (Traumatic pneumothorax), S270 (Traumatic pneumothorax 
closed), S2701 (Traumatic pneumothorax open), S271 (Traumatic haemothorax), S2710 
(Traumatic haemothorax closed), S2711 (Traumatic haemothorax open), S272 (Traumatic 
hemopneumothorax), S2720 (Traumatic haemopneumothorax closed), S2721 (Traumatic 
hemopneumothorax open). 
Information was collected on demographics, injury (mechanism of injury, description of injuries, 
Injury Severity Score (ISS)), management (type, size of drain, length of drain placement) and 
pneumothorax characteristics (laterality, size and accompanying haemothorax). Airway support 
was characterised as either requiring positive pressure ventilation pre-hospital or in the 
Emergency Department (initial PPV) or requiring PPV subsequently due to GA administration or 
clinical deterioration (subsequent PPV). Size of pneumothorax was taken for chest radiographs at 
hilum and apex, as per the BTS guidelines of pneumothorax(113). On CT, the largest collection 
was measured along a line perpendicular from chest wall to lung or mediastinum, this parameter 
is used in other clinical studies on traumatic pneumothoraces, due to the unreliability of chest 
radiographs(206).  Clinical parameters were taken from initial observations on attendance to the 
Emergency Department. Respiratory distress was determined if either respiratory rate was ≥30 or 
<8; if supplementary 02 or mechanical or manual ventilation was used; a Sp02 ≤90% or if the 
patient was in respiratory arrest. Hemodynamic instability was determined if SBP <90mmHg or 
heart rate ≥ 100bpm. Conscious level impairment was determined if either GCS <15 or the patient 
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was ventilated at arrival. Treatment failure was defined as requiring an invasive pleural 
intervention. 
 
2.5.1. Statistical analysis  
Descriptive statistics were used to summarise patient characteristics and clinical data. Means 
(±SD) were calculated for parametric data and medians (IQR) were calculated non-parametric 
data. Several checks for normality, including Kolmogorov-Smirnov, Shapiro-Wilk, kurtosis and 
skewness calculations were performed. Continuous parametric variables were analysed using 
independent t-test and continuous non-parametric variables were analysed using Mann-Whitney 
test. Categorical data was analysed using Chi-squared test. A P-value of <0.05 was considered 
statistically significant. 
Univariate proportional hazard ratios were calculated using Cox regression analysis for factors 
associated with failure of conservative treatment (size of pneumothorax, mechanism of injury, 
ISS, presence of ribs fractures, clinical features (respiratory, hemodynamic, GCS), presence of 
haemothorax, bilateral versus unilateral pneumothorax, use of PPV and surgical procedures). 
Further multivariable cox regression analysis was performed to determine which factors (size of 
pneumothorax, ISS, presence of ribs fractures, clinical conditions (respiratory, hemodynamic, 
GCS), presence of haemothorax, bilateral versus unilateral pneumothorax, use of PPV and surgical 
procedures) were independently predictive of failure of conservative management. These factors 
were decided on in a priori statistical analysis plan. All statistical analysis was performed using 
IBM SPSS statistics version 23.0 (SPSS Inc. Chicago, IL) 
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2.6. Study design: Heimlich Valves in Secondary Spontaneous 
Pneumothorax: Enhancing Care (HI-SPEC trial)  
As part of this thesis, I undertook a multicentre randomised controlled trial to evaluate the effect 
of Heimlich valves on length of stay in patients admitted to hospital with secondary spontaneous 
pneumothorax.  
The study design was conceived by Prof Maskell and the initial protocol was written by Dr 
Bintcliffe. I submitted the protocol to ethics and the HRA. I designed the CRFs, constructed the 
on-line database and initiated site setup.  I completed various minor and major amendments (see 
Appendix G). I was the RCT’s trial manager, involved in recruitment and managing safety issues.   
At the time of writing the thesis, 35 patients had been recruited.   
 
2.6.1. Primary outcome measure description 
The primary outcome is the total number of hospital bed days due to a secondary spontaneous 
pneumothorax, during the first 30 days from randomisation. This will include readmissions.  
Patients remaining in hospital overnight will be classed as 1 day; those discharged on the same 
day will have a zero length of stay. Otherwise figures will be rounded up to the nearest complete 
day. 
This outcome was chosen as the primary outcome as it was felt to the most clinically relevant in 
a trial of ambulatory management of pneumothorax, and an outcome of most interest to 
patients.  
It is recognised that it would not be feasible in adequate blind the study participants to the 
intervention, so a trial outcome was chosen that was easily measurable, objective and can be 
measured in an unbiased manner.    
 
2.6.2. Secondary outcome measures 
1. Daily VAS Score for Breathlessness over the first 28 days after randomisation 
2. Daily VAS Score for Chest pain over the first 28 days after randomisation 
3. Quality of Life measured by EQ-5D-5L questionnaire daily over first 14 days after 
randomisation 
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4. Quality of Life measured by EQ-5D-5L questionnaire at 4 and 12 weeks after 
randomisation 
5. Length of hospital admission until classified medically fit for discharge 
6. Length of initial hospital admission from randomisation to initial discharge 
7. Length of initial hospital admission from date of admission with pneumothorax until 
discharge  
8. Failure of initially randomised treatment in 1st week 
9. Time till pneumothorax resolution 
10. Time till drain removal (Days from randomisation) 
11. Time till further intervention (Days from randomisation) 
12. Surgical intervention for pneumothorax elective (Days from randomisation until thoracic 
surgical intervention) 
13. Adverse events (See Adverse event section for detail) 
14. Recurrent pneumothorax (Occurrence of ipsilateral recurrent pneumothorax at end of 
follow up) 
 
2.6.3. Clarification of secondary endpoints  
 
Secondary outcomes where chosen that were measurable and clinically meaningful. 
 Daily VAS Score for Breathlessness  
A secondary outcome is the difference in daily breathless score as assessed by VAS over 28 days. 
Outcomes will be reported over the first 7 and 28 days. This outcome was chosen as it is patient 
centred and felt to be of clinical significance. Breathlessness is a common and disabling symptom 
in pneumothorax.  
This secondary outcome measure is difference in breathlessness measured using VAS scores, 
which has proven to be a robust and clinically important outcome measure in previous studies by 
this collaboration. The VAS scores will be recorded daily (at the same time each day, ideally in the 
morning) by participants over 28 days post-randomisation, with encouragement by the trial team 
to the participants and ensuring compliance at follow-up visits. VAS score measurements will be 
conducted using a standard operating procedure (SOP) with two assessors measuring each VAS 
score independently, with the first person’s measurement taken, where there is a difference of 
≤2mm between the two measurements and in the event of a difference of >2mm a written policy 
will be followed with respect to re-measurement. 
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The daily VAS scores will be analysed to provide an average measure of breathlessness for each 
individual. 
 Daily VAS Score for chest pain over the first 28 days after randomisation 
A secondary outcome is the difference in daily pain score as assessed by VAS over 28 days. 
Outcomes will be reported over the first 7 and 28 days. This outcome was chosen as it is patient 
centred and felt to be of clinical significance. Chest pain is a common and disabling symptom in 
pneumothorax. 
This secondary outcome measure is difference in pain measured using VAS scores. The VAS scores 
will be recorded daily (at the same time each day, ideally in the morning) by participants over 28 
days weeks post-randomisation, with encouragement by the trial team to the participants and 
ensuring compliance at follow-up visits. VAS score measurements will be conducted using a 
standard operating procedure (SOP) with two assessors measuring each VAS score independently, 
with the first person’s measurement taken, where there is a difference of ≤2mm between the two 
measurements and in the event of a difference of >2mm a written policy will be followed with 
respect to re-measurement. 
The daily VAS scores will be analysed to provide an average measure of pain for each individual. 
 
 Quality of Life measured by EQ-5D-5L questionnaire daily over first 14 days after 
randomisation 
In addition to the outcome measure in this study of patient related breathlessness and pain, HVs 
may have important effects on other aspects of health related QoL 
 
 Quality of Life measured by EQ-5D-5L questionnaire at 4 and 12 weeks after 
randomisation 
In addition to the outcome measure in this study of patient related breathlessness and pain, HVs 
may have important effects on other aspects of health related QoL 
 
 Length of hospital admission until classified medically fit for discharge 
In addition to the primary outcome measure duration of hospital admission, the number of 
inpatient days until the patient was deemed medically fit will be collected. This will be for the 
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index admission only. This was chosen as an outcome, as it is recognised that there will other, 
non-pneumothorax related factors that will influence hospital length of stay.  
Patients remaining in hospital overnight will be classed as 1 day; those discharged on the same 
day will have a zero length of stay. Otherwise figures will be rounded up to the nearest complete 
day. 
 
 Length of initial hospital admission – date of randomisation until date of discharge  
In addition to the primary outcome measure duration of hospital admission, the total number of 
inpatient days from randomisation until the patient was discharged will be collected for the 
index admission only.  
 Patients remaining in hospital overnight will be classed as 1 day; those discharged on the same 
day will have a zero length of stay. Otherwise figures will be rounded up to the nearest complete 
day. 
 
 Length of initial hospital admission - date of admission with pneumothorax until 
discharge 
In addition to the primary outcome measure duration of hospital admission, the total number of 
inpatient days from the date of admission with pneumothorax until the patient was initially 
discharged or deemed medically fit for discharge, will also be collected for the index admission 
only. Patients remaining in hospital overnight will be classed as 1 day; those discharged on the 
same day will have a zero length of stay. Otherwise figures will be rounded up to the nearest 
complete day. 
 
 Failure of initially randomised treatment in 1st week 
Failure of allocated treatment will be recorded for the first week appointment. Patients will be 
considered to have failed initial treatment if they require a pleural intervention other than that 
which they were randomised to. This is a measurable and clinically meaningful outcome.  
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 Time till pneumothorax resolution 
The time (in days) until full resolution of initial pneumothorax will be recorded. Whether 
ambulatory management expedites or slows time until full pneumothorax resolution is clinically 
meaningful.  
 Time till drain removal  
The time (in days) from the index drain insertion until the drain is removed will be recorded. 
Whether ambulatory management increases or decreases time until drain is removed is 
clinically meaningful. 
 
 Time till further intervention (Days from randomisation) 
The date of any further interventions will be captured. Interventions of interest are pleural 
aspirations, pleural vent insertion or chest drain insertion during the 6 month trial period.  
 
 Surgical intervention for pneumothorax (Days from randomisation until thoracic 
surgical intervention) 
The date of any thoracic surgical intervention for the index pneumothorax will be documented. 
This will be documented as either urgent (surgery for cessation of ongoing airleak) or elective (to 
prevent recurrence).  
Time and date of medical talc pleurodesis will also be recorded.  
 
 Adverse events (See Adverse event section for detail) 
Any relevant adverse events related to trial interventions (Heimlich valve or chest drain with 
underwater-seal) will be recorded to evaluate rates of associated complications (including 
subcutaneous emphysema, pleural infection, chest pain and bleeding) 
 
 Recurrent pneumothorax (Occurrence of ipsilateral recurrent pneumothorax at end 
of follow up) 
The date of any ipsilateral pneumothorax recurrence within the first 6 months will be 
documented. Recurrence is defined as an ipsilateral pneumothorax identified on chest x-ray, 
after a chest x-ray has confirmed complete resolution for at least 24 hours following the removal 
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of all catheters/drains. Any re-accumulation prior to this will be attributed to the initial 
pneumothorax (i.e., ongoing leak) rather than a recurrence. 
 
2.6.4. Recruitment 
Hi-SPEC is a multi-centre trial recruiting from centres with interest and experience of recruiting to 
trials in pleural disease. Patients admitted to a recruiting centre with SSP are identified within 
emergency departments, acute medical or respiratory wards. Patients are screened using the 
inclusion and exclusion criteria. Consecutive eligible patients are invited to participate. Patients 
are provided with the patient information sheet and the trial will be explained. Written informed 
consent is obtained prior to enrolment. 
Recruiting centres kept records of all patients screened and this information will be provided to 
the coordinating centre for review and monitoring purposes. 
2.6.5. Assessment and Treatment of Patients 
 Pre-randomisation 
Potential patients are screened against the eligibility criteria. Consent for trial entry is obtained 
prior to enrolment and randomisation. Eligible patients have a newly identified SSP. There is no 
maximum specified time after a diagnosis for enrolment and randomisation to take place however 
eligible patients need a chest drain for management of the current episode. Clinical management 
must not result in a clinically important delay as a result of trial participation. 
 
2.6.6. Inclusion Criteria  
New diagnosis of a secondary spontaneous pneumothorax as confirmed by a chest radiograph or 
CT scan 
AND 
Secondary spontaneous pneumothorax defined by known underlying lung disease or a patient > 
50 years old with a significant smoking history (>20 Pack years) 
AND 
Chest drain insertion indicated for treatment of pneumothorax according to current BTS 
guidelines 
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AND 
Chest drain insertion possible at both 2nd intercostal space in the midclavicular line and in the 
mid axillary line (safe triangle) 
 
2.6.7. Exclusion Criteria  
1. Current iatrogenic or traumatic Pneumothorax 
2. Drain already in place for Pneumothorax  
3. Previous history of tension pneumothorax. 
4. Features of tension pneumothorax associated with current presentation 
5. Evidence of significant hydropneumothorax or haemopneumothorax  
6. Age <18 years 
7. Patients bed-bound prior to pneumothorax 
8. Contraindication to either chest drain insertion or Rocket Pleural Vent insertion 
9. Females who are pregnant or lactating 
10. Patients with no access to a telephone 
11. Inability to comply with trial requirements or provide informed consent 
 
 Randomisation 
Eligible patients who provide informed consent are randomised (1:1) to treatment with a 
Seldinger chest drain and underwater seal (standard care) or to treatment with a Rocket Pleural 
Vent (intervention). Treatment allocation is performed through a randomisation server. A 
member of the trial team randomises the patients as soon as eligibility has been confirmed and 
consent obtained. Every effort was made to minimise delays between randomisation and the 
procedure being performed. 
 Trial Procedure 
The procedure, to which patients have been randomised to, is performed by an appropriately 
trained member of staff. Procedures followed a standard operating procedure which will ensure 
- 83 - 
 
standardisation of practice. A trial specific procedure manual was provided to each site to 
encourage a standardised approach and trouble shoot questions.   
 Post-randomisation 
Following insertion of a Rocket Pleural Vent or a standard chest drain, patients’ care proceeds 
according to standard care guided by the treating clinician. Clinical observations are performed 
following drain insertion and at regular intervals subsequently. Abnormal observations or a failure 
to symptomatically improve following intervention prompt clinical review by an appropriately 
qualified member of staff and consideration of necessary radiological investigation for further 
evaluation. Patients are provided with instructions on the care of the Rocket Pleural Vent or chest 
drain respectively. 
 
 Removal of Drains 
Decisions regarding removal of the chest drains or Pleural Vent are made by the treating clinician 
in reference to BTS guidance and standard local practice. Chest drains or Pleural Vents should be 
removed at the earliest opportunity following clarifying the absence of an ongoing air leak. An 
ongoing air leak can be excluded through the absence of bubbling through the underwater seal 
or air leak through the Heimlich valve device and full lung re-expansion on CXR. 
 Hospital discharge 
Patients should be discharged when clinically appropriate to do so, and patients with a Heimlich 
valve device can be discharged with the device in place provided discharge is safe and there are 
local arrangements for outpatient follow-up. As is standard practice, patients randomised to 
standard care are not be discharged with a chest drain and underwater seal. The discharge criteria 
should have been met prior to discharging a patient with a Heimlich valve in place. Patients are 
provided written information in relation to care of the Heimlich valve and with contact details in 
the event of any deterioration or problem with the device. 
 
 Clinical Follow up 
Patients are followed up as frequently as necessary. Specifically, patients discharged with a 
Heimlich valve device in place should be reviewed closely to enable safe and efficient care, the 
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prompt identification of any complications that may arise and to ensure Heimlich valves are 
removed at the earliest clinically appropriate opportunity. 
  Trial Follow up 
Data is collected from patients from follow up at 4 weeks (+/- 3 days) and at 12 weeks (+/- 1 week). 
Data relating to the trial outcomes was collected at the 4 week and 12-week trial visit. Patients 
have a CXR at 4 weeks and 12 weeks. Spirometry was performed at 12 weeks when not 
contraindicated. Patients have telephone follow up at 26 weeks (+/- 1 week) to gather data on 
episodes of recurrent pneumothorax. 
Data is collected from the day of randomisation (Day 0), which may not be the same day as chest 
drain insertion.  
2.6.8. Statistics and Data Analysis 
 Sample Size Calculation 
The primary outcome measure in this study is length of hospital stay (days). Length of stay is 
significantly longer in SSP than in PSP (207).   Audit data demonstrated a length of stay of 115 days 
in secondary spontaneous pneumothorax patients. This data is positively skewed, the mean 
length of stay in these patients is 12.30 (SD = 9.89) and median length of stay is 8 days 
(interquartile range: 4 – 17.5 days). 
 
Overall length of stay in primary pneumothorax in the UK was 6.3 days in data collected from 2010 
to 2012 (110). In a prospective case series studying the use of Heimlich valves in pneumothorax 
length of stay was reported as 3.3 days +/- 3.5.(208) 
Assuming 90% power and 5% significance the sample size is determined by the coefficient of 
variation and the effect size. The coefficient of variation is 0.8 (standard deviation divided by the 
usual mean).  
In order to detect an effect size of 0.5 (halving in length of stay) with a coefficient of variation of 
1 we would require 30 patients per group. The calculated coefficient of variation within our audit 
data is lower, suggesting a smaller sample size is necessary; however, a study size of 60 patients 
allows some margin for error in relation to the effect size. Including a 10% loss to follow up rate 
would suggest a total required sample size of 66. 
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 Recruitment Target 
The recruitment target of the trial is 66 patients. Assuming the trial runs across 9 sites an 
estimated recruitment rate of 4 patients per site per year would lead us to achieve the 
recruitment target within the estimated trial duration of 2 years. Progress towards the 
recruitment target will be reviewed by the TSC. Recruitment targets will be agreed with 
individual sites based on local experience and expectations.  
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CHAPTER 3. RESULTS 
In this chapter I will outline the full results of 4 non-randomised studies and the interim results 
of 2 randomised controlled trials: 
• Survival in refractory transudative effusions 
• Natural history of cardiogenic pleural effusions 
• Randomised controlled trial evaluating the efficacy of indwelling pleural catheters in 
persistent non-malignant pleural effusions - the REDUCE trial (interim results) 
• Results: Recurrence rates in primary spontaneous pneumothorax: a systematic review 
and meta-analysis 
• Conservative Management in Traumatic Pneumothoraces: An Observational Study. 
• Heimlich Valves in Secondary Spontaneous Pneumothorax: Enhancing Care – the HI-
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3.1. Results: Survival in refractory transudative effusions 
In the observational trial on outcomes of patients with non-malignant pleural disease, data was 
obtained for a total of 782 patients, with 774 included in analysis.  Eight participants were 
excluded for multiple reasons, including no diagnosis reached at 12 months and withdrawal of 
consent. Further analysis was conducted on the 356 (46%) patients with NMPE (see Figure 6) 
  
Figure 6.  Flow chart of patient numbers  
The baseline characteristics for NMPE cohort are presented in table 2, with characteristics by 
aetiology presented in table 3.  The majority of NMPE were exudative (73%), unilateral (88%) with 
pleural infection being the commonest aetiology (40.6 %). Nearly a quarter (23.6%) of the NMPEs 
were felt to have more than one identifiable cause. 
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Table 2. Clinical Characteristics of non-malignant pleural effusion cohort.  
Characteristics 
Age, mean (SD), y 68 (17) 
Male 245 (69) 
Inpatient 171 (48) 
ECOG PS 
 
0 54 (20.6) 
1 97 (37) 
2 70 (26.7) 
3 33 (12.6) 
4 8 (3.1) 
Bilateral 42 (11.8) 
Transudates 90 (27) 
Diagnosis 
Heart failure 86 (24.2) 
Liver failure 12 (3.4) 
Renal failure 13 (3.7) 
Inflammatory pleuritis 35 (9.8) 
Pleural infection 144 (40.6) 
Post Coronary Artery Bypass Graft 6 (1.7) 
Diffuse pleural thickening/ BAPE 28 (7.9) 
Pulmonary embolism  5 (1.4) 
Other 27 (7.6) 
*Values expressed as number (percentage) unless otherwise indicated. ECOG PS, Eastern Cooperative Oncology Group Performance 
score; BAPE, benign asbestos pleural effusion. 


















Mortality rates and multivariate predictors of mortality in NMPE cohort are displayed in table 4, 
with hazards ratio of bilateral compared to unilateral effusion, transudative compared to 
exudative effusion and aetiology compared to malignancy.  There were high 1-year mortality rates 
in patients with congestive heart (50%), renal (46%) and liver failure (25%). Thirty-day mortality 
was low, at 9% for CHF and no deaths in the liver and renal failure cohort. Malignant pleural 
effusions had the highest mortality at 49% and 70% at 6 and 12 months respectively. In patients 
with NMPE, bilateral and transudative effusions were associated with a significantly worse 
prognosis with HR 3.55(2.22-5.68) and 2.78(1.81-4.28) when compared to unilateral and 
exudative effusions respectively. A serosanguinous effusion was associated with a significantly 
increased risk of death (HR 2.8, CI 1.1-6.8, p-value 0.027) when compared to eosinophilic 
effusions. 
 










Heart failure 78.7 1.8 65 19.8 
Liver failure 61.8 1.2 75 0 
Renal failure 78.1 2 66.6 23.1 
Inflammatory pleuritis 67.6 0.72 10 8.6 
Pleural infection 60.7 1.4 8.9 9 
Post CABG 69.8 1.2 0 16.7 
BAPE/DPT 71 1 11.1 3.6 
Pulmonary embolism  70.4 1 0 20 
Other 63 1.1 12 7.4 
CABG, Coronary Artery Bypass Graft; BAPE, benign asbestos pleural effusion; DPT, Diffuse pleural 
thickening.  
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Table 4.  Mortality rates and multivariate predictors of mortality in non-malignant pleural effusion 
cohort. 
 
6 month mortality 1 year mortality 
Mortality 
(%) 
HR (95% CI) p-value 
Mortality 
(%) 















































































1 referent to unilateral effusions; 2 referent to exudative effusions; 3 referent to malignant pleural effusions 
CABG, Coronary Artery Bypass Graft; BAPE, benign asbestos pleural effusion; DPT, Diffuse pleural thickening; PE, 
Pulmonary embolism. 





Figure 7. Kaplan-Meier survival plots for long-term mortality by aetiology  
 
 
Figure 8. Kaplan-Meier survival plots for long-term mortality for unilateral versus bilateral effusion 
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Figure 9. Kaplan-Meier survival plots for long-term mortality for exudate versus transudate effusion   
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3.2. Results: Natural history of cardiogenic pleural effusion 
In this observational study on natural history of cardiogenic pleural effusion, 110 patients, out of 
1142 patients in the pleural patient database had a primary diagnosis of a cardiogenic pleural 
effusion. Five patients were excluded due to no echocardiogram, leaving 105 patients in final 
analysis. The patient demographics are listed below.  The average age was 78.9 years (SD 9.6), 
with 64/105 (60%) males. The majority of effusions were unilateral, 62/105 (59%) and 
transudative, 54/96 (59%).  The left ventricular (LV) function was described in 98 patients, with 
54/98 (55%) having a least mild LV dysfunction.  72(69%) were recruited as an outpatient.  
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Table 5. Clinical Characteristics of the cardiogenic pleural effusions 
Characteristics 
Age, mean (SD), y 78.9 (9.6) 
Male 64 (60) 
ECOG PS 
 
0 3 (3) 
1 29 (28) 
2 29 (28) 
3 20 (19) 
4 3 (3) 
Unknown 21 (20) 
Bilateral 43 (41) 
Transudates 54 (51) 
NT-ProBNP (SD), pg/l 7796.8 (15383) 
Echocardiogram  n(%)  
Preserved LV 44 (44.9) 
Mild LV impairment 13 (13.3) 
Moderate LV impairment 20 (20.4) 
Severe LV impairment 19 (19.4) 
Severe Pulmonary hypertension 15/97 (15.5) 
Size of pleural effusion on CXR, n(%)  
1  4 (3.8) 
2 34 (32.8) 
3 43 (41) 
4 21 (20) 
5 1 (1) 
missing 2 (1.5) 
Diuretic dose (furosemide equivalent) mean (SD) mg  60.7 (50.4) 
*Values expressed as number (percentage) unless otherwise indicated. ECOG PS, Eastern Cooperative Oncology Group Performance 
score; BAPE, benign asbestos pleural effusion. 
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In 8 patients, it could not be determined if they required further invasive pleural management 
during their disease course. Of the remaining 97 patients, 23 (23.7%) were defined as refractory 
and 74 (76.3%) were defined as non-refractory. 67 patients were taking per oral (po) furosemide, 
10 were taking po bumetanide, 8 were not receiving diuretic, and in 20 patients the medications 
were not clear. The diuretic dose of furosemide (using a bumetanide dose equivalent of 
1mg:40mg furosemide) was 60.7mg (SD 50.4). Of the non-refractory patients, 47 had a diagnostic 
aspirate and 23 had a therapeutic aspiration as first-line management. 1 had an ICD as first line, 
two had a LAT, without talc instillation as 1st line. Two patients had IPCs placed, although these 
weren’t classed as refractory cases as the patients were not on diuretics. 2 patients were 
described as having full resolution after valve replacement. Of the 23 patients who had refractory 
pleural effusions, they had a mean of 1.9 (SD 1.7) therapeutic aspirations. 5 had IPCs inserted. 
One of these patients also had contralateral chest drain and talc pleurodesis. One patient had a 
chest drain inserted, and one had a LAT with talc poudrage.  
 
Table 6. Univariant analysis of refractory versus non-refractory cohort in cardiogenic effusion 
patients 
Variable Refractory cohort 
(n 23) 
Non-refractory 
cohort (n 74) 




















1.5 (0.4, 5.7) 









1.4 (0.5, 4.6) 









1.9 (0.5, 7.1) 
Gender   1.3 (0.5, 3.4) 





































0.4 (0.2, 1.1) 
Pleural effusion on CXR 
Moderate to Large (Grade ≥3) 







1.1 (0.4, 2.9) 
OR: Odd ratio- 1st row versus 2nd row 
 
No single variable of the 8 analysed were predictive of the refractory cardiogenic pleural 
effusion (see table 6).  
 
3.3. Results: Randomised controlled trial evaluating the 
efficacy of indwelling pleural catheters in persistent non-
malignant pleural effusions (REDUCE trial)  
 
The first patient was recruited for the REDUCE trial on the 7th April 2015. The trial is currently 
recruiting, with an end-recruitment date of 1st August 2019. Currently 65 patients have been 
recruited (see Appendix C for full recruitment details). The proposed recruitment date is 1st 
August 2019, with 3-month follow-up, and a study end date of 1st December 2019.   Monthly 
reminders will be sent for data queries and missing data from 1st May 2019.  The data will be 
cleaned from August 2019 and Stata code will be developed by the trial statistician from the 
statistical analysis plan in November 2019. We anticipate the final manuscript will be ready for 
publication by Summer 2020.    
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3.3.1. Screening 
Centres were asked to be place potential candidates with pleural effusion suspected from being 
secondary to heart, liver or renal failure, requiring or being considered for a pleural aspiration. 
The main purpose of this screening data is as an indicator of whether trial participants were likely 
to be representative of all eligible participants.  
A total of 214 patients were screened for the REDUCE trial from the 13 centres. 70 of the patients 
included in the screening data were deemed ineligible for the trial by the local trial team. 
Eighteen out of the 214 (8%) were described as improving with diuretics. A time scale for this 
improvement was not available from the screening log.  22/214 (10%) patients were described as 
requiring optimisation, although none of these patients were subsequently randomised. One of 
these patients died during this optimisation period, 14 days after initial screening.   
19 patients declined the trial, with 6 patients explicating stating they did not want an IPC. 4 
patients were described as not receiving benefit from the initial aspiration. 9 patients at the time 
of screening had pleural effusions that were too small and didn’t required an aspiration.  
From this screening data, only a small proportion (8%) improved were explicitly excluded due to 
improvement on diuretics. It is possible that the further 10% of patients who were described as 
requiring optimisation, but not subsequently enrolled also improved, though this is uncertain. This 
figure is smaller than we’d anticipate would improve with diuretics(20), however the screening 
patients were very likely a highly selected group of patients themselves to have been identified 
by the trial team, and had likely failed to respond to initial medical therapy. The screening data in 
this trial was meant to determine whether trial participants were likely to be representative of all 
patients seen. It must be noted that there is often substantial between-site variability in how 
screening data are collected and for whom(209). The accuracy of accuracy of the reported reasons 
for screen failures may limited, as sites often limit the reason for non-enrolment to the primary 
reason. Additionally, certain eligibility criteria such as, in this case, whether ‘a pleural effusion that 
persists despite optimised medical therapy’ can take longer to ascertain than others. This results 
in a bias against the reporting of reasons that are more resource intensive to assess. 
This screening data for this trial is not suitable for determining, for the above reasons, the natural 
history of transudative effusions. The screening data does imply the screened patients are a more 
highly selected patient cohort, than patients who present de-novo with a cardiac and liver related 
pleural effusion, where we would anticipate a higher proportion of response to medical 
management.   




Figure 10. REDUCE Trial Consort diagram 
IPC: indwelling pleural catheter  
 
3.3.2. Baseline characteristic of trial patients 
The baseline characteristics of the first 60 randomised patients are displayed in table 7. Baseline 
data was missing for one patient. The mean age was 73.7 years (SD 12.9) and 47/59 (80%) were 
male. The majority of effusions 39 (66%) secondary to heart failure, which is consistent with the 
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available literature(19). There was no significant difference between the IPC and standard care 
cohort in pre-determined characteristics.   
Table 7. Baseline Characteristic of 1st 60 patients in the REDUCE trial 
 IPC (n=30) Standard care (n=30) 
Age – mean (SD) 72.1 (11.7) 75.3 (14.1) 
Male – no. (%) 24 (80) 23(76.7) 
Primary cause of effusion- no. (%)   
Heart failure 19 (63.3) 20(66.7) 
Renal Failure 3 (10) 1 (3.3) 






Smoking status – no. (%)   
     Current smoker 1 (3.3) 1 (3.3) 
     Ex-smoker 14 (46.7) 16 (53.3) 
     Never-smoker 





WHO performance status at 
randomisation – no. (%) 
  
     0 1 (3.3) 0 (0) 
     1 9 (30) 12 (40.0) 
     2 11 (36.7) 13(43.3) 
     3 8 (26.7) 4 (13.3) 
     4 






The majority of patients in this patient cohort had a poor performance status, with 62% (37/59) 
of patients having an ECOG-PS (Eastern Cooperative Oncology Group-Performance Status) ≥2. 
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ECOG-PS of 2 denotes patients that are ‘ambulatory and capable of all selfcare but unable to 
carry out any work activities and up and about more than 50% of waking hours’. ECOG-PS of 3 
denotes patients ‘capable of only limited selfcare and confined to bed or chair more than 50% of 
waking hours’. ECOG-PS of 4   denotes patients who are ‘completely disabled, cannot carry on 
any selfcare and totally confined to bed or chair’(189). 
 
 Sub-Analysis per aetiology  
Most study participants had pleural effusions secondary to heart failure, 39(66%), with 16(27%) 
secondary to liver failure and 4(7%) secondary to renal patients (see figure 11). Patients with heart 
failure were older with a mean age of 78.00 (9.37) compared to 62.85 (8.17) and 63.84 (12.69) for 
liver and renal failure respectively.  Seventy two percent of heart failure patients had a WHO 
performance status ≥2, compared to 37.5% and 75% for liver and renal failure respectively. 
 
 
Figure 11. Distribution of first 60 REDUCE study subject by aetiology  
 Pleural effusion characteristics  
Most pleural effusion’s requiring intervention were right-sided, 48/59 (81%).  In 35/59 (58.3%) 
the effusion occupied less than half the hemithorax. This is consistent with the literature 
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detailing most transudative effusions as small to moderate in size(29). The mean LDH was 162.8 
(SD 88.2) and mean protein 29.4 (SD 9.9), which would be consistent with a transudative 
effusion. The pleural fluid characteristics for each study group are displayed in table 8.  
 
Table 8. Characteristic of Pleural effusions of 1st 60 patients in the REDUCE 
trial 
 IPC (n=30) Standard care (n=30) 
Side of effusion requiring intervention- no. 
(%) 
  
     Right  25 (83.3) 23(76.6) 
     Left 





Size of effusion- no. (%) 
Less than half hemithorax 










Fluid biochemistry  
Fluid LDH, U/L- mean (SD) 











 Management at baseline 
Data was collected on the management of patients at enrolment, including ipsilateral drainages 
during the last 3 months month and diuretic medications.  The baseline management for each 
study group are displayed in table 9. Most patients, 46/60 (76.7%) were on a loop-diuretic, 
typically furosemide, 35/46 (76.1%), with 11/46 (23.9%) on bumetanide. The mean dose of 
furosemide was 52.8mg (SD 65.6) and mean dose of bumetanide was 0.65mg (SD 1.6). 14/60 
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(23.3%) of patients were taking spironolactone, at a mean dose of 32.3 mg (SD 74). 45/60 (75%) 
of patients had an ipsilateral aspiration in the last 3 months. There is limited comparative data to 
determine if this is representative of other studies on refractory transudative effusions. The study 
by Kataoka et al which demonstrated a 75% improvement resolution rate in patients with cardiac 
pleural effusions, did not state medication doses. In that study 48% of patients were on diuretics, 
38% on digoxin and 30% on ACE-inhibitors(20).  The study by Srour et al detailing the use of IPCs 
for cardiogenic pleural effusions also did not state medication dosing, only that patients ‘were 
required to have failed to respond to maximal medical therapy or have complications from 
medical therapy (e.g. renal failure while receiving diuretics or hypotension during dialysis)’(72). 
Other similar studies also are limited by their lack of dosing data(66, 71, 75). The mean dose of 
diuretics appears lower than one would anticipate in a population managed for refractory 
transudative effusions. This may be that patient were experiencing complications secondary to 
high-dose diuretics, or perceived unresponsive of the pleural effusions to diuresis.    The mean 
aspiration volume in the 3 months prior to enrolment was 2228.6ml (SD 2627.8). Again, there is 
little comparable data detailing aspiration amounts in this patient cohort.  
 
Table 9. Baseline management of 1st 60 patients in the REDUCE trial 
 IPC (n=30) Standard care (n=30) 
Ipsilateral Pleural Drainage in last 
3 months- no. (%) 
 
23 (76.7) 22 (73.3) 
Ipsilateral drainage amounts in 
last 3 months, mls- mean (SD) 
2549.9 (2889.72) 1907(2343.7) 
Loop Diuretic- no. (%) 21 (70) 26 (89.3) 
Furosemide dose, mg- mean 
(SD) 
53.7 (69.3) 51.8 (62.0) 
Bumetanide dose, mg- mean 
(SD) 
0.6 (1.6) 0.7 (1.6) 
Spironolactone- no (%) 4 (13.3) 10 (33.3) 
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     Spironolactone dose, mg- 
mean (SD) 
21.7 (66.2) 45.8 (81.3) 
 
Table 10. Diuretic dose per aetiology 










































































Table 10 details the breakdown of diuretic doses in patients with heart, liver and renal failure. The 
majority on heart failure patients were on loop diuretics (either furosemide or bumetanide), with 
36/38 on diuretics. This is compared to lower proportions in patients with liver and renal failure, 
with 8/16 and 2/4 respectively on loop diuretics. Potassium-sparing diuretics such as 
spironolactone were used more frequently in liver failure patients with 8/16 receiving them, 
compared to 6/38 and 0 in heart failure and 0/4 in renal failure. 
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3.4. Results: Recurrence rates in primary spontaneous 
pneumothorax: a systematic review and meta-analysis 
We undertook a literature search of adult with PSP, with an outcome of interest was recurrence, 
as outlined in the method section. The search identified 3,607 publications, of which 29 were 
eligible for inclusion (Figure 12). Overall pooled recurrence rate was 32.1% (95% CI 27.0% to 
37.2%) (Figure 13). 12 studies documented 1-year recurrence, with a pooled recurrence rate of 
29.0% (95% CI 20.9% to 37.0%).  
  
 
Figure 12. PRISMA flow diagram of study selection.                                                                                                
PSP: primary spontaneous pneumothorax. 
 
A total of 13,548 patients were included in the studies, with a median sample size of 79(range 18 
to 10,956). 85% were male. Study dates ranged from 1965 to 2017. Four randomised control trials 
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(RCT) were included; one compared NA to ICD insertion, 2 compared pleurodesis with standard 
care and one compared conservative management to surgery.  Twenty-five observational studies 
were included: 21 retrospective, 3 prospective and one population-based epidemiological study.  
Average follow-up time varied significantly between studies, with mean duration ranging from 3 
to 96 months. A summary of included studies is provided in Table 11.  
There was considerable variation in reported recurrence rates, ranging from 8%  to 74% (173). I2 
for the random effects meta-analysis was 94% (p<0.0001).  This is likely to reflect the wide variety 
of patient populations, methodologies and interventions studied in the included papers. 
Assessment of risk of bias showed a high risk of bias in at least one domain for all included studies.   
 
Table 11. Characteristics of included studies 











Al-Alawi (210) 2009 Retrospective  208 Cx, ICD,   Nil Not stated 42MN 0.35 
Al-Mourgi 
(211) 
2015 RCT 22 Cx, S Underwent 
surgery(19) 
1st 32.4MN 0.41 
Andersen 
(212) 
1965 Retrospective  138 Cx, ICD SSP (48) 1st 71MN 0.16 
Casali (163) 2013 Retrospective  176 Cx, ICD,   Nil 1st 58 MN  0.46 
Chan (202) 2006 Retrospective  89 NA Nil 1st & 
recurrent 
12  0.16 
Chen (213) 2008 Retrospective  18 ICD, S  Underwent 
surgery (34) 
1st 16MN 0.28 
Chen (214) 2008 Retrospective  33 NA, P Underwent 
pleurodesis 
(31) 
1st 13 MN 0.33 
Chen (215) 2013 RCT 108 ICD, P  Underwent 
pleurodesis 
(106) 
1st 12 0.49 
Ganesalingam 
(164) 
2010 Retrospective  100 Cx, ICD Nil 1st  57MN 0.54 
Harvey (95) 1994 RCT 73 NA vs ICD Nil 1st  12  0.21 
Huang (216) 2017 Epidemiologic
al 
10956 Cx, ICD, S  Underwent 
surgery (8606) 
1st 60 to 
144  
0.24 
Karasaki (217) 2014 Retrospective  93 HVCD Underwent 
surgery (6) 
1st  12.5MD 0.34 
Kim (218) 2014 Retrospective  55 Cx, ICD, S  Underwent 
surgery  (1) 
1st & 
recurrent 
 Unclear 0.16 




1st 3 0.08 





Lichter (220) 1974 Retrospective  24 Cx, ICD, S SSP (54) 
Underwent 
surgery (18) 
1st 60-144  0.08 







29.1MN  0.32 
Martinez-
Ramos(162) 
2007 Retrospective  55 Cx, ICD Nil 1st 30.7MN 0.24 
Mehta (200) 2016 Retrospective  216 ICD Nil Not stated 14 MD  0.13 
Nishiuma 
(221) 
2012 Retrospective  66 NA Failed NA (25) 1st & 
recurrent 
12  0.36 
Noh (222) 2015 Retrospective  109 Cx, ICD, S ≤19 age (328) 
+ Underwent 
surgery (76) 
Not stated   Unclear 0.48 
Noh (223) 2015 Retrospective  79 Cx, ICD Underwent 
surgery (183) 
Not stated Unclear 0.37 
Olesen (158) 2016 Prospective 
cohort study  
257 Cx, ICD Nil 1st 43.2MD  0.56 
Ouanes -
Besbes (174) 







1st 34 MN 0.23 
Primavesi 
(173) 
2016 Retrospective  23 Cx, ICD, S Underwent 
surgery (33) 
1st 67 MD 0.74 
Sadikot (156) 1997 Retrospective  153 Cx, NA, ICD Nil 1st 54 MN 0.54 
Sayar (224) 2014 Prospective  154 ICD, S  Underwent 
surgery (27) 





78 Cx, ICD, S  Underwent 
surgery (97) 




96 MN 0.39 




1st 39 MD  0.56 
Tulay (226) 2015 Retrospective  68 ICD, S Underwent 
surgery (14) 
1st Unclear 0.27 
Cx: Conservative; HVCD: Heimlich valve chest drain; ICD: intercostal drain; MN: mean; MD: Median; NA: needle aspiration; NS: not stated; RCT: 
randomised control trial; P: Pleurodesis; S: Surgery 
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3.4.1. Study types 
All studies included participants drawn from clinical populations, apart from one epidemiological 
study that analysed population-level data, from a national health research database in 
Taiwan(23).  This study of over 10,000 people, from a 13 year period, reported a slightly lower 
recurrence rate of 23.7% (95% CI 22.9 to 24.5), when surgically managed patients were excluded, 
compared with the pooled estimate for clinical studies (32.6%, 95% CI 26.1 to 39.2). Recurrence 
rates were similar for randomised and non-randomised studies (35.4%, 95% CI 18.7 to 52.1 vs 
31.7%, 95% CI 26.3 to 37.1). 
 
Figure 13. Estimate of recurrence of primary spontaneous pneumothorax (PSP) in clinical and    
populations studies. 
NA: not applicable. #: weights are from random effects analysis. 
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3.4.2. Factors associated with recurrence 
Twelve observational studies examined the association between gender and PSP recurrence(156, 
158, 163, 164, 173, 174, 200, 201, 210, 216, 222, 223), with eight demonstrating increased 
recurrence rates in females (156, 158, 163, 164, 174, 201, 210, 222). Odd ratios could be 
determined from seven studies,(156, 164, 174, 200, 201, 210, 222) with random-effects meta-
analysis demonstrating an OR of 3.0 (95% CI 1.24 to 7.41, p=0.015) for female gender (see Figure 
14). 4 studies reported hazard ratios for gender and meta-analysis yielded an estimated HR of 1.2 
(95% CI 0.83 to 1.67, p=0.35) associated with being female (158, 163, 164, 173). Two studies, 
which demonstrated no difference between genders, were not included as either OR/HR could 
not be calculated(216), or only contralateral recurrences were examined in the gender subgroup 
analysis(223).  
 
Figure 14. Meta-analysis of odds ratios for primary spontaneous pneumothorax recurrence in males 
versus females from seven observational studies.  
#: weights are from random effects analysis. 
Several different definitions and cut-offs were used to categorise smoking habits, weight and age, 
and therefore meta-analysis was not possible. Five observational studies examined the 
relationship between current smoking and recurrence (156, 158, 164, 201, 210) with only one 
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demonstrating a convincing association(210). However, smoking cessation was associated with 
reduced recurrence in 2 studies with OR of 0.22 (95% CI 0.05 to 0.97) and 0.28 (95% CI 0.10 to 
0.89) respectively, with a pooled OR 0.26 (95% CI 0.10 to 0.63) (156, 210).  
Eight observational studies examined BMI or weight (156, 158, 163, 173, 201, 210, 222, 223) with 
2 demonstrating a significant association between low BMI/weight and recurrence(158, 201).  
Thirteen studies examined whether age correlated with recurrence(156, 158, 163, 164, 173, 174, 
201, 202, 210, 216, 218, 222, 223), with ten studies finding no association (156, 158, 163, 164, 
174, 201, 210, 218, 223, 227, 228). Three studies demonstrated an increased risk with younger 
patients (216, 222, 223) 
Four studies examined CT radiographic scoring systems, based on number, size and distribution 
of air-filled lesions (162, 163, 173, 174). The scores were not comparable, and produced 
conflicting results, which were not suitable for meta-analysis. Two studies found an association 
between radiographic evidence of blebs and recurrence risk (163, 173) and two studies did not 
(162, 174). One study concluded that chest radiograph features such pleural thickening, 
blebs/bullae, pleural irregularities and pleural adhesions were associated with an increased 
likelihood of recurrence (164). 
Only one study compared recurrence in patients treated with needle aspiration versus chest drain 
(164), therefore precluding meta-analysis.  There were no RCTs comparing medical interventions 
with conservative management. Six non-randomised studies compared conservative 
management with either NA or ICD, with neither approach demonstrating a reduction in 
recurrence risk (OR 0.78, 95% CI 0.47 to 1.31, p 0.353 - see Figure 15)  (156, 158, 164, 216, 218, 
222). 
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Figure 15. Odds ratios for recurrent pneumothorax following conservative management or 
intervention (needle aspiration or intercostal drainage) from six observational studies.  
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3.4.3. Meta-regression 
Univariable meta-regression did not demonstrate any significant association between PSP 
recurrence and study size, publication year, eligibility criteria, type of study, PSP type (first or 
recurrent) or follow up period (see Table 12).  
There was considerable unexplained residual heterogeneity even after adjusting for the different 
study characteristics.  
Table 12. Univariable meta-regression of study characteristics 
  N Studies Pooled recurrence 




Study sample size  
<100 18 28.8 (21.7, 36.0)  0.234 94.05% 
>100 11 37.0 (28.4, 46.6)   
  
Publication year 
Before 2000 6 26.3 (11.5, 41.1) 0.324 94.05% 
After 2000 23 33.6(27.8, 39.4)   
  
Pneumothorax type 
1st pneumothorax 18 35.7 (27.9, 43.5) 0.273 94.02% 
1st & recurrent 
pneumothorax 
6 23.4 (16.7, 30.1) 
  
Not stated 5 29.4 (17.0, 41.8)   
Follow-up period 
<24 months 10 26.5 (17.7, 35.2)    0.303 93.84% 
>24months  15 35.9 (27.9, 43.9)   
  
Not stated 4 31.9 (18.4, 45.4)   
Type of study 
Non-randomised 25 31.7 (26.3, 37.1) 0.729 93.91% 
Randomised  4 35.4 (18.7, 52.1)   
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3.5. Results: Conservative management in traumatic 
pneumothoraces: an observational study  
 
3771 trauma patients presenting to major trauma centre (MTC) at Southmead Hospital, Bristol, 
were registered on the TARN database from April 2012 to December 2016. 765 patients were 
identified using the search criteria. 636 patients with pneumothoraces were identified, with 602 
patients (see Figure 16) included for analysis.  Table 13 summaries patient demographics, 
mechanism of injuries, ISS, pneumothorax characteristics, management and outcomes for 
patients managed non-conservatively and conservatively.  Table 14 summaries the characteristics 
and outcomes for successful and failed observed management.  
 
Figure 16. Diagram: demonstration of the numbers of patients included in the study, providing reasons 
for non-inclusion where necessary. 
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Traumatic pneumothoraces were present in 636/3771 (17%) of trauma patients during the study 
period. The mean age was 48 (SD 22), 438/602 (73%) were male, and 330/602 (55%) suffered their 
injury as a result of a road traffic accident. The mean ISS score (26) represented very severe 
injuries; and 189/602 (31%) required immediate invasive ventilation and 56/602 (9%) died during 
admission. 325/602 (54%) of patients had an intervention performed pre-hospital or on 
admission, either with needle decompression, chest tube insertion or chest surgery, with the 
remaining 277/602 (46%) of the pneumothoraces were initially treated conservatively. The 
patients managed conservatively, had significantly smaller pneumothoraces compared to patient 
managed with an immediate intervention (median 5.5mm vs 22mm), with the majority less than 
10mm in size (see Figure 17). 
 








Age, yr (SD) 48.8 (21.5) 47.1 (21.9) 0.36 
Male Gender (%) 252 (77.5) 186 (67.1) 0.04 
Mechanism of injury (%)   0.04 
• Vehicle collision 175 (53.8) 155 (56)  
• Fall <2 meters 58 (17.8) 55 (19.9)  
• Fall >2 meters 52 (16) 48 (17.3)  
• Stabbings 25 (7.7) 5 (1.8)  
• Crush injuries 7 (2.2) 8 (2.9)  
• Blows 8 (2.5) 6 (2.2)  
Mean ISS (SD) 26.9 (14.7) 25.0 (12.3) 0.08 
Median Pneumothorax size, mm (IQR) 22 (35.9) 5.5 (8.8) <0.001 




Figure 17. Distribution of pneumothorax size in conservatively management patients  
 
Significant (>2cm) haemothorax (%) 58 (17.8) 17 (6.1) <0.001 
Initial PPV (%) 127 (39.1) 62 (22.4) <0.001 
Subsequent PPV (%) 159 (48.9) 139 (50.2) 0.12 
Presence of Respiratory distress (%) 199 (61.2) 138 (49.8) 0.06 
Presence of hemodynamic compromise (%) 132 (40.6) 71 (25.6) <0.001 
Presence of decreased GCS (%) 135 (41.5) 90 (32.5) 0.03 
Median Hospital length of stay, days (IQR) 10 (17) 10 (13.5) 0.351 
Median ICU length of stay, days (IQR) 2 (9.5) 0 (5) <0.001 
Mortality (%) 11.1% 7.2% 0.1 
GCS: Glasgow coma scale, ICU: intensive care unit,  
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Patients who were managed with an immediate intervention also had a higher incidence of 
respiratory, hemodynamic and neurological compromise, and a higher proportion of significant 
haemothorax than those managed conservatively. Both groups, have comparable ages, ISS score, 
mortality rate and total LOS.  
Of the 277/602 (46%) of patients managed conservatively, 252/277 (90%) did not require 
subsequent thoracic intervention. This included the majority, 56/62 (90%), of patients requiring 
immediate PPV who were treated conservatively. There was no significant difference in the failure 
rate between the patients on PPV (6/62, 9.7%) and those not requiring PPV (19/215, 8.8%) in the 














Age, yr (SD) 46.7 (22.4) 51.2 (16.2) 0.33 
Male Gender (%) 169 (67.1) 17 (68) 0.92 
Mechanism of injury (%)   0.72 
• Vehicle collision 142 (56.3) 13 (53)  
• Fall <2 meters 49 (19.4) 6 (24)  
• Fall >2 meters 42 (16.7) 6 (24)  
• Stabbings 5 (2) 0  
• Crush injuries 8 (3.2) 0  
• Blows 6 (2.4) 0  
Mean ISS (SD) 24.9 (12.5) 25.0 (11.0) 0.97 
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Using univariate analysis, size of pneumothorax, mechanism of injury, presence of rib fractures, 
clinical condition, surgery and ISS were not significantly associated with failure of conservative 
management (Table 15). The median size of pneumothorax (5.3 vs 8.2 mm p 0.13) was comparable 
between groups and did not increase the likelihood of progression requiring chest tube insertion, 
with HR of 1.61 (p 0.08) and 2.84 (p 0.07) on univariate and multivariable analysis 








Male Gender 1.05 0.92 (0.45, 2.2) 
Size of pneumothorax (≥2cm vs <2cm) 1.61 0.08 (0.94, 2.76) 
Bilateral vs unilateral pneumothorax. 1.34 0.25 (0.83, 2.12) 
ISS score (very severe vs severe and moderate 
severe) 
1.17 0.69 (0.54, 2.58) 
Presence of rib fractures 1.15 0.57 (0.71, 1.88) 
Haemothorax (>2 cm) 4.08 <0.01 (1.53, 10.88) 
Median Pneumothorax size, mm (IQR) 5.3 (8.6) 8.2 (16.5) 0.13 
Significant (>2cm) haemothorax (%) 12 (4.9) 5 (20) <0.01 
Initial PPV (%) 56 (22.2) 6 (24) 0.84 
Subsequent PPV  (%) 123 (49) 16 (64) 0.15 
Presence of Respiratory distress (%) 124 (50.2) 14 (60.9) 0.33 
Presence of hemodynamic compromise (%) 67 (27.2) 4 (18.2) 0.36 
Presence of decreased GCS (%) 80 (32.3) 10 (40) 0.43 
Median Hospital length of stay, days (IQR) 10 (13.8) 11 (14.5) 0.66 
Median ICU length of stay, days (IQR) 0 (4) 3 (12.0) 0.15 
Mortality (%) 7.1% 8% 0.88 
GCS: Glasgow coma scale, ICU: intensive care unit,  PPV:  Positive Pressure Ventilation 
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Received initial Positive Pressure Ventilation 1.1 0.84 (0.44, 2.76) 
Received subsequent Positive Pressure 
Ventilation 
2.10 0.08 (0.91, 4.87) 
Presence of Respiratory distress 1.23 0.33 (0.810, 1.87) 
Presence of hemodynamic compromise 0.78 0.37 (0.45, 1.34) 
Presence of decreased GCS 1.17 0.45 (0.78, 1.74) 











P Value 95% Confidence interval 
 
Haemothorax >2cm  5.29 <0.01 (1.78, 15.79) 
 
Univariate and multivariable analysis also confirmed that acute PPV does not appear to confer an 
additional risk of failure of conservative management (HR 1.56 p 0.51 and HR 1.05 p 0.96 
respectively). Additionally, requiring subsequent PPV during inpatient stay, either due to clinical 
deterioration, or for general anaesthesia did not represent an increase risk of failure of 
conservative management. In contrast, the presence of a haemothorax was associated with 
increased likelihood of failure of expectant management (hazard ratios of 4.08 (p < 0.01)) and 
confirmed by multivariable cox regression analysis (Table 17). 
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Table 17. Overt and Occult pneumothoraces characteristics  




Age, yr (SD) 52.04 (23.80) 56.30 (20.45) 
Male Gender (%) 48 (78.7) 47 (72.3) 
Median size of pneumothorax 
on CT, mm (IQR) 
7.26 (12.39) 25.07 (37.46) 
Median ISS (IQR) 20.00 (9.50) 16.00 (11) 
CT: computerised tomography 
 
Of the 25/252 patients who failed observed management, 23 had a large chest drain inserted and 
2 went to have thoracic surgery (rib fixation with haemothorax evacuation). The main indication 
for chest tube insertion was increasing pneumothorax (19/23) and enlarging 
haemopneumothorax (4/23). The mean duration prior to chest tube insertion was 2.96 days (SD 
4.03). Requiring subsequent chest insertion in the conservative arm led to a non-significant 
increase in length of stay (11 vs 10 days p 0.597). The 2 mortalities in this group had severe ISS of 
40 (>25 represents severe/critical injuries) with intracranial haemorrhages and it is unlikely that 
the pneumothorax contributed to the overall outcome. 
Table 17 demonstrates the characteristics of patients with a pneumothorax visible on chest 
radiograph (overt pneumothorax) and those not visible on chest radiograph (occult 
pneumothorax). 177 patients had a chest radiograph as their initial chest imaging. 137 of these 
patients proceeded to a CT chest. Of these 137 patients, 11 had a chest drain in-situ at time of 
chest radiograph. Of the remaining 126, 61/126 (48%) had no visible pneumothorax. Occult 
pneumothoraces were generally smaller than the overt pneumothoraces, with respective median 
size of 7.26mm vs 25.07mm (p<0.001). 
There was a 10% complication rate associated with chest tube insertion. 15 (4.4%) patients 
required their drain to be re-sited, 4 (1.2%) patients had their drains dislodged, 5 (1.5%) had 
intraparenchymal drains on CT, 2 (0.6%) patients developed an empyema, and 1 (0.3%) patient 
had a guidewire left in the pleural cavity.  8 (2.4%) patients required a subsequent drain after 
initial removal due to re-accumulation of air or fluid. 
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3.6. Results: Heimlich Valves in Secondary Spontaneous 
Pneumothorax: Enhancing Care (HI-SPEC trial) 
The first patient was recruited for the Hi-SPEC trial on the 21st March 2017. The trial is currently 
recruiting, with an end-recruitment date of 12th June 2019. Currently 35 patients have been 
recruited (see Appendix F for full breakdown of recruitment). 
The end-recruitment date is 12th June 2019, with 6-month follow-up, and the study end date will 
be 12th December 2019.   Monthly reminders will be sent for data queries and missing data from 
1st June 2019.  The data will be cleaned from August 2019 and Stata code will be developed by 
the trial statistician from the statistical analysis plan in November 2019. I anticipate the final 
manuscript will be ready for publication by Summer 2020.   
 
3.6.1. Screening  
92 patients were screened for the Hi-SPEC trial, with 35 enrolled at time of PhD submission. The 
majority of patients were excluded from the trial (33/92) as they had already had a drain inserted 
prior to screening. This was either due to the drain inserted as an emergency procedure out of 
hours (n 18) or the potentially eligible patient was missed by the trial team (n 15). The technical 
reasons were typically concerning difficult drain placement, i.e. tethered lung or apical or small 
pneumothorax.  
- 120 - 
 
 
Figure 18. HI-SPEC trial Consort diagram 
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3.6.2. Patient Baseline characteristics 
The baseline patient characteristics for the first 30 patients is included in table 18.  
Table 18. Baseline characteristic of first 30 patients in Hi-SPEC trial   
 Heimlich Valve (n=15) Standard care (n=15) 
Age – mean (SD) 64.4 (12.3) 66.5 (8.6) 
Male – no. (%) 10 (66.7) 12 (80) 
Side of pneumothorax - no. (%)    
Right 9 (60) 9 (60) 
Left 6 (40) 6 (40) 
Size of pneumothorax at 
presentation (Interpleural 
distance at hilar point) -cm  
3.8 (2.7) 4.7 (2.) 
Smoking status – no. (%)   
     Current smoker 6 (42.9) 5 (38.5) 
     Ex-smoker 8 (57.1) 7 (53.8) 
     Never-smoker 0 1 (7.7) 
     Pack year history- Mean (SD) 32.8 (15.5) 31.7 (16.4) 
Previous pneumothorax – no. 
(%) - 
6 (42.9) 9 (38.5) 
Respiratory history – no. (%)   
     COPD 10 (71.4) 10 (76.9) 
     Asthma 1 (7.1) 4 (30.8) 
     Interstitial Lung Disease 0 0 
     Non-CF Bronchiectasis  0 0 
     Lung Cancer 0 0 
     Pulmonary infection 0 1 (7.7) 
   
- 122 - 
 
From the analysis of the baseline characteristics for the first 30 patients, there was no significant 
difference between the HV and standard care cohort in pre-determined characteristics.  The 
patients were predominately male (67%), with right sided pneumothorax (60%), predominately 
secondary to COPD (71%). This COPD and right sided preponderance of SSP is consistent with pre-
existing literature(124). The overwhelming majority were smokers or ex-smokers (97%).  
 
3.6.3. Adverse events 
The population of patients involved in the Hi-SPEC trial is such that a high number of AEs are to 
be expected. By virtue of the eligibility criteria all patients will have pre-existing lung disease and 
at risk of AEs related to pre-existing disease. Additionally, AEs may be expected from trial 
interventions. Expected AEs are those documented in the reference documents for events 
associated with trial interventions. Data will be collected on CRFs for expected AEs. 
Expected adverse events which relate to chest drain insertion or Rocket Pleural Vent insertion 
include: 
• Minor Bleeding (defined as not causing haemodynamic compromise or requiring blood 
transfusion) 
• Minor Pain (defined as settling spontaneously or controlled with analgesia) 
• Subcutaneous emphysema (unless causing airway compromise or requiring surgical 
intervention) 
• Pleural infection (unless requiring surgical intervention) 
• Subcutaneous infection at drain insertion site 
• Unintentional removal or dislodgement of chest drain or Rocket Pleural Vent 
• Requirement for further pleural procedures 
 
Other expected adverse events include: 
• Delayed discharge (unless due to a device defect) 
• Recurrent pneumothorax 
• Readmission to hospital 
• Death due to pre-existing disease 
Non serious AES  
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All such events, whether expected or not, should be recorded in patients’ clinical records. 
Information related to specific non-serious AEs will be collected within the trial data collection. 
Serious AEs  
Any event which meets the criteria for an SAE should be discussed with the local principal 
investigator. If in their opinion there is a reasonable possibility that the event is related to trial 
intervention, or if the event is of particular medical interest, it should be recorded on an SAE form. 
An SAE form should be completed and faxed to North Bristol NHS Trust (the trial sponsor) within 
24 hours of the investigator’s knowledge of the event. However, events meeting the criteria for 
an SAE but which are attributed to pre-existing lung disease or comorbidity, and hospitalisations 
for elective treatment of pre-existing conditions do not need reporting on the SAE form. 
 
 
 Serious Adverse Events 
As of 15th January 2019, there were 11 SAEs. The breakdown according to cohort was as follows:  
• Intervention arm: 7 SAEs   
• Standard care arm: 4 SAEs 
 
 Relevant AEs with Pleural vents 
There was particularly interest in AEs for the Pleural vent, which were felt relevant to a safety 
signal, but did not meet the criteria for SAE.  
 Overall, when AEs and SAEs were examined for the pleural vents there were 7 events which 
needed to be examined further by the TSC: 
• 2 vents dislodged - one resulted in subcutaneous emphysema, both required chest drain 
insertion (one developed subcutaneous emphysema after chest drain insertion) 
• 5 non-functioning vents - all resulted in subcutaneous emphysema, 4 required chest drain 
insertion  
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3.6.4. Details of Adverse Events with Pleural Vent 
 N06 
Event: subcutaneous emphysema and vent blocked 
When: 2 days after insertion  
Description: subcutaneous emphysema 05/05/2017 to 27/06/2017 requiring suction. Vent 
blocked 12/05/2017. Discharged with vent in place 16/05/2017 
Outcome: vent removed due to successful lung re-expansion 26/05/2017. 
 B08 
Event: Rocket pleural vent became dislodged  
When: 1 day after insertion (01/09/2017) 
Description: Rocket pleural vent become dislodged whilst patient was sleeping.  
Outcome: Chest drain inserted 02/09/2017. Subcutaneous emphysema 05/09/2017. VATS 




Event: Pneumothorax increased in size + developed subcutaneous emphysema – vent removed 
When: 1 day after insertion 
Description: Pneumothorax increased in size and developed subcutaneous emphysema despite 
vent 
Outcome: Chest drain inserted 02/05/2018 and 08/05/2018 while having bullectomy and talc 
pleurodesis. Discharged 17/05/2018 
 
 S15 
Event: subcutaneous emphysema on day 2, vent blocked and removed. 
When: 2 days after insertion 
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Description: ‘Vent blocked- not working’ 
Outcome: Chest drain inserted 
 
 N18 
Event: subcutaneous emphysema on day 2, vent blocked and removed. 
When: 2 days after insertion 
Description: ‘Vent blocked- not working’ 
Outcome: Chest drain inserted 
 
 N27 
Event: Pneumothorax increased in size + developed subcutaneous emphysema 
When: 2 days after insertion 
Description: Initial Vent inserted. Initially good re-inflation. Static pneumothorax next day – 
Discharged. Day 2 review: Pneumothorax increased in size with evidence of subcutaneous 
emphysema, vent removed  
Outcome: Admitted- Chest drain inserted 
 
 F28 
Event: Pneumothorax increased in size + developed subcutaneous emphysema 
When: 2 days after insertion 
Description: Initial Vent inserted. Initially good re-inflation. Discharged day 2. Re-presented with 
SOB and subcutaneous emphysema.  
Outcome: Admitted and wide-Bore Chest drain inserted 
3.6.5. Trial safety: Adverse events in the Hi-SPEC study 
Trial participant safety was the most important consideration for the Hi-SPEC trial. Adverse events 
were recorded in a written log, and this was uploaded to the online database by the local trial 
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team. These were reviewed episodically by the trial coordinators. Any event which met the criteria 
for an SAE was faxed to the trial sponsor within 24 hours of the investigator’s knowledge of the 
event. All SAEs were reviewed monthly by the trial team, with no predefined safety stopping 
boundary. As this trial was unblinded to both investigator and patient, the SAEs could be analysed 
as the trial progressed. 
In January 2019, in the Hi-SPEC trial, it was recognised that there was a numerical imbalance 
between SAEs in the intervention (7) and the standard care treatment arm (4). On review of the 
SAEs, there appeared to be related causality to the study intervention (pleural vent) in the 
majority of cases. Additionally, on review of the AEs log, there were AEs which shared common 
features as the SAEs, although not reaching the threshold criteria for SAEs. Of particular concern 
were 5 pleural vents which become non-functional, with 4 of these patients requiring subsequent 
chest drain insertion. Additionally, 2 pleural vents became dislodged, both requiring chest drain 
insertion. 
These concerns were addressed at an emergency TSC meeting. These SAEs were not felt to be 
associated with any particular study site or a procedural competency that could be remedied. No 
patients came to significant harm from the pleural vent and no patients died as a result of the 
intervention. A discussion was held as to whether to terminate the trial prematurely. 
 
3.6.6. Rationale for early trial cessation 
Randomised controlled trials can be stopped early for four major reasons(229). Firstly, the trial 
can be stopped early due to concerns regarding for unacceptable safety if it shows serious adverse 
effects. Secondly, the trial can be stopped due to ‘futility’, where interim differences between the 
two groups are so unimpressive that any prospect of a positive result with the planned sample 
size is deemed to be extremely unlikely. Thirdly, new external information may arise during the 
conduct of the study that either convincingly answers the primary study question or raises serious 
safety issues. Finally, interim analysis may demonstrate such convincing benefit in the 
intervention, that the investigators may elect to stop the trial early due to the apparent benefit.  
In our trial, a discussion was held to consider whether to stop the trial early due to potential harm 
to the trial participants in the intervention arm (pleural vent). There are several ethical 
considerations to be made at this point.  Before starting a randomized controlled trial there must 
be a defined area of uncertainty amongst the medical profession. This is sometimes referred to 
as ‘group’ or ‘collective equipoise’(230). In our study, there was collective equipoise, with 
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perceived uncertainty about the intervention, and systematic review of the literature suggested 
a benefit, but with recognised lack of reliable data(180). In an open, unblinded study, it should be 
recognised that it is possible that this collective equipoise is not shared by individual investigators 
which may affect recruitment.  
The dangers of premature cessation of a study must be recognised.  Terminating RCTs early due 
to apparent benefit has been shown by a simulation study published in 1989 by Pocock et al to 
lead to an overestimate of treatment effects(231). The role of chance must be appreciated as well, 
as famously demonstrated by a ‘double-blind’ clinical trial where patients with chronic disease 
were randomised between treatment with prayer compared to control. The first 6 results showed 
an advantage to the group treated with prayer, and this could have led to the termination of the 
study (232). However, five of the next six showed an advantage to the ‘control’ group.  
The dilemma regarding stopping a trial early due to potential harm can be summarise as: 
• Stopping too soon with only modest evidence of harm, thereby risking abandonment of 
a treatment that might have proved beneficial had additional longer-term data been 
obtained.  
• Permitting a trial to continue in the face of growing evidence of harm, thereby risking 
further patient exposure to a harmful treatment(233). 
3.6.7. Outcome of Hi-SPEC trial steering committee  
During the TSC the individual AEs were examined. It was recognised that out of the 13 patients 
receiving a pleural vent, 5 become non-functioning and 2 become dislodged. This was felt to be 
an unacceptably high risk of failure for study participants. A retrospective analysis of the risk of 
requiring additional chest drain insertion in patients with pleural vents versus standard care, 
suggested an increased risk signal as the study progressed  (see Figure 19). Here I calculated the 
Hazard ratio for patients requiring additional chest drain at 6 monthly interims in Pleural vents 
versus standard care. This was to determine if this increase risk had been present earlier on in the 
trial. As figure 19 illustrates, the HR at 6 months was 0.693 (95% CI 0.043,11.16), 12 months was 
0.745 (95% CI 0.05, 12), 18 months 1.37(95% CI 0.2, 8.2) and 24 months 3.1(95% CI 0.6, 15.4). 
Whilst the confidence intervals were broad and none of the lower intervals were greater than 1, 
the trend is clearly one of escalating treatment failure with the Pleural Vent as the trial 
progressed.  
 




Figure 19. Hazard ratio and 95% CI for patients requiring additional chest drain at 6 monthly interims 
in Pleural vents versus standard care 
 
With the increasing evidence that Pleural Vents were more prone to treatment failure and with 
an alternative device available in the intervention arm (Atrium Pneumostat) a decision was made 
to withdraw the Rocket Pleural Vent and continue with just the Atrium Pneumostat in the 
intervention arm. This would mitigate the potential risk posed by continuing use of the Rocket 
Pleural Vent, whilst allowing the overall trial on ambulatory management of SSP to continue. 
An urgent safety measure written by myself and sent to the HRA. All recruiting sites were notified 
and asked to acknowledge receipt of notification.  Personal correspondence was made with all 
sites PI to answer and queries. 
We were aware that another currently recruiting trial was using the Rocket Pleural Vent on a 
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CHAPTER 4. DISCUSSION 
 
4.1. Refractory transudative effusions  
 
Non-malignant pleural effusions are not a benign process and represent a significant mortality 
risk. The results obtain via the survival cohort study demonstrates that patients with effusions 
secondary to organ failure (heart, liver, and kidney) are at significantly higher risk than those 
related to a local disease process, whether this be infection or inflammation. Correspondingly, the 
transudative, bilateral effusions that often accompany organ failure are independently associated 
with a worse prognosis., with 43% and 18% 1-year mortality in transudative and exudative 
effusions respectively and a 57% and 20% 1-year mortality rates in bilateral vs unilateral effusion.  
This supports the findings that pleural effusions secondary to organ (heart, renal and liver) 
dysfunction, as opposed to an exudative effusion secondary to localised inflammation are an 
indicator of poorer prognosis. This supports the findings of an earlier paper demonstrating high 
mortality rates in CHF, liver and renal failure(62).  These mortality rates are not dissimilar to that 
seen in some malignant disease. Effusions refractory to medical therapy and repeated aspiration 
may require more definitive management strategies. This may involve disease specific 
procedures, including transjugular intrahepatic portosystemic shunt (TIPS) procedure or liver 
transplantation in liver disease, or pleural interventions including pleurodesis or indwelling pleural 
catheter placement. 
The one year-mortality rate for patients with an effusion secondary to heart failure in this cohort 
was found to be 50%, similar to the 1- year mortality rate (46%) of patients with acute 
decompensated heart failure admitted to intensive and coronary care units(234) and significantly 
more than the 1 year mortality for outpatients with NYHA class IV CHF (28%)(235). Hepatic 
hydrothorax was also a predictor of significant mortality, with a quarter of patients dying within 
a year. This is higher than patients  with chronic alcoholic liver disease (16.4%)(236) and 
equivalent to a high MELD (Model For End-Stage Liver Disease) score of 20-29(236) which would 
be considered an indication for liver transplant.  The renal cohort in our study had a high 1-year 
mortality rate (46%)  which is  triple the one-year mortality (15.6%) of patients on dialysis (237). 
The increased hazard ratio associated with renal failure does not, however, reach significance, 
presumably due to low numbers in the cohort.  
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To my knowledge this is the largest prospective study to date examining the mortality rates in 
NMPE. It included approximately equal inpatient and outpatient numbers and involved patients 
managed by a range of specialities. All patients presenting with an undiagnosed pleural effusion 
were eligible aside from those excluded if they could not give informed consent, declined to 
participate in the trial or were pregnant or lactating. The findings are consistent with a previous 
study demonstrating high mortality rates in patients with CHF and bilateral effusions(62). A 
limitation of this study is that it was performed at a single centre. All these patients required 
pleural aspiration, either for diagnostic or therapeutic purposes. A diagnostic aspirate would not 
usually be indicated for an effusion with a high pre-test probability of cardiac aetiology and a low 
probability for an alternative cause. Hence it is likely that the CHF effusions aspirated were either 
refractory to medical management or there was a level of concern in the treating physician that 
warranted further invasive investigation. This is the likely explanation for pleural infection 
representing the commonest cause of NMPE in our cohort, as opposed to CHF worldwide(19). We 
cannot comment on the mortality rate amongst patients that did not require a pleural procedure, 
and it is likely that requiring an aspiration in NMPE is an indicator of disease severity.  
This study demonstrated that pleural effusions secondary to organ dysfunction, in particular 
cardiac, have an extremely high 1-year mortality and the presence of an effusion requiring 
aspiration is a marker of severe disease and poor prognosis. The median survival in these patients 
was not dissimilar to some malignancies, and it supports the idea that these patients should be 
managed in a symptom-based approach, and to minimise hospital length of stay.  
The follow-on study examined a cohort of 105 patients with cardiogenic pleural effusions. This 
cohort were predominantly outpatients (69%), with a high proportion (45%) with persevered LV 
function. The mean NT-proBNP was high as 7797 pg/L, however this value is likely positively 
skewed, as only 36 values available to this analysis, based on clinical decision at the time to 
perform the test. The mean diuretic dose, at 60mg, was a lower dose one might expect for 
patients failing to respond to diuretics management. This may be because higher doses of 
diuretics were contraindicated due to other comorbidities or side-effects. Eight patients were not 
on diuretics at time of enrolment to study. This may be because of diagnostic uncertainty of the 
underlying cause of the effusion at time of enrolment, with 5 of these patients having unilateral 
effusions. All these patients had a pleural aspirate to enter the study, the majority of which 
(62/105) were diagnostic.  
The overall proportion of patients who needed a further therapeutic pleural procedure (24%), is 
higher than the previously cited figure of 10% (20). The population studied may be more prone to 
re-accumulation, having already required one pleural procedure. No single variable studied was 
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predictive of re-accumulation. It may be with the small absolute numbers of patients experiencing 
re-accumulation (n 23), with a large number of variables studies (9), that the study was 
underpowered to detect a significant determinate. There are no previous studies examining 
factors associated with reoccurrence of cardiogenic pleural effusions. Morales-Rull et al examined 
factors associated with initial formation of pleural fluid in patients with CHF, finding that male 
gender, NT-pro-BNP levels >3500pg/ml, systolic pulmonary artery pressure (sPAP) >55mmHg and 
a serum prealbumin <15 were associated with pleural effusion development in a multivariate 
analysis(29). It must be noted that hypoalbuminaemia was uncommon in our patient cohort, with 
no patients with an albumin less than 15, and only one patient with an albumin less than 20mg/l.  
The study has its limitations. The original study design, a prospective cohort of patients with 
undifferentiated pleural effusions was not designed explicitly for patient with heart failure. Whist 
the majority of patients diagnosed with CHF had an echocardiogram, these were not reported in 
a standardised manner. Additionally, the collection of NT-proNBP was not standardised or 
consistent. As mentioned previously, the study may have been underpowered to detect a 
significant variable in determining recurrence.   
Overall, these studies have demonstrated that nearly a quarter of patients with cardiogenic 
effusions will have a symptomatic re-accumulation of their pleural effusion and have a poor 
prognosis.  With this in mind, the REDUCE trial, a randomised control trial examining the use of 
IPCs in non-malignant pleural effusion to alleviate symptoms in this cohort of patients, will add 
much needed evidence. The trial process was difficult, with recruitment slower than anticipated. 
In patients with pleural effusions caused by heart failure, screening demonstrated that there was 
a significant lag between identifying potentially eligible patients and recruitment. This was mainly 
due to ensure patients were medically optimised by their treating cardiologist. During this time, 
the patients could either be successfully medically optimised, in which case this was a useful 
finding, but rendered them ineligible to the trial, or they deteriorated to a point where insertion 
of an IPC was not recommended. Several patients also elected of immediate IPC insertion. As this 
is a commercially available device, with   U.S. Food and Drug Administration (FDA) 510(k) clearance 
for the use in specific non-malignant recurrent pleural effusions aetiologies, including congestive 
heart failure, the IPC is an available option. In patients with liver failure there were various 
recruitment challenges. Liver transplant is a definitive and curative option for eligible patients 
with hepatic hydrothorax. There is clinical equipoise as to whether IPCs should be inserted as 
bridge to transplant due to perceived increased infections risks, with transplant centre taking 
diametrically differing view. This partially reflects the sparsity of prospective research on the 
matter. A prospective study on IPC in hepatic hydrothorax demonstrated a high infection rate 
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(16%) however, there was no mortality related to IPC infection, with all three patients treated for 
pleural infection ultimately successfully undergoing liver transplantation (238). A retrospective 
case series demonstrated a higher rate of infectious complications in 18% (n 11) of patients, three 
of whom died of related sepsis(50). Of the 19 patients listed for transplant, 8 patients died prior 
to the procedure, including 2 of sepsis secondary to IPC-related empyema. Another recent 
retrospective study had a 10% rate of pleural infection (n 8), two of whom died secondary to 
sepsis(75). The situation is further complicated by the phenomenon of ‘spontaneous bacterial 
empyema’, secondary to intrathoracic translocation of infected ascites fluid (spontaneous 
bacterial peritonitis), with can occur in 13% of hepatic hydrothoraces. This is distinct from a 
genuine infected pleural space, and may explain why the reported rates of pleural infection are 
so high(239).  
Despite the recruitment challenges, recruitment rate increased as the trial proceeded. This was 
likely because of increased trial awareness amongst researchers and their sub-speciality 
colleagues. Increasing the numbers of sites, and the pool of potentially eligible patient also 
contributed to the increased recruitment. 
 
4.2. Pneumothorax  
4.2.1. Recurrence rates 
This thesis describes the first systematic review of the literature on recurrence rates in adults with 
PSP who have been medically managed. Meta-analysis of data from 29 studies, totalling over 
13,000 patients showed that 32% of patients will experience PSP recurrence, with most occurring 
within the first year.  Furthermore, it outlined several factors which increased the risk of 
recurrence. There was strong evidence that female gender was a risk factor for recurrence.  This 
is consistent with an epidemiological study that found an increased rate of pneumothorax 
recurrence in female patients, particularly in the age group 31-50 years of age, with re-
hospitalisation rates of 54% compared with 46% in males (127). It is recognised that a proportion 
of pneumothoraces in women are secondary to underlying gender-specific pathophysiology, 
including lymphangioleiomyomatosis (LAM) and catamenial (endometriosis and non-
endometriosis related) pneumothoraces.   Whilst catamenial pneumothoraces were historically 
thought to be a rare entity, with an early study attributing only characterising 1% of PSPs as 
such(240), a recent retrospective study demonstrated that up to 25% of women referred to 
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surgery for recurrent pneumothoraces had evidence of thoracic endometriosis (241). The 
presence of these underlying conditions may explain the higher risk of recurrence seen in women.    
Low BMI is an established risk factor for the initial development of PSP (105, 242).  Whilst two 
studies (158, 201) demonstrated increased risk of recurrence with low weight and BMI 
respectively, differing classifications precluded  meta-analysis. The hypothesis that PSP 
recurrence is linked with low body weight, either due to nutritional deficiencies affecting α1-
antitrypsin levels or due to unbalanced physical development was supported by two papers (158, 
201, 243-245). 
There is strong evidence supporting the link between smoking and developing a pneumothorax, 
with a clear dose-response relationship (105, 246). However, only one study in this review 
demonstrated an association between smoking  and recurrence,(210) with several studies 
demonstrating a trend towards increased recurrence in non-smokers (156, 158, 159, 164, 201, 
210).  It has been suggested that there is a difference in aetiology between PSP in smokers and 
non-smokers, with ‘never smokers’ suffering from a genetic predisposition to pulmonary bullae, 
regardless of smoking habit. However, a more likely explanation is that the detrimental effect of 
smoking was obscured by the high base-line rates of cigarette smoking in the included studies and 
the heterogeneous classifications used to define smoking status.  The fact that smoking cessation 
reduced the risk of PSP recurrence adds further weight to the relationship between smoking and 
PSP.  Interestingly, this finding also suggests that smoking-related risk is reversible, at least in 
terms of early PSP recurrence (156, 210).   
There were insufficient number of studies included to determine if the choice of medical 
interventions (NA vs ICD) for PSP influenced recurrence rates. A recent meta-analysis comparing 
RCTS of NA versus ICD insertion found no difference of recurrence at one year between the 
interventions (247). There was no randomised data comparing conservative management to NA 
or ICD, but non-randomised data demonstrated no difference in recurrence between conservative 
management and intervention. It has been hypothesised that conservative management 
decreases the risk of recurrence, as slow re-expansion of the lung enables healing of the pleural 
defect (89, 165). However, conversely, it has been postulated that chest drain insertion may 
inflame the pleural surfaces, promoting pleural symphysis and preventing long-term recurrence 
(210). An RCT comparing standard and conservative management is currently recruiting and may 
offer clarification(89).  
The presence of bullae on imaging has been postulated as a predictor of recurrence, however, 
this theory was not supported by the findings of this review.  The lack of standardised radiographic 
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scoring system may explain the conflicting results, although the hypothesis that rupture of bullae 
causes PSP is also debated (174, 244).  The modified dystrophic severity score (DSS), which 
assessed both blebs and bullae, appeared to be the most useful radiographic scoring system, 
however with a negative predictive value of over 90% but a positive predictive value of just 68%, 
it is of greatest value as a rule-out test (163).  The DSS has been used in one small subsequent 
study, but further prospective validation is required(173). 
The recurrence rates reported in the included studies varied widely, likely as a result of differences 
in study design and population, with no single identifiable study characteristics which explained 
the variation.   
This is the first systematic review of PSP recurrence rates, and it provides the most reliable 
estimate of overall recurrence to date, based on comprehensive evaluation of existing data.  
Having an accurate estimate for recurrence will enable clinicians to provide better counselling for 
patients who have experienced their first PSP.   Sub-group analysis identified factors associated 
with higher recurrence rates, including female gender and continued cigarette smoking.  This 
finding will facilitate communication with patients and could be useful in guiding further 
treatment or investigations.  For example, if a patient is thought to be at high risk of recurrence, 
early referral for surgery may be considered.  Thus, this systematic review has clear clinical 
relevance and immediate potential for impact.  
The methodology of the review was rigorous, with dual, independent screening of abstracts, 
review of papers, data extraction and assessment of study quality.  Hence, I feel the result of this 
review is a reliable summation of the existing literature. Nonetheless, the review does have 
limitations.  There was significant heterogeneity between the included studies, and although a 
random effects meta-analysis model was used, this heterogeneity may have reduced the precision 
of the final estimated recurrence rate. Some of this heterogeneity is likely to be a result of differing 
study populations, and it should be acknowledged that for specific populations their true 
recurrence rate might appreciably differ from the estimates given.  The inclusion of studies with 
heterogeneous populations means the resultant estimate for recurrence rate can be considered 
representative of the population at large, at the expense, however, of more accurate estimates 
for specific populations. This review is also limited by the quality of the data in the included 
studies.  RCT data was limited, and all included studies were at high risk of bias in at least one 
domain.  Non-randomised observational studies are at risk of selection bias and confounding by 
indication, and since many of the studies were also retrospective, there was a high risk of 
reporting and ascertainment bias.   
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4.2.2. Conservative management 
This thesis has outlined an increasing interest in conservative management of spontaneous 
pneumothorax, including the hypothesis that this encourages optimate pleural defect healing and 
reduce the risk of future recurrence. In patients with traumatic pneumothorax, there is similar 
uncertainty on the role of conservative approach. Chest drain insertion is not without risk of 
complication, with documented complications rates ranging from 15-30% (133, 248-250). Current 
guidelines recommends chest tube placement for traumatic pneumothorax, particularly in 
patients on PPV(137), with a caveat that asymptomatic non-ventilated patients can be managed 
with observation or aspiration at the treating clinician’s discretion. Existing literature has 
examined whether occult pneumothoraces can be managed conservatively (133, 134). Scoring 
systems, to determine whether chest tube intervention is required for occult pneumothoraces,  
are in their infancy and have not been prospectively validated (251). We sought to determine 
whether traumatic pneumothoraces can be treated conservatively and examine factors that 
safely identify patients who could avoid chest tube insertion. Here we show the majority of 
patients managed conservatively did not require further invasive intervention, including patients 
requiring PPV. 
Recent studies(133, 134) have focused on whether there is a role for conservative management 
for ‘occult’ pneumothoraces not initially visible on chest radiograph. The resultant positive 
findings, including patients on PPV, have been incorporated into clinical guidelines(252). Whilst 
these studies have been useful in establishing management pathways for traumatic 
pneumothoraces, they do have limitations. It is difficult to translate these findings into a clinical 
practice where CT is becoming the first line investigation, with the majority of patients (70%) in 
our study having a CT scan as their initial imaging. Furthermore, the distinction between overt 
and occult can be misleading; whether a pneumothorax is seen on chest film, is not solely related 
to its size, and can be influenced by other factors, e.g. use of supine chest radiograph has 
decreased sensitivity (140), with ‘occult’ pneumothoraces in our study reaching over 80mm in 
size.  
With this is mind we looked at the outcomes for traumatic pneumothoraces as a whole. Nearly 
half (46%) of the patients included were managed conservatively, with the majority of these, 
252/277 (90%), not requiring subsequent invasive treatment for their pneumothorax. This 
included 56/62 (90%) of patients who received immediate PPV. Multivariable analysis supported 
that immediate or subsequent PPV did not confer an additional risk of failure of conservative 
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management. This is consistent with the most recent study on occult pneumothoraces, with 
Moore et al demonstrating a failure rate of 14% of patients on PPV managed with observation. 
Whilst this was higher than their 4.5% failure rate for those not on PPV, PPV was not identified as 
an independent predicator of failed management on multivariate analysis (133)  and no patient 
developed tension pneumothorax related to delayed tube insertion.  Smaller, earlier studies 
found conflicting results. Wilson et al conducted a retrospective review of a Canadian trauma 
registry, identifying 68 occult pneumothoraces, comparing tube thoracostomy group to a without 
tube thoracostomy group. Both cohorts had patients who received PPV, 83% in the tube 
thoracostomy group and 48% in observed group.  Mortality was similar at approximately 10% in 
each group. Importantly, there were no instances of tension pneumothorax or pneumothorax 
progression requiring tube thoracostomy in the observation group, including patients who 
received PPV(134). Brasel et al(143) and Enderson et al (141) demonstrated  a 22% (2 out of 9)  
and 53%  (8 of 15) failure rate  respectively for patients with occult pneumothoraces on PPV 
managed with observation. In Brasel’s(143) paper, no patients developed tension and they 
concluded that observation was safe in these patient, whilst Enderson(141) et al, found that 3 
patients developed tension and recommended tube thoracostomy for all patients requiring PPV. 
It is possible that this failure rates may be related the ventilated settings over 20 years ago. This 
has led to ongoing debate regarding the management of occult pneumothorax on PPV. The East 
Practice Management Guidelines (2011) on occult pneumothoraces (252) recommend that occult 
pneumothoraces may be observed in stable patients regardless of PPV.  
The currently recruiting OPTICC trial (NCT00530725) which is randomising occult pneumothoraces 
on PPV between chest tube insertion in ventilated patients. The primary outcome was a 
composite of respiratory distress (RD) (need for urgent pleural drainage, acute/sustained 
increases in O2 requirements, ventilator dysynchrony, and/or charted respiratory events). An 
interim analysis from the OPTICC trial was published in 2013, including 90 patients, 40 were 
randomized to tube thoracostomy, and 50 were randomized to observation. There was no 
difference in mortality or ICU, ventilator, or hospital days between groups. In those observed, 20% 
required subsequent pleural drainage, predominantly for pleural fluid (60%). One patient (2%) in 
the observation group developed tension. There was a high degree of complications associated 
with tube thoracostomy, occurring in 15% of patients, with suboptimal tube thoracostomy 
position occurred in an additional 15% (253).  
There were limitations in these earlier studies, particularly selection bias. In Brasel at al’s study 
only 39 of 86 eligible patients were enrolled, with physician judgement, patient refusal, and 
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“enrolled but not randomized” listed reasons for exclusion. The OPTICC trial is also excluding 
patients if the physician believed drainage was necessary. 
In my study, the size of pneumothorax was not associated with failed observation on univariate 
and multivariate analysis, with non-significant differences in size of pneumothorax between the 
successful and failed observed groups. Pneumothorax size had previously been thought to be a 
predictor of progression(254), with De Moya et al(251) proposing a scoring system using size of 
occult pneumothorax and its relationship to the hilum to guide management. However this has 
not been successfully validated(133), with Moore et al demonstrating that pneumothorax size 
was not an independent predicator of failed observation (133). 
The presence of a haemothorax appears to be associated with failure of conservative 
management in both overt and occult pneumothoraces(133). This is consistent with clinical 
practice. A significant haemothorax is an indication for chest tube insertion, to evacuate blood 
from the pleural space and avoid complication such as infection and a fibrothorax and when 
combined with the presence of pneumothorax, this provides a strong incentive for intervention.  
When this information is combined with previous trials on traumatic pneumothoraces it appears 
that there is a subpopulation that can be managed conservatively. Certainly, when there is no 
significant haemopneumothorax (<2cm in size) there can be consideration for expectant 
management.  Mechanism of injury, ISS or size of pneumothorax do not appear to provide a strong 
indication for intervention. Additionally in our study, clinical condition did not confer an adverse 
prognosis, although in other studies respiratory distress has (133). Although the use of ventilation 
has been controversial, it appears from our findings and previous studies that pneumothoraces 
can be managed conservatively with careful observation on PPV with no increased risk of 
harm(133, 134).  
This is an observational trial and as such will be subject to the inherent limitations of such a study. 
Selection bias may have been introduced by physician selection, and the decision to intervene 
may have affected the conservatively treated cohort characteristics and it is likely that the high-
risk unwell patients were underrepresented in the conservatively treated arm.  It is recognised 
that the outcomes are measuring clinical behaviour (non-protocolised management).  
The ‘negative’ outcome of interest in our study was, treatment failure, as defined as the 
requirement for an invasive pleural intervention. This only occurred in 25 of the 277 patients 
managed conservatively. With 11 potential predictors of treatment failures, the statistical model 
used was underpowered to detect whether these variables could predict treatment failure, and 
it’s possible that some of these factors are in fact valid predictors.  Those treated with an 
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immediate intervention, despite similar ISS, likely represented a more unwell population, with 
higher rates of cardiorespiratory compromise, PPV use and higher mortality rates. The length of 
stay criteria (length of stay is 3 days or more or admitted to a High Dependency Area regardless 
of length of stay) is likely to have biased against patients successfully conservatively managed and 
not requiring a prolonged hospital admission, suggesting that the overall rate of effective 
conservative management is probably greater. Efforts were made to minimise bias, by including 
large number of consecutive unselected patients into the analysis and careful documentation and 
comparison of cohort characteristics.  
This study represents the largest observational study on traumatic pneumothoraces to date. It 
demonstrates that the majority of conservatively managed patients were successfully managed 
without requiring a chest drain. This includes the majority of patients on positive pressure 
ventilation (PPV), the use of which did not present an increased risk of failure of expectant 
management. This study provides support for an observed, expectant approach if the treating 
physician does not feel an immediate chest drain is warranted in the patient with a traumatic 
pneumothorax. However, this is a highly selected patient group and at present there isn’t strong 
randomised evidence to support a conservative approach over chest tube thoracostomy in 
ventilated patients. Future prospective randomised trials examining the outcomes of a 
conservative approach in traumatic pneumothorax, regardless of pneumothorax size or use of 
PPV would help clarify which patients are best managed expectantly. The OPTICC trial is expected 
to be published soon, as should be a fully powered noninferiority trial studying management of 
mechanically ventilated patients with occult pneumothorax.   
 
4.2.3. Ambulatory management  
The Hi-SPEC trial is the first randomised control trial of Heimlich Valves in patients with secondary 
spontaneous pneumothorax. There were various challenges during the trial process with 
recruitment slower than anticipated. Examination of the screening log demonstrated multiple 
explanations for this. A proportion of patients presented out of hours when there was no 
delegated individual available to consent or insert the intervention. Patients with SSP are often 
unwell, and the screening log demonstrated that a significant proportion were felt to be too 
unwell to consent. Additionally, the lung in the SSP often does not collapse circumferentially and 
is often tethered to the chest wall. This made several patients ineligible for the trial, particularly 
as the protocol dictated that the two different interventions were inserted into two specific 
locations in the chest wall, and both options had to be feasible in order to be eligible. 
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The study was impeded by slow study set-up. There was an initial decision to set the principle 
centre (Bristol) up first for a period, to ensure the device worked safely, with additional sites set-
up later. However, there was a significant delay from centres between the date the local 
information pack was sent out and the study green-light. The sending of the local information 
pack should initiate a 70-day recruitment team-frame. This delay likely reflected the pressure on 
local research and innovation (R&I) departments, limiting the ability for prompt site set- up.  An 
earlier approach to sites, and an inclusion of R&I capacity in the feasibility assessment may have 
improved the timeliness of site set- up.  
Ultimately, recruitment rate increased, aided by substantial amendments that were initiated and 
enhanced recruitment strategies. This included broadening the inclusion criteria to allow the 
pleural interventions to be inserted where the operator felt appropriate, which reflects standard 
practice, and enabling patients with drains already in-situ to be potentially eligible by the 
attachment of the Atrium Pneumostat chest drain valve.  
As part of ongoing review of adverse events in the trial, it was noted that there was an imbalance 
in the rate of serious adverse events in the intervention arm. These SAEs were similar in nature 
and described either an enlarging pneumothorax or increasing subcutaneous emphysema in 
patients with the Rocket Pleural Vent. In these patients a conventional chest drain needed to be 
inserted to manage the pneumothorax, which resulted in a more prolonged admission. Feasible 
explanations for this were that the 8Fr cannula in the Rocket Pleural Vent was not of sufficient 
calibre to manage the large air-leaks that can occur with SSP, or there was increased propensity 
for luminal debris to collect within the vent in patients with SSP. This situation was closely 
monitored, and after two similar episodes occurred in January 2019, an urgent Trial Steering 
Committee was organised the following week.   
As discussed previously, it was felt that the nature of these events raised sufficient level of concern 
regarding the use of the Rocket Pleural Vent in the study participants and it was agreed that use 
of the device be discontinued with immediate effect. However, there was consensus that the trial 
should continue, with the Atrium Pneumostat Valve as the sole intervention arm. 
 
4.3. Recruitment 
Both RCTs conducted during this thesis recruited slower than anticipated. The differing trial 
designs posed their own unique enrolment challenges. Difficulty in recruiting to RCTs it not 
uncommon, with more than 50% of trials requiring a funding extension because of recruitment 
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issues and more than at third of trials not meeting recruitment targets(255). This leads to 
excessive costs, unrepresentative study samples and equivocal results due to under-recruitment. 
Statistically non-significant findings can increase the risk that a potentially effective interventions 
being abandoned prior their true value being established or lead to a delay in demonstrating their 
value whilst more trials are carried out(256). It has been calculated that there were as many as 10 
000 unnecessary deaths in the USA due to recruitment delays to an RCT of streptokinase in acute 
myocardial infarctions(257).  
Barriers to recruitment can be found at various levels: the patients, the recruiting clinician and 
team, the trial centre, the trial organisation and the trial design(258). Factors that can influence 
recruitment at each of these levels and can be summarised as(259): 
i) Competition for research participants (e.g. competition with similar studies);  
ii) Intersections between clinical care and research (e.g. proximity of team to clinical areas); 
iii) Patient costs and benefits (e.g. access to additional extra service resources for 
participants) 
iv) The clinical research team (e.g. commitment of research team to the particular study). 
 
4.3.1. The Hi-SPEC Trial  
There were multiple barriers to recruitment identified during the Hi-SPEC trial. These were 
predominately regarding the intersections between clinical care and research. Physical barriers 
were identified, with a geographical distance between the research team and the clinical area 
where the patient presented.  This was addressed by maintaining a presence within the A&E 
department, liaison with A&E research nurses and presentations at governance meetings. Time 
barriers, such as out of hours presentations, affected recruitment, with screening data 
demonstrating that patients often presented outside core working hours. Research personnel 
were available out of hours, however despite this there was still reduced uptake. The introduction 
of the option of attaching the Atrium Pneumostat valve to a pre-existing   chest drain, maintained 
the eligibility of patients who had chest drain inserted out of hours. Resource barriers, particularly 
in A&E, where non-research staff have limited resources to undertake research tasks were also 
likely to have influenced recruitment. A&E staff were incentivised with training opportunities. 
Protocol barriers were considered, for example the rigid criteria for pleural intervention 
placement site was loosened, balancing internal and external trial validity.  
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4.3.2. The REDUCE trial  
The recruitment barriers for the REDUCE trial were typically at the point of consent. With more 
specialities involved, there was a higher probability of the responsible clinicians deciding the trial 
was not acceptable for the patient, i.e. lack of individual research equipoise. This was particularly 
true for patients with hepatic hydrothorax, where some clinicians had views on the acceptability 
of IPC use in this population. Conversely certain patients, particularly with heart failure found the 
idea of repeated aspiration less acceptable. Time was spent forming links with colleagues from 
different specialities (i.e. cardiology, hepatology and nephrology) and explaining the rationale of 
the trial and the collective research equipoise that exists. Time was also spent communicating 
with patients and addressing perceived patient barriers.  
 
4.3.3. Feasibility assessment  
Recruitment for both studies was below projected figures. I have discussed various possible 
reasons and the measures taken to address the under-recruitment.  A key element of trial design 
is trial feasibility, and a major aspect of this is whether the trial will be able to recruit to target. 
When determining feasibility, there are several factors which need to be examined. The patient 
population of interest must be assessed to determine how many potential patients there are with 
the aetiology of interest within a defined time-period. The potential patient population should be 
reviewed to determine whether they meet the specific trial inclusion and exclusion criteria. 
Furthermore, recruitment confounding factors need to be examined to determine how feasible it 
is to recruit this patient population, i.e. where and when do these patient present, and are there 
referral networks in place to facilitate recruitment.  
When assessing feasibility, the acceptability of the trial to patients, clinicians and research teams 
needs to be determined. Other factors to consider are the availability of qualified site personnel 
and equipment as well as the investigator and site experience in conducting similar trials. Whilst 
these factors are all important when designing a trial, they are equally applicable to the feasibility 
assessment when assessing individual sites interest in recruiting to the study. 
An in-depth study feasibility assessment would enable more accurate predictions in recruitment 
rates and number of sites required, enabling the use of targeted strategies to optimise 
recruitment. Likewise, a thorough site feasibility assessment would determine whether the 
anticipated recruitment figures are achievable at a given site and facilitate discussion regarding 
site-specific barriers to recruitment.   
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CHAPTER 5. CONCLUSION 
 
In this thesis I sought to examine the role of ambulatory management of non-malignant pleural 
disease. My hypothesis was ambulatory management of non-malignant pleural disease will lead 
to improved patient-related outcomes and shorter length of hospitalisation. The two populations 
of interest were patients with pleural effusions secondary to organ dysfunction (heart, liver and 
renal) and patients with pneumothorax secondary to underlying lung disease (secondary 
spontaneous pneumothorax).  
I sought to answer this hypothesis in 6 studies, with a range of research methodologies.  Firstly, I 
examined in a prospective non-randomised study the survival of patients in NMPE using time-to-
event statistical analysis.  This demonstrated, in the largest study of its kind, that patients with 
NMPE have a poor prognosis, and patients with pleural effusion secondary to heart failure 
demonstrating a particularly high 1-year mortality. Features associated with pleural effusion 
secondary to organ dysfunction, i.e. transudative and bilateral effusions, conferred a poorer 
prognosis. The presence of an effusion requiring aspiration in patients with heart, liver and renal 
failure was shown to be a marker of severe decompensated disease and ultimately poor 
prognosis. These findings are important as they have changed the narrative that these effusions 
are benign, indeed they are still commonly referred to as benign pleural effusion. This has 
implications on what we tell our patients and how we manage them. It supports an approach 
which focuses on symptom improvement and minimisation of hospital stay in these patients who 
have limited survival. A significant proportion of cardiac pleural effusions require repeated 
therapeutic procedures after their initial aspirate. This thesis has shown that 24% of cardiac 
pleural effusions require a further invasive procedure, which is more the double to the previously 
citied figure.  
Management of patient with malignant effusions has moved towards an ambulatory approach to 
facilitate these aims, with the use of IPCs as a first line option in patients with MPE. Whilst, there 
have been care-series examining their use in patients with organ dysfunction, there are presently 
no randomised trials. As part of this PhD, I managed the REDUCE trial, facilitating the study 
process, initiating site-setup and trial amendments.   This randomised controlled trial was chosen 
to examine whether ambulatory IPC was superior to the current standard of care, repeated needle 
thoracentesis. The primary outcome, breathlessness as measured by VAS score, was chosen as 
this was felt to be the most relevant patient-related outcome. There were several challenges with 
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recruitment to a study which involved several different specialties and required their buy-in to 
enrol patients into the study. The patient cohort was typically an unwell population, and there 
was often a narrow recruitment window before the patients decompensated to the point where 
trial participation was no longer appropriate. Another barrier was a lack of individual equipoise in 
a proportion of clinicians involved. This was particularly apparent in patients with hepatic 
hydrothorax, regarding the decision to use IPCs as a bridge to transplant. Some centres, i.e. 
Cambridge, use IPCs so routinely as a bridge to transport that they were not prepared to consider 
the use of simple aspiration. A polar approach was taken by other centres, where some transplant 
surgeons considered IPC placement a contra-indication to transplant due to perceived infection 
risk. Whilst recruitment was undeniably affected by these opinions, it highlights the importance 
of the trial, to provide randomised control data on the use of IPCs in this population. The study 
has recruited 65 of the target 86 patients, and is due to be completed in August 2019. After 
analysis of the results, I aim to submit for publication in 2020.    
In patients with pneumothorax I felt it was important to examine several aspects of the natural 
history and management. There is no consensus on recurrence rates in patients with PSP, with 
recurrence rates frequently cited between 16 and 52%, with more extreme outlying figures also 
published. This makes counselling about future risk difficult and creates uncertainty regarding the 
optimal management. To address this question, a systematic review was performed of all studies, 
both randomised and non-randomised, examining the recurrence rates in medically managed 
patients with PSP. This demonstrated, for the first time, a pooled recurrence rate of all the 
available literature. It demonstrates that 32% of patients will develop a recurrence, with most of 
the risk in the first year. Recurrence rates did not differ based on the initial intervention for PSP.  
Several factors were associated with a higher risk of recurrence, including female sex, lower BMI 
and radiological evidence of dystrophic lungs, whilst smoking cessation was associated with lower 
recurrence rates. With this data we can more confidently discuss recurrence rates with our 
patients and make more evidence-based decisions on the requirement for definitive surgical 
management.  Furthermore, we identified factors that were associated with recurrence, such as 
smoking. This enable clinicians to give pragmatic advice on minimising risk of recurrence, although 
there was insufficient data to consider development of a risk stratification system. 
The second study on pneumothorax examined outcomes of patients with a traumatic 
pneumothorax who were managed without invasive intervention.  There is increasing interest in 
managing patients with pneumothorax conservatively, based on the theory that allowing the lung 
to re-expand without the aid of invasive management results in optimal healing of the pleural 
defect and lowers risk of recurrence. It is also recognised that drain insertion is not without 
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potential complications. There has been increasing interest in traumatic pneumothoraces, due to 
increased use of CT imaging identifying small ‘occult’ pneumothoraces that would have previously 
not been identified by chest x-ray, and therefor presumably have gone untreated. The aim of our 
study was to use a large trauma patient cohort to create a profile of consecutive patients 
presenting with traumatic pneumothoraces to examine the outcomes of conservatively managed 
patients and determine whether there are factors that can help predict whether a chest tube is 
required. The study, the largest of its kind, demonstrated that the majority of patients who were 
treated conservatively initially, were successfully managed without requiring a subsequent chest 
drain. This, importantly, included a high-risk group of patients that required positive pressure 
ventilation.  It is likely that a proportion of traumatic pneumothoraces can be managed 
conservatively, however further randomised trials are needed to verify these findings and further 
delineate which patients are most suitable for this approach.  
Finally, to test the hypothesis of ambulatory management in patients with pneumothorax, a 
randomised controlled trial design was chosen to examine whether the ambulatory Heimlich valve 
system was superior to the current standard of care of chest tube insertion attached to 
underwater seal, in patients with SSP. Recruitment was slower than expected, with challenges in 
recruiting patients who were acutely unwell, often presented out of hours and can be technically 
difficult to manage.   Strategies were put in place to maximise enrolment, including an 
amendment that allowed an ambulatory flutter valve to be attached to a pre-existing chest drain 
in the intervention arm. Further challenges were noted, with reports of difficulties with the 
interventional device, the Rocket Pleural Vent. There were several reports of problems with the 
devices, centred around the device not adequately managing the air-leak, resulting in enlarging 
pneumothorax or subcutaneous emphysema developing.  The situation was observed closely, 
however in January 2019, with 2 similar events occurring in the space of a week, the decision was 
to hold a TSC to examine the events. The ultimate decision was to discontinue use of the Rocket 
Pleural Vent in the trial, and to continue with Atrium Pneumostat Valve, compared to standard 
care. These finding suggest that the Rocket Pleural vent in its current form is not suitable for the 
management of SSP, either due to the greater air-leak produced, or an increased propensity of 
the device to block. The Hi-SPEC trial is expected the complete in June 2019, with publication in 
2020.  
- 145 - 
 
5.1. Overall Summary 
Non-malignant pleural disease is a common cause of morbidity and mortality, with few high-
quality studies available to support management. This thesis aimed by way of robust non-
randomised and randomised trials to provide an evidence base to improve patient care.  
It showed, in the largest study of its kind that transudative pleural effusions secondary to organ 
dysfunction should not be regarded as ‘benign pleural effusions’. These complicated transudates 
are instead associated with a poor prognosis, comparable with certain malignant pleurisies. 
Approximately a quarter of patients with a cardiogenic pleural effusions, require further pleural 
procedures.   These finding have important implications for the management of these conditions 
where there should be an emphasis on improving quality of life, with freedom from procedures 
and shortening length of hospitalisations. The REDUCE trial, the first randomised control trial 
examining IPCs in this population, is recruiting well in a challenging study population and will guide 
subsequent management for these patients.  
Using meta-analysis, we have determined a pooled recurrence rate of PSP, combining rates from 
a broad range of sources to provide a pooled overall risk. This will inform discussions with patients 
post pneumothorax and help determine the utility of definitive surgical treatment. Our study on 
conservative management of traumatic pneumothoraces provides support for an observed, 
expectant approach if the treating physician does not feel an immediate chest drain is warranted 
in the patient with a traumatic pneumothorax. Finally, the Hi-SPEC study examines the role of 
ambulatory management of SSP with a flutter valve. This study faced recruitment difficulties in an 
acutely unwell patient cohort who often need urgent management out of hours. Careful 
consideration has been made regarding continuation of the trial in the light of adverse events 
noted in the study intervention group. 
Involvement in the coordination of two clinical trials has been an invaluable learning experience, 
with the lessons learned in trial design, management and analysis forming a platform for future 
academic work.   
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CHAPTER 6. FUTURE DIRECTIONS  
The results of the Hi-SPEC and REDUCE trials are awaited with interest and after submission of the 
PhD thesis I will analysis and disseminate the results.  The following sections will outline potential 
for further research in areas addressed by this thesis. 
 
6.1.1. Prognostication of non-malignant pleural effusion  
Whilst this thesis has demonstrated that patient with a NMPE have a poor prognosis, and certain 
features such as transudative and bilateral effusions are associated with a worse prognosis, we 
could not develop a prognostic score to predict outcomes for individual patients. With the LENT 
and PROMISE score we have clinical risk scores to help predict survival and guide management 
for patients with MPE(58, 59). Although we know that age, left atrial dilatation low systolic blood 
pressure, renal impairment, anaemia and certain biomarkers (CRP, CA-125 NT-proBNP) are 
associated with poor prognosis in patients with heart failure, we do not have a prognostic scoring 
system for cardiogenic pleural effusion to predict response to treatments or survival(61, 260-262).  
Development of a scoring system could help deliver a more personalised approach for patients 
with a complicated transudate.    
 
6.1.2. The REDUCE trial  
If the REDUCE trial demonstrates that IPCs are a safe method of managing non-malignant 
effusions, then further work should focus on investigating how best to optimise this method. It is 
recognised that a proportion of patients with IPCs achieve self-pleurodesis, with 42% of patient 
with IPCs for cardiogenic effusions achieving spontaneous self-pleurodesis. This thesis has 
demonstrated that  non-malignant pleural effusions have a poor prognosis, with 50% of patients 
with refractory cardiogenic pleural effusions dying within a year (263). As the mean duration until 
pleurodesis in CHF ranges from 56 to 150 days(66, 264) there is a strong incentive to achieve a 
more accelerated pleurodesis.  There has been increased interest about how to achieve a more 
rapid pleurodesis effect in MPE, including instillation a talc preparation into the IPC(265). This 
would combine the pleurodesis effect of talc, with the outpatient management of the IPC. The 
IPC Plus study demonstrated the safety and efficacy using the IPC as a port to instill a talc slurry 
preparation in patients with malignant pleural effusions, demonstrating significantly higher rates 
of pleurodesis in the talc arm (43%) at day 35 compared with 23% in the placebo group, with no 
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difference in mortality, adverse events or days in hospital. This technique has not been 
investigated in patients with heart failure.  
A recent retrospective cohort study of 36 patients (43 IPCs placements) with cardiogenic effusions 
examined 15 patients undergoing talc poudrage (Group 1) with subsequent IPC placement and 26 
patients receiving only IPC placement (Group 2)(73). Pleurodesis rates were higher in Group 1, 
with 80% achieving pleurodesis at a median time 11.5 days, compared to a 25% pleurodesis rate 
at a median time of 66 days. The shorter time to pleurodesis and subsequent drain removal is 
likely to have reduced the risk of IPC infection, with only 2 cases of pleural infection, both in Group 
2, who did not receive pleurodesis. This study suggests that treating patient with talc pleurodesis 
and then placing an IPC is safe; leads to increased rates of pleurodesis and is associated with 
decreased rates of infection. 
More studies are needed to examine the use of an accelerated pleurodesis regime. I have written 
a draft protocol for A Randomised Controlled Trial Evaluating the Efficacy of Indwelling Pleural 
Catheters Plus Sclerosant in Persistent Symptomatic Pleural Effusions Secondary to Heart Failure 
(REDUCE 2) , examining whether the use of talc as a sclerosant in conjunction with an indwelling 
pleural catheter (IPC) increase the number of patients achieving successful pleurodesis in patients 
with CHF when compared to using an IPC alone. All enrolled patients will have an IPC inserted, 
and then invited back after 7 days, during which they will have community drainages. If there is 
no evidence of significant trapped lung, then participants will be assigned randomly (1:1) to either 
receive talc slurry sclerosant via the IPC, or to receive a pleural placebo instillation of 0.9% sterile 
saline.  
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Figure 20. REDUCE 2 study schedule  
An alternative trial design would be to compare IPCs to talc slurry pleurodesis in patients with 
heart failure. This study would provide needed head to head comparison between two definitive 
forms of treatment and is a possible future research project.  
 
6.1.3. Conservative management of traumatic pneumothorax 
The observational work on traumatic pneumothorax outlined in this thesis suggests there is a role 
for conservative approach in certain patients. Work needs to be carried out to determine which 
patient would be most suited to this approach. Additionally, a randomised clinical trial is required 
to established whether these observational findings are valid. The OPTICC trial (NCT00530725) is 
currently recruiting and randomising patients with occult pneumothoraces in mechanically 
ventilated patients between chest tube insertion and observation and should contribute to this 
evidence base.  
 
6.1.4. Systematic review of PSP recurrence rates 
The systematic review of studies examining recurrence rates in PSP was helpful in determining a 
pooled average recurrence rate. Whilst it identified certain factors associated with increased risk 
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(i.e. smoking, female gender), it was unable to create a risk model to identify risk recurrence in 
the individual patient. Further work needs to be done to determine if radiographic markers, such 
as bleb scores, or other parameters, such as air-leak data can help determine recurrence risk and 
help create a risk calculator, which would guide management. 
 
6.1.5. The Hi-SPEC trial  
For the Hi-SPEC trial it seems likely, due to the adverse safety signal, that the Rocket Pleural Vent 
is not an appropriate intervention for managing SSP.  The results from the alternative ambulatory 
intervention, the Atrium Pneumostat, will be useful in determining a power calculation for future 
trials on ambulatory management of SSP. Future research could also examine whether we can 
characterise which patients are most suited to ambulatory management, either using radiological 
parameters or airflow data from digital air-leak devices.  It is also increasingly recognised that 
conservative management is a suitable option in certain patients with PSP(165).  There is little 
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APPENDIX A:  ADDITIONAL MATERIAL FOR 
PSP RECURRENCE META-
ANALYSIS 
Search Strategy for PSP Recurrence meta-analysis 
MEDLINE (Ovid SP) search strategy 
#1 ((pneumothor*[Title]) AND recurr*[Title/Abstract]) 
#2 (((pneumothor*) AND recurrence[MeSH Terms]))  
#3 (pneumothorax[Title]) AND epidemiology[Title/Abstract] 
#4 (#1 OR #2 OR #3) 
 
Embase (Ovid SP) search strategy 
#1 pneumothor*.ti and recurr*.ab 
#2 (pnuemothor* and recurr*).ti 
#3 pneumothor*.ti and recurrence.kw 
#4 (pneumothor* and epidemiology).ti 
#5 (1 or 2 or 3 or 4) 
 
Data collection Sheet for PSP Recurrence meta-analysis 
Name of study   
Authors   
Date   
Type of study    
Interventions   
N (PSP)   
M:F   
Excluded patients   
1st or 2nd recurrence included   
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Overall recurrence    
Follow-up period (months)   
1 year recurrence   
2 year recurrence   
weight categories    
Weight Recurrence   
Gender Recurrence   
Smoking Recurrence   
Proportion Surgery   
Proportion pleurodesis   
Conservative Recurrence   
Aspiration Recurrence   
ICD Recurrence   
Ipsilateral/contralateral   
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Figure 22. Risk of bias graph: review authors’ judgements about each risk of bias item presented as 
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APPENDIX B:  SITE SET UP FOR REDUCE 
STUDY  
 
Eight centres were recruiting by March 2016 when I began my academic placement.  A decision 
was made to increase. the number of recruiting centres up to 14, to increase the available pool of 
eligible patients. Potential sites were assessed using a feasibility form, which assessed whether 
the sites had used IPCs for NMPE, their views on using them for this indication, and whether the 
cardiologist and hepatologists would refer their patients for this procedure.   Once a site was 
chosen as a recruitment site, the green-light process was commenced. Once the site was sent the 
local information pack, the site had 70 days to recruit their first patient.  
Table 19 shows the sites recruiting for the REDUCE trial.  
Table 19. REDUCE trial sites 
Site PI name 
North Bristol Prof Nick Maskell 
London  Dr Alex West 
North Tees & Hartlepool Dr Ben Prudon 
Middlesbrough Dr Rehan Mustafa 
Oxford Prof Najib Rahman 
North Midlands Dr Mohammed Haris 
South Manchester Dr Matt Evison 
Cambridge Dr Jurgen Herre 
Ayrshire Dr Anur Guhan 
Newport  Dr Alina Ionescu 
Essex, Chelmsford  Dr Keith Hattotuwa  
Blackpool Dr Adeel Ashraf 
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Macclesfield Dr Thapas Nagarajan 
Bath Dr James Walters 
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Appendix  C:  Recruitment up for  REDUCE 
study  
The first patient was recruited for the REDUCE trial on the 7th April 2015. The trial is currently 
recruiting, with an end-recruitment date of 1st August 2019. Currently 65 patients have been 
recruited.  
Recruitment was slower than anticipated. Screening logs demonstrated several common reasons 
for screen failures: 
1. Patients were optimised with medical management (i.e. diuretics) 
2. Patient preferred to be managed with recurrent aspirations 
3. Patients were too unwell for study 
In order to maximise recruitments, several strategies were implemented including two substantial 
amendments, in order to increase the number of patients potentially eligible.  These included: 
1. Regular Newsletter circulated around the research team 
Newsletters were sent to every site, detailing current recruitment by site, overall recruitment, 
congratulating sites on recent participant enrolments and providing advice in a ‘Top Tips’ section.  
Initially the newsletters were sent out quarterly, then every other month from 2018. From 
November 2018 a newsletter was sent out with every randomisation to enhance communication.  
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Figure 23. Example of REDUCE trial newsletter  
2. Investigator meetings at British Thoracic Society   
An investigator meeting was held at the BTS Winter meeting 2017, to raise awareness, encourage 
recruitment and trouble-shoot. 
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Figure 24. BTS Winter meeting REDUCE trial update 
 
3. Increased communication between respiratory/pleural team and cardiologists, hepatologists 
and nephrologists.  
Regular communication was encouraged between the sub-speciality teams to facilitate 
identification of potential patients. This also ensures prompt medical optimisation. 
  
4. Incentivised prizes for recruiting teams at study landmarks (at 45,50,55,60,75 and 80) 
A decision was made to provide incentivised prizes for recruiting team at study landmarks.  
These were well-received.  
 
5. Teleconferences with trial team  
Teleconferences were arranged with the trial teams to discuss trial issues and recruitment 
6. Investigating the set-up of a WhatsApp group  
We approached sites about joining a WhatsApp group to encourage discussion of trial issues and 
recruitment. Only 5 research staff entered their details on the log and there were several replies 
from investigators who were not receptive to the idea. One example given was ‘while this is a nice 
idea it means that one can never separate from work so no thank you’. 
7. Pens distributed as aide-memoire. 
8. Evaluated individual site targets in August 2018 to enable sites to re-set a realistic target, to 
incentivise recruitment.  
A decision was made to increase the number of sites from 9 to 14 to increase the pool of eligible 
patients.  
The trial was extended twice: 
• Recruitment extension 1: Extend trial 2 years to 01/08/2018 
• Recruitment extension 2: Extend trial 1 years to 01/08/2019  
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Figure 25. REDUCE Trial Cumulative Randomisations 
 
 
























Site (number of days  since last randomisation)
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APPENDIX D:  AMENDMENTS FOR REDUCE 
STUDY  
 
Changes to the protocol after trial commencement  
Several amendments were made to the trial protocol after initial ethical approval was granted. At 
discussion at the trial steering committee (TSC) on 15/1/16 a decision was made to include 
patients with pleural effusions secondary to renal failure. A substantial amendment, with 
amended protocol and associated documents, was submitted to ethics committee to allow the 
inclusion of pleural effusion secondary to renal failure. It was felt that including the renal subgroup 
of patients into the trial would help answer the question of how best to manage patients with 
pleural effusions secondary to renal failure and make our study more generalizable to patients 
with transudative effusion of differing aetiologies. 
A further amendment was made to the inclusion criteria in order to address exclusion of 
participants with a non-malignant pleural effusion, who are currently incorrectly excluded due to 
a focus on Light’s criteria in determining the aetiology. We proposed to include participants with 
pleural effusions classified as an exudate by Light’s criteria, where malignancy and infection had 
confidently been excluded as a cause and the primary cause as assessed by the treating physician 
was felt to be cardiac, liver or renal failure. This reflects the well-recognised limitation of Light’s 
criteria, when used to classify pleural effusions, which is highly weighted towards sensitivity in 
identifying exudative processes and suffers in sensitivity in identifying transudates. This can lead 
to over-diagnosis of transudative effusions as exudates in up to 20% of cases. By amending the 
inclusion criteria in this manner, the inclusion criteria of the trial will better reflect standard 
clinical practice. 
The other amendments were non-substantial in nature and involved the change of primary 









Documents Reviewed Details of Amendment 
  
30/09/2014 Substantial SA1 Protocol v1.1 Secondary resarch questions added, inclusion & exclusion criteria amended, SF-36 removed, error in 
power calculation corrected, minimisation factors updated 
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PIS v1.1` minor spelling and formatting changes 
VAS booklet cover v1.0 original 
VAS booklet v1.0 original 
VAS for hospital FU v1.0 original 
Procedure and Drainage Record v1.0 original 
IRAS amendment form v1.0 original 
11/05/2015 Substantial SA2 Trial Summary v 1.0 original 
Contact details v 1 original 
EQ-5D-5L v 2.1 Addition of boxes to include patient ID number 
Consent form 1.1 Removal of one box for patient ID number to be consitent with rest of documentation 
Protocol v1.2 The protocol has been edited in respect of the sections on prerandomisation 
and randomisation to clarify to intended 
patient flow through the trial. We have specified that blood tests and chest radiographs do not need 
to be repeated if 
they have been performed in the 10 days prior to randomisation to minimise the number of 
procedures undertaken by 
patients in circumstances in which they can be avoided. Within the appendix, the trial schedule has 
been updated to 
provide a more comprehensive overview of data collection points. 
16.07.2015 Substantial SA3 Protocol v3.0 update version numbers 
      PIS v3.0 update version numbers & include radiation risk statement 
      Consent form v2.0 update version numbers 
      REDUCE EQ-5D-5L v 2.0 update version numbers 
21/09/2015 non-substantial MA01 Consent v2b change wording of NHS recrds to be applicable to Scottish systems 
11/04/2016 Substantial SA4 Protocol v4.0 add Steve Walker as trial coordinator & include renal patients 
      Poster for clinicians include renal patients 
      PIS v4.0 include renal patients 
      GP letter v2.0 include renal patients 
      Trial Summary v2.0 include renal patients 
        extend to 01/08/2018 
05/12/2016 non-substantial MA02 NA change of PI at North Tees from Richard Harrison to Ben Prudon 
13/01/2017 NA - request for 
HRA approval 
NA NA request for pre-HRA Approval study to come under HRA Approval 
01/06/2017 Substantial SA05 Protocol v5.0 01/06/2017 amend the inclusion criteria in order to minimise exclusion of potential participants with a 
nonmalignant 
        pleural effusion, who are currently incorrectly excluded due to a focus on the Light’s criteria in 
determining 
        aetiology of the effusion. 
12/07/2017 non-substantial MA03 NA Addition of Royal Gwent Hospital, Newport and Broomfield Hospital,  
Chelmsford, Essex as a new site  
29/09/2017 non-substantial MA04 NA Addition of Royal United Hospital, Bath and Macclesfield General Hospital, East Cheshire NHS Trust  
as a new site  
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30/10/2017 non-substantial MA05 NA Addition of Blackpool 
02/03/2018 non-substantial MA06 NA Change the PI from Dr Said Isse to Dr Keith Hattotuwa at Broomfield Hospital, Mid Essex. 
24/07/2018 non-substantial MA07 NA One year extension (01/08/2019) 
25/06/2018 non-substantial MA08 NA Addition of Queen Margaret Hospital, Dunfermline as a new site  
11/07/2018 non-substantial MA09 NA Addition of RoyalFree Hospital, London as a new site  
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APPENDIX E:  SET-UP FOR HI-SPEC STUDY  
The initial decision of 9 recruiting sites was based on a recruitment projection of 4 patients 
recruited per site per year. As recruitment figures were below these projections, a decision was 
made to increase the number of recruiting sites to 13.  
Potential sites were assessed using a feasibility form, which assessed whether the sites had 
experience of using HV for pneumothoraces and views on their use for this indication.   
Table 20 shows the sites recruiting for the Hi-SPEC trial.  
 
Table 20. Hi-SPEC sites  
Site PI name 
Bristol  Prof. Nick Maskell 
Oxford Prof. Najib Rahman 
Taunton Dr Justin Pepperell  
London (St Thomas) Dr Alex west 
Blackpool Dr Amrithraj Bhatta 
Swindon Dr Andrew Stanton  
North Midlands Dr Nadeem Maddekar 
Watford Dr Matthew Knight 
Reading Dr Edward McKeown 
Mansfield  Dr Mark Roberts 
Bath Dr James Walters  
London (Royal Free) Dr James Goldring 
Fife Dr Ian Fairburn  
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Once a site was chosen as a recruitment site, the green-light process was commenced. Once the 
site was sent the local information pack, the site had 70 days to recruit their first patient. Site set 
up time was highly variable, though invariably was longer than 70 days (Mean 155 days ±87), 
which impacted on recruitment (see table 21) 
 
Table 21. Hi-SPEC Site Set-up 
Site Date site pack sent SIV Green Light Total 
duration 
Oxford 08/10/2016 11/11/2016 16/03/2017 159 
Taunton 10/11/2016 13/12/2016 03/07/2017 235 
London 22/11/2016 21/11/2016 01/03/2017 99 
Blackpool 18/10/2016 15/12/2016 21/02/2017 126 
Swindon 11/11/2016 24/02/2017 24/02/2017 105 
North Midlands 24/11/2016 19/05/2017 23/05/2017 180 
West Hartfordshire 
(Watford) 
09/07/2017 10/10/2017 11/10/2017 94 
Reading 30/05/2017 02/10/2017 08/02/2018 254 
King’s Mill 08/03/2018 3/6/18 10/05/2018 63 
Royal Free 14/03/2018 12/8/18 21/09/2018 191 
Bath 12/04/2018 1/5/18 10/05/2018 28 
Fife 03/04/2018 21/1/19 27/02/2019 330 
 
 
- 181 - 
 
APPENDIX F :  Recruitment for  HI -SPEC 
study 
The first patient was recruited for the Hi-SPEC trial on the 21st March 2017. The trial is currently 
recruiting, with an end-recruitment date of 12th June 2019. Currently 35 patients have been 
recruited.  
Recruitment was slower than anticipated. Screening logs demonstrated several common reasons 
for screen failures: 
• Chest drain already inserted 
• Technical (broad range): some which may be addressed by amendment 
• Out of hours (these patients will often have chest drain inserted) 
Table 22. Reasons for screen failure 
Reason for screen fail  Strategy addressing this: 
Chest drain already inserted Amendment to include patients with chest drain 
previously inserted 
Technical Amendment to remove stipulation that chest drain 
insertion is restricted to both second intercostal space in 
the mid-clavicular line and safe triangle 
Not SSP  CT inclusion criteria may increase this 
Out of hours Amendment to include patients with chest drain 
previously inserted 
Too unwell at initial presentation Amendment to include patients with chest drain 
previously inserted 
Patient factors  
Was not aware of patient Amendment to include patients with chest drain 
previously inserted 
Other strategies to encourage recruitment included:  
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• Regular Newsletter circulated around the research team 
• Teleconferences with trial team  
• Pens distributed as aide-memoire. 
• Implementation of training sessions to each site 
• Investigator meetings at British Thoracic Society   
 
A decision was made to increase the number of sites from 9 to 14 to increase the pool of eligible 
patients.  
The trial was extended once: 
• Recruitment extension 1: Extend trial 2 years to 12/06/2018 to 12/6/19 
 
 
Overall recruitment is displayed in figure 27, with recruitment per site displayed in figure 28.  
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Site (number of days  since last randomisation)
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APPENDIX G:  AMENDMENTS FOR HI-SPEC 
STUDY  
Several amendments were made to the trial protocol after initial ethical approval was made. The 
reference of ‘> 20 pack years’ was removed from inclusion criteria, as this was deemed arbitrary 
and not reflective of BTS guidelines. The exclusion criteria were amended to only exclude patients 
with significant hydropneumothorax or haemopneumothorax (≥25 lung field), as it was 
recognised that a third of patients with a pneumothorax will develop a small effusion secondary 
to blood from bleb rupture. A secondary research question was added and corresponding 
outcome measure to ascertain whether Heimlich valves lead to a shorter duration of admission 
until patient is deemed medically fit for discharge, to determine if factors independent of 
pneumothorax confounded length of stay.   
After a trial steering committee on 27th September 2017, slow recruitment was identified as an 
issue. Screening data was interrogated to identify reasons for screen fails (see Table 23). The 
commonest reason for screen fail was a drain was already in-situ, typically inserted out of hours 
or due to an emergency. It was also recognised that patient population was sufficient with 89 SSP 
identified in 1 year. During discussions regarding how to address this, an amendment was 
proposed to allow the attachment of a Heimlich valve device i.e. the Atrium Pneumostat chest 
drain valve, to the end of a previously inserted chest drain.  We felt the introduction of the 
Heimlich valve chest drain (HVCD) would improve the trial in various aspects. As a pneumothorax 
is a potential medical emergency, a chest drain is frequently inserted as a matter of urgency, and 
there is therefore limited consent to an interventional trial. Allowing the option of randomising 
patients after chest drain insertion will enable us to recruit in a more controlled environment. 
Secondly, the Pneumostat valve is widely used throughout the UK, and by including its use in the 
intervention arm, we will be increasing the generalisability of the study, and ensuring the trial is 
evaluating use of Heimlich valves in secondary spontaneous pneumothorax in general, as opposed 
to with only one device.  
To facilitate this amendment, changes were made to protocol, PIS, discharge letter and trial 
summary. The inclusion criteria were also broadened to extend the definition of secondary 
spontaneous pneumothorax, to include evidence of smoking-related emphysema on CT scan as 
part of the definition of secondary spontaneous pneumothorax to ensure we were able to recruit 
patients with undiagnosed emphysema. The inclusion criteria 4) ‘Chest drain insertion possible at 
both 2nd intercostal space in the mid-clavicular line and the mid axillary line (safe triangle)’ was 
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also removed to be in line with clinical practice and British Thoracic Society (BTS) guidance and 
replaced with ‘Chest drain insertion indicated and technically possible for treatment of 
pneumothorax according to current BTS guidelines’. 
Table 23. Screen fails for Hi-SPEC trial  
Reason for screen fail  N  
Chest drain already inserted (out of hours 
presentation) 
18 
Chest drain already inserted (missed) 15 
Technical 15 
Not SSP  16 
Too unwell 6 
Patient factors 4 
Not documented 5 
Total screened 92 
 
The Trial Management Team held a Trial Steering Committee on 5th February 2019 in light of 7 
adverse events associated with the Rocket Pleural Vent, two of which occurred in the previous 
week. All events were expected events and related to the device either blocking or becoming 
dislodged and the majority of patients subsequently had a chest drain inserted. There were no 
concerns regarding the Atrium Pneumostat. Various options were discussed, including stopping 
the trial completely based on safety to participants; continuing the trial in its current form with 
advice on increasing number of flushes; or thirdly continuing the trial with only the Atrium 
Pneumostat Valve available in the ambulatory arm. Ultimately, it was agreed that the nature of 
these events raised sufficient level of concern regarding the use of the Rocket Pleural Vent in the 
study participants and that continued use of the device was not recommended.  However, the 
consensus was that the trial should continue with the Atrium Pneumostat Valve as the sole 
intervention arm. This would address safety concerns, as the trial would no longer be using the 
Rocket Pleural vent, and would enable the trial to continue evaluating ambulatory management 
of SSP. This change would also have the additional benefit of increasing the number of trial 
participants receiving the Atrium Pneumostat and might inform on future trials.  
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An urgent safety notification was sent to the trial teams on the 7th February 2019, and substantial 
amendments were made, removing the option of the Rocket Pleural Vent from the intervention 
arm, and instead limiting management to the Atrium Pneumostat chest drain valve. To facilitate 
this the protocol, PIS, consent form, discharge letter and trial summary were amended.  
A table of all the amendments made during the Hi-SPEC trial is displayed in the Appendix C.  
 
Amendment 






Category Documents Reviewed Details of Amendment 
21/09/2016 Minor 1 
B 
(20/10/2016) 
NA Addition of Taunton, Swindon & London 
24/10/2016 Substantial 1 
A 
(02/12/2016) 
Protocol v3.0 24/10/2016 Trial questionnaires combined into booklet 
        Patient booklet v1.0 13/10/2016 
QoL measurments clarified in text as illustrated in 
appendix 2 
        Trial Summary v2.0 01/09/2016 contact details for SAE reporting 
          Blackpool added as a site 
13/01/2017 Minor 2 
C 
(18/01/2017) 
Patient booklet v1.1 13/01/2017 wording error corrected 
05/04/2017 Substantial 2 
A 
(13/06/2017) 
Protocol v4.0 05/04/2017 
remove reference of ‘> 20 pack years’ from inclusion 
criteria 2 
          
exclusion criteria 5:  only exclude significant 
hydropneumothorax or haemopneumothorax (≥25 lung 
field) 
          
add a secondary research question and corresponding 
outcome measure to ascertain whether Heimlich valves 
lead to a shorter duration of admission until patient 
classified medically fit for discharge 
18/05/2017 Minor 3 
B 
(23/05/2017) 
CV and GCP for PI at Stoke change of PI at Stoke 
16/06/2017 Minor 4 NA NA 
Addition of Watford General Hospital and Royal 
Berkshire Hospital 
14/08/2017 Minor  5 Category B NA 
Change of PI from Patricia Yunger to Matthew Knight at 
Watford General Hospital 
19/12/2017 Substantial 3 Category A 
Protocol v5.0 with tracked changes 
Hi-SPEC discharge letter v2 0 19/12/2017 – 
trackedHi-SPEC Trial Summary v3.0 19/12/2017 –
tracked 
Hi-SPEC_Patient_Information_Sheet_v3 0 
19/12/17 - tracked 
Added another Heimlich valve to allow patients with a 
drain already inserted (within the previous 36 hours) to 
participate 
 
Secondary spontaneous pneumothorax defined can also 
be defined by evidence of smoking-related emphysema 
on CT scan 
 
Removed Chest drain insertion possible at both 2nd 
intercostal space in the mid-clavicular line and the mid 
axillary line (safe triangle) 
 
Approval for up to 14 sites 
 
Extention of recruitment end date to 12/06/2019 
20/03/2018 Minor  6 
  
NA 
Addition of Royal United Hospital, Bath; King's Mill 
Hospital, Mansfield and Royal Free Hospital, London as 
new sites to Hi-SPEC trial. 
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01/04/2018 Minor  7 
C 
(17/04/2018) 
Consent form v2.0 06/02/2018 Updated consent to v2.0 in line with PIS v3.0 
25/06/2018 Minor  8 
NA 
NA 
Addition of Queen Margaret Hospital, Dunfermline as 
new site to Hi-SPEC trial. 
11//7/18 minor 9 NA NA Addition of Royal Free london as new site 
14/01/2019 minor 10 Category B NA Change of PI at Swindon 
05/02/2019 Substantial 4   
Cover letter to REC 
Protocol v6.0 
Patient Information sheet v4.0 
Trial Summary v4.0 
Discharge letter v3.0 
Removing the use of the Rocket Pleural vent for the 
remainder of the study in relation to an urgent safety 
measure prompted by a high ocurrance of Aes of issues 
with the vent becoming blocked or dislodged. 
 
